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1. General introduction 
 
1-1 Natural products chemistry 
 
 Nature is very fascinating even if we only look at it. The bright green of plants delights our eyes, and 
lovely behavior of animals heals our hearts. Furthermore, they bring us precious gifts to make our life more wealthy. 
We always have used the blessings of nature obtained from animals and plants as drugs, fragrances and dyes since 
long ago. Natural products chemistry began when we tried to elucidate active components of these materials from 
a viewpoint of chemistry. It has developed greatly from the early 19th century, then new pharmaceutical drugs were 
born from natural products. For example, an anti-inflammatory agent acetylsalicylic acid was synthesized based on 
the chemical structure of salicin isolated from willow, and an antibiotic penicillin G was discovered from the 
Penicillium fungi (Figure 1-1).[1]  
 
 
Figure 1-1. Structures of acetylsalicylic acid, salicin, and penicillin G. 
 
 Now, the field of natural products chemistry has diversified and progressed, which has enabled the 
discovery and synthesis of more complex molecules and the elucidation of functional mechanism of bioactive 
compounds. Representative results include the total synthesis of an anticancer drug paclitaxel[2a] isolated from the 
Pacific yew, elucidation of the activation mechanism of T-cells using an immunosuppressive drug FK506[2b] 
produced by a soil bacterium, and the functional elucidation of the sodium channel using a pufferfish neurotoxin 
tetrodotoxin[2c] (Figure 1-2). A lot of natural products have been continuously discovered from a variety of 
organisms. These compounds possess structural and functional diversity. Natural products chemistry takes an 
important role especially in bioscience. 
 
 
Figure 1-2. Representative natural products contributed to the development of bioscience. 
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1-2. Trisoxazole macrolides 
 
Trisoxazole macrolides are cytotoxic and antifungal natural products discovered in marine invertebrate. 
These macrolides have a characteristic macrolactone ring (C1–C24) including three continuous oxazole units and a 
side-chain (C25–C35) with an N-methyl enamide terminus as common structures. The earliest report of these kinds 
of compounds were ulapualides, which were isolated by Scheuer et al. from the egg masses of a nudibranch 
Hexabranchus sanguineus collected at Pupukea, O’ahu in 1986 (Figure 1-3).[3] Around the same time, kabiramides 
were also reported by Fusetani et al. from the egg masses of the conspecific nudibranch Hexabranchus sp. collected 
at Kabira Bay, Ishigaki Island (Figure 1-4).[4] After these studies, halichondramides from the marine sponge 
Halichondria sp. and mycalolides from the marine sponge Mycale sp. were discovered (Figure 1-5 and 1-6).[5,6] 
Since then, more than 40 kinds of natural trisoxazole macrolide analogs have been found from the nudibranch H. 
sanguineus, and sponges of the genera Halichondria, Jaspis, and Mycale, and a stony coral of the genera Tubastrea 
(Figure 1-7 and 1-8).[7,8] These molecules have slight differences in oxidation patterns, alkyl substituent groups, and 
so on. For example, a part of halichondramides and mycalolides have C5–C7 ,-unsaturated ketone and others are 
saturated ketones or Michael adducts. At the C30 position, these macrolides have ketone or secondary alcohols, or 
esters. Additionally, there are derivatives whose oxazole rings are oxidized and/or cleaved like kabiramides H and 
I. These structural differences provide the diversity of trisoxazole macrolides family. 
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Figure 1-3. Structures of ulapualides. 
 
 
Figure 1-4. Structures of kabiramides. 
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Figure 1-5. Structures of halichondramides. 
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Figure 1-6. Structures of mycalolides. 
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Figure 1-7. Structures of jaspisamides. 
 
 
Figure 1-8. Structures of halishigamides. 
 
 In addition to unique chemical structures, trisoxazole macrolides show various and potent biological 
activities, such as antitumor, antifungal, and actin-depolymerizing activity. In particular, actin-depolymerizing 
activity of these compounds have been well studied.[9] Actin is a globular protein having four subdomains 1–4 
(Figure 1-9).[10a] It exists universally in eukaryotic cells and is one of the three major components of the cytoskeleton. 
In cells, actin forms two structures that is a monomer called G-actin and a polymer called F-actin (Figure 1-10). The 
assembly of G-actin to form F-actin is reversible. G-actin assembles into F-actin at the barbed end in the part of 
subdomains 1 and 3, and F-actin dissociates at the pointed end in the part of subdomains 2 and 4. This actin dynamics 
repeating polymerization and depolymerization plays an important role in cellular functions such as cell motility, 
cell adhesion, and cytokinesis.[11]  
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Figure 1-9. Structure of G-actin from a rabbit muscle (PDB[10b] ID: 3HBT). The subdomains are labelled: 1 (yellow), 
2 (magenta), 3 (cyan), and 4 (green). 
 
 
Figure 1-10. The model for actin dynamics. 
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 As for the interaction of trisoxazole macrolides with actin, their binding mode and an actin-
depolymerizing mechanism were clarified by the observation of their behavior against fluorescent-labeled actin and 
X-ray analyses of their actin complexes with several these macrolides.[9f–h] Trisoxazole macrolides highly 
specifically bind to actin by intercalating their side-chain moieties into the hydrophobic cleft between subdomains 
1 and 3, and form a 1:1 complex. For example, the X-ray crystal structure of the actin–kabiramide C is shown in 
Figure 1-11.[9f] Because of this binding ability at the barbed end, trisoxazole macrolides strongly inhibit the 
polymerization of G-actin. Some trisoxazole macrolides also sever filamentous F-actin and cause depolymerization 
after they bind to a protomer in F-actin (Figure 1-12).[9] Due to such interactions with actin, it is thought that 
trisoxazole macrolides disturbs actin dynamics and finally cause cell death.[11c] 
 
 
Figure 1-11. Crystal structure of the actin–kabiramide C complex (PDB ID: 1QZ5). Kabiramide C is shown as a 
stick model in red. A) Kabiramide C is binding to the cleft between the subdomains 1 and 3. B) The macrolactone 
ring is located on actin surface and the side-chain is inserted into the cleft. 
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Figure 1-12. The model of the actin-depolymerizing mechanism caused by trisoxazole macrolides. (a) Trisoxazole 
macrolides bind to G-actin and form a 1:1 complex. (b) The complex is not incorporated in the polymerization. (c) 
Trisoxazole macrolides severs F-actin and caps the barbed end. 
 
 As shown in Figures 1-3–1-8, trisoxazole macrolides have various functional groups, and these 
differences are shown to affect the ability to interact with actin. For example, Allingham and co-workers reported 
that actin binding ability of ulapualide A is weaker than that of kabiramide C.[9h] There are differences in ulapualide 
A and kabiramide C on the C24–C35 side-chain, such as the substituent at C32 (acetyl or methoxy groups). They 
suggested that the difference changes the electron density of the C31–C35 region and diminishes an interaction with 
actin. Additionally, Oh and co-workers reported that halichondramide and (19Z)-halichondramide show potent F-
actin severing activity, however jaspisamide A and neohalichondramide do not, which are the water adduct (C5) 
and the double bond migrated (C5–C6 to C4–C5) analogs of halichondramide.[12] 
 Trisoxazole macrolides have variety structures and biological activities. In several trisoxazole macrolides, 
their structural difference affects the affinity with actin. But, the relationships between structures and the interaction 
with actin remain unclear. Clarifying the relationships might lead to the development of useful artificial molecules 
for actin-related biological and biochemical studies. 
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1-3. Mycalolides 
 
Mycalolides belong to trisoxazole macrolides and have been isolated from the marine sponge of the genus 
Mycale and the stony coral Tubastres faulkneri (Figure 1-6).[6] Mycalolides are mainly categorized in two group by 
the oxidation pattern at C30 position, one is the ketone like mycalolide A, and the other is the secondary alcohol or 
the ester like mycalolide B. The absolute stereochemistry of mycalolides had remained obscure for a decade after 
their planar structure had been reported. In 1998, Fusetani and co-workers determined the absolute stereochemistry 
of mycalolides A–C, 30-, 32-, 30,32-hydroxymycalolide A, and 38-hydroxymycalolide B on the basis of chemical 
degradation and derivatization.[6d,6e,13] After the total synthesis of mycalolide A was accomplished by Panek and co-
workers, its structure was confirmed.[14]  
Mycalolides show various biological activities likewise other related trisoxazole macrolides. It was 
initially reported that mycalolides A-C exhibit potent antifungal activity against a wide range of pathogenic fungi 
and cytotoxicity against B-16 melanoma cells with IC50 values of 0.5-1.0 ng/mL.[6a] The use of mycalolides directly 
for cancer therapy was expected, but it was unsuccessful due to their high toxicity.[5b,6a,15] The actin-depolymerizing 
activity of mycalolide B was reported.[9a–d] Mycalolide B severs F-actin to G-actin, forms 1:1 complex with G-actin, 
and inhibits polymerization by sequestering of the barbed end in actin. Applying this specific nature, mycalolide B 
is used as a tool to elucidate the functions of actin and actin-related cell systems.[16]  
 Due to interesting biological activities of mycalolides, several synthetic studies of mycalolides have been 
reported, since the Panek’s total synthesis of mycalolide A[14]; the fragment synthesis of mycalolide A by Cossy,[17] 
and the fragment and an artificial analog synthesis of mycalolide B by Kigoshi.[18] A number of trisoxazole 
macrolides have been reported, but most of these were not synthesized. So, It is thought that establishment of various 
synthetic approaches toward trisoxazole macrolides is important. If an effective synthetic route of these molecules 
could be established, the elucidation of bioactivity becomes easier. Based on the synthetic route established by a 
total synthesis, effective design and synthesis of artificial analogs make possible for further structure-activity 
relationship studies. By the chemical modification of trisoxazole macrolides to reduce its natural toxicity, a novel 
class of drugs that regulates actin dynamics in cells might be developed. Therefore, further studies are needed to 
understand entire functions of mycalolides. It is expected that synthetic studies of mycalolides contribute to an 
application for pharmaceutical and bioscience researches. 
 In this research, the author carried out the synthesis and biological activities of trisoxazole macrolactone 
analogs of mycalolides, and the total synthesis of mycalolides A and B. 
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2. Synthesis and biological activities of the trisoxazole macrolactone analogs of mycalolides 
 
2-1. Introduction 
 
 Trisoxazole macrolides including mycalolides possess attractive biological activities, such as potent 
cytotoxicity against tumor cells and specific interaction with actin, as described in chapter 1. By the X-ray crystal 
structure analyses of actin complexes with several trisoxazole macrolides, it was revealed that these macrolides 
interact with actin to insert the C25–C35 side-chain into the hydrophobic cleft (Tyr133, Ala135, Val139, Tyr143, 
Gly146, Thr148, Glu167, Gly168, Tyr169, Leu346, Leu349, Thr351, Phe352, Met355 and Phe375) between the 
subdomains 1 and 3 of actin and to put the C1–C24 macrolactone ring on the hydrophobic patch (Gly23, Asp25, 
Ala144, Ser145, Glu334, Ile341, Ile345, Ser348 and Leu349) adjacent the cleft such as Figures 1-11 and 2-1.[9f,9g] 
The side-chain analog 1 of mycalolides was synthesized by Suenaga et al., and 1 shows actin-depolymerizing 
activity (Figure 2-2).[18a,18b] The importance of the side-chain part for the actin-depolymerizing activity was 
established, but 1 has little cytotoxicity. On the other hand, the macrolactone ring part interacts with actin surface 
in the X-ray crystal structures (Figure 2-1).[9f,9g] But, there is no report about the biological activity of the 
macrolactone ring part alone. Because of the interest that the macrolactone ring part might be important for the 
cytotoxicity of parent molecules, the author decided to synthesis the trisoxazole macrolactone ring analog 2 of 
mycalolides and evaluate its activity (Figure 2-2).  
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Figure 2-1. Kabiramide C binding site on actin. Kabiramide C is shown as stick representation in green. Actin 
surfaces contacting the macrolactone part and the side-chain part are shown in magenta and blue, respectively. 
 
 
 
Figure 2-2. Structures of mycalolides analogs. 
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2-2. Synthetic plan 
  
Synthetic plan of the trisoxazole macrolactone analog 2 is shown below (Scheme 2-1). In the synthetic 
studies of mycalolide B, the usefulness of metathesis reactions for connecting the C19–C20 double bond in 
mycalolides was reported.[18c,18d] According to the findings, the author decided to synthesize the macrolactone 2 
from diene 3 through ring-closing metathesis (RCM) for the construction of the C19–C20 double bond. The diene 
3 could be assembled by connecting aldehyde 4 and iodoolefin 5 with the use of Nozaki–Hiyama–Kishi (NHK) 
coupling.[19] Iodoolefin 5 could be synthesized by the condensation of carboxylic acid 6 and alcohol 7. Aldehyde 4 
could be prepared from methyl ether 8 based on the procedure established by collaborators. 
 
 
Scheme 2-1. Synthetic plan for the trisoxazole macrolactone analog 2. 
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2-3. Synthesis of the trisoxazole macrolactone analogs 
 
First, (−)-aldehyde 4[18d] was prepared (Scheme 2-2). (−)-Methyl ether 8 was prepared in 9 steps[18c] from 
L-serine methyl ester hydrochloride (9), which was hydrolyzed with hydrochloric acid and condensed with 2-
chlorooxazole-4-carboxylic acid (10)[20] to give amide 11. Cyclodehydration by N,N-diethylaminosulfur trifluoride 
(DAST) and subsequent oxidative aromatization with bromotrichloromethane and 1,8-diazabicyclo[5.4.0]undec-7-
ene (DBU)[21] afforded trisoxazole 12. Dihydroxylation of the olefin moiety in 12 followed by vinylation using 
Stille coupling gave 13. Oxidative cleavage of the diol 13 with sodium periodate gave aldehyde 4. 
 
 
Scheme 2-2. Synthesis of (−)-aldehyde 4. Reagents and conditions: a) 3 M HCl aq., EtOAc, rt; b) 10 (1.1 eq), EDC･
HCl, HOBt, Et3N, CH2Cl2, rt, 78% in 2 steps; c) Et2NSF3, CH2Cl2, –78 °C, 85%; d) BrCCl3, DBU, MeCN, rt, 54%; 
e) OsO4, NMO, THF–H2O (4/1 [v/v]); f) tributylvinyltin, PdCl2(PPh3)2, 1,4-dioxane, reflux, 83%; g) NaIO4, EtOH–
H2O (4/1 [v/v]), rt, 98%. 
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Next, synthesis of iodoolefin 5 and segment coupling were carried out (Scheme 2-3). Homoallylic alcohol 
15 (syn/anti = 93:7) was prepared from methyl (S)-(+)-3-hydroxy-2-methylpropionate ((+)-14, >99%ee) in 3 
steps[22]. Methylation of 15 by methyl trifluoromethanesulfonate (MeOTf) and removal of the tert-
butyldiphenylsilyl (TBDPS) group by tetra-n-butylammonium fluoride (TBAF) gave primary alcohol 7.  
An E/Z mixture of (+)-methyl ester 17 (99%ee, E/Z = 6.7/1)[18d] with LiOH afforded carboxylic acid 6. 
Then, 6 and 7 were condensed by Yamaguchi procedure[23] to give iodoolefin 5. Segment assembly between 5 and 
aldehyde 4 by NHK coupling gave allylic alcohol 18 as a single E isomer with a 3:2 diastereomeric mixture at C7. 
Oxidation of 18 with Dess–Martin periodinane[24] yielded a RCM precursor diene 3. Additionally, removal of the 
TBDPS group of 4 by TBAF and acetic acid gave a C3 hydroxy RCM precursor 19. 
 
 
Scheme 2-3. Synthesis of iodoolefin 5 and RCM precursors. Reagents and conditions: a) MeOTf, 2,6-di-tert-
butylpyridine, CH2Cl2, rt, 90%; b) 
nBu4NF, THF, rt, 96%; c) 1 M LiOH aq., THF, 40 °C, 80%; d) 2,4,6-
trichlorobenzoyl chloride, Et3N, THF, rt, then N,N-dimethyl-4-aminopyridine (DMAP), benzene, rt, 92%; e) CrCl2–
NiCl2 (99/1 [w/w]), THF–DMF (3/1 [v/v]), rt, 73%; f) Dess–Martin periodinane, CH2Cl2, 0 °C, 94%; g) nBu4NF–
AcOH (1/1), THF, rt, 72%. 
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 With the key intermediates 3 in hand, RCM reactions were examined (Table 2-1). Treatment of 3 with 30 
mol% of the second generation Hoveyda–Grubbs catalyst (20a)[25] in refluxing toluene under high dilution 
conditions (1 mM) gave macrocycle 21 as a separable 1.0/1.9 mixture of E and Z isomers at C19 position in 61% 
yield along with dimer 22 (entry 1). Similarly, the reaction at 40 °C in hexane preferred the 19Z isomer 
more (E/Z = 1.0/2.5, entry 2). With the use of ,,-trifluorotoluene which is more polar solvent than toluene 
and hexane, the product ratio of 19E isomer slightly increased (entry 3). Interestingly, in the same solvent at lower 
temperature, the E/Z product ratio was reversed and 19E isomer was given preferentially (entry 4). The use of ethyl 
acetate as a solvent also gave the similar selectivity (entry 5). At the refluxing conditions in dichloromethane, the 
RCM progressed with the most 19E selective manner and the highest yield (82%, E/Z = 1.8/1.0, entry 6). These 
results suggested that both the solvent polarity and the reaction temperature affected the stereoselectivity of the 
RCM reaction of 3. 
 
Table 2-1. RCM of diene 3. 
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 Next, the author examined the effect of the bulky TBDPS group at C3 for RCM stereoselectivity. 
Therefore the RCM reaction of C3 hydroxy analog 19 was examined (Scheme 2-3). Treatment of 19 with 30 mol% 
of catalyst 20a in refluxing dichloromethane (1 mM) gave macrolactone 2 (72%, E/Z = 2.5/1.0). While the reaction 
was slower and the yield was lower than the case of the RCM of 3 (see Table 2-1, entry 6), the stereoselectivity was 
slightly improved. This result suggested that C3 hydroxyl analog 19 would have a specific conformation to prefer 
the formation of the 19E isomer with smaller steric hindrance at C3 position. 
 
 
Scheme 2-3. RCM of C3 hydroxy analog 19. 
 
  
18 
 
Both of the stereoisomers of the trisoxazole macrolactone (19E)- and (19Z)-2 were also afforded by 
removal of the TBDPS groups of (19E)- and (19Z)-21 by TBAF and AcOH (Scheme 2-4). 
 
 
Scheme 2-4. Synthesis of the trisoxazole macrolactone analogs. Reagents and condition: a) nBu4NF–AcOH (1/1), 
THF, rt, 87% for (19E)-2, and 91% for (19Z)-2. 
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2-4. Biological activity 
 
 Biological activities of the synthesized trisoxazole macrolactone analogs were examined, which include 
cytotoxic, actin-depolymerizing, and antifungal activities (Table 2-2). Both of the (19E)- and (19Z)-2 exhibited 
moderate cytotoxicity against HeLa S3 cells with IC50 values of 2.4 and 1.9 g/mL, respectively, which were 
approximately 100 times less than that of mycalolide B. However, they showed no actin-depolymerizing effects at 
30 M nor antifungal activity against several pathogenic fungi at 30 g/mL. Considering these results and the fact 
that the side chain analog 1 has actin-depolymerizing activity without cytotoxicity, both the side-chain and the 
macrolactone moieties were suggested to be essential for the potent cytotoxicity or antifungal activity of mycalolides. 
 
Table 2-2. Biological activities of mycalolide B and its analogs. 
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2-5. Conclusion 
 
The trisoxazole macrolactone analogs of mycalolides were synthesized through the use of NHK coupling 
connecting at C6–C7 bond and RCM for the construction of C19 double bonds. The stereoselectivity at C19 in the 
RCM was affected by reaction solvent polarity, temperature, and the protecting group at C3 (E/Z = 2.5/1.0–1.0/2.5). 
Both of the 19E and 19Z macrolactone analogs exhibited cytotoxicity against tumor cells, but they were 
approximately 100 times less cytotoxic than mycalolide B. Furthermore, it was clarified that the macrolactone 
analogs showed no actin-depolymerizing effects and no antifungal activity. Thus, both the side-chain and the 
macrolactone moiety were suggested to be essential for the potent biological activities of mycalolides. 
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3. Total synthesis of mycalolides A and B 
 
3-1. Introduction 
 
 Mycalolides and related trisoxazole macrolides have attracted attention as synthetic targets because of 
their extraordinary structures and biological activities. To date, total synthesis of mycalolide A and ulapualide A 
has been accomplished. 
 In 2000, Panek et al. reported the total synthesis of mycalolide A by the convergent assembly of the C1–
C19 segment 24 and the C20–C35 segment 25 (Scheme 3-1).[14] Both of the segments were synthesized by using 
NHK coupling of aldehydes 26 and 29 with iodoolefins 27 and 28 as key steps. After the segments were connected 
at the C19–C20 double bond by Schlosser–Wittig reaction, Yamaguchi macrolactonization was employed to furnish 
macrocyclic structure. Finally, macrolactone 23 was converted to mycalolide A by the installation of enamide and 
removal of protecting group. This synthesis was the first report of all trisoxazole macrolides, and confirmed the 
absolute stereochemistry of (−)-mycalolide A. 
 
 
Scheme 3-1. Strategy for the total synthesis of mycalolide A developed by Panek et al. 
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 In 2007, Pattenden et al. achieved the total synthesis of ulapualide A (Scheme 3-2).[27] Ulapualide A was 
divided into C1–C14 and C15–C35 segments, and the C1–C14 segment 31 was synthesized from aldehyde 33 and 
alkyliodide 34 through a Cr(II)-mediated coupling. The C15–C35 segment 32 was synthesized by the connection of 
the aldehyde 37 and phosphonate 38 by using Horner–Wadsworth–Emmons (HWE) reaction before the installation 
of monooxazole 35 for the aldehyde 36 by using Schlosser–Wittig reaction. These segments were condensed by 
using Yamaguchi procedure, and the macrocyclic core was constructed by the oxidative cyclization of the middle 
oxazole ring in 30. Enamide formation and the removal of protecting groups accomplished the total synthesis of 
(−)-ulapualide A. 
  
 
Scheme 3-2. Strategy for the total synthesis of ulapualide A developed by Pattenden et al. 
 
 As mentioned above various synthetic routes that provide trisoxazole macrolides have been established. 
These synthetically provided compounds are expected to be useful for structure-activity relationship studies. The 
author have challenged the total synthesis of mycalolides A and B. Through the syntheses, the author aimed to 
develop a new synthetic route for the related trisoxazole macrolides and their artificial analogs. 
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3-2. Synthetic plan 
 
Synthetic strategies toward mycalolides A and B are illustrated in Scheme 3-3. Mycalolides A and B could 
be synthesized from macrolactone 39 by the formation of C35 N-methyl enamide moiety, and the C30 functionalities 
(ester or ketone). Based on the finding that olefin metathesis is a useful method for connecting the C19 double bond 
in mycalolide analogs described in previous reports[18c,18d] and chapter 2, the author decided to synthesize 
macrolactone 39 from the C1–C19 segment 40 and the C20–C35 segment 41 on two ways using esterification/RCM 
or CM/macrolactonezation for efficient segment assembly (Scheme 3-3 B). An esterification/RCM approach could 
easily reach macrolactone 39, although it might have difficulty regarding the stereoselectivity at C19 double bond, 
as with the RCM of C1–C24 model compound 3 in chapter 2. As for CM/macrolactonization approach, it was 
predicted that both segments need to protect their carboxy or hydroxy groups for CM since the yield of RCM of 19 
having a free hydroxy group was low. Therefore, the author decided to examine both approaches. 
The C1–C19 segment 40 could be prepared from aldehyde 4 and iodoolefin 27 by using NHK coupling. 
The C20–C35 segment 41 was planned to use Julia–Kocienski olefination[28] between phenyltetrazole- (PT-) sulfone 
42 and aldehyde 43. 
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Scheme 3-3. Strategies for the total synthesis of mycalolides A and B. A) Entire synthetic plan; B) Two synthetic 
pathways for macrolactone 39 from the C1–C19 segment 40 and the C20–C35 segment 41. 
 
  
25 
 
3-3. Synthesis of C1–C19 segment 
 
 First, the author started to prepare the C1–C19 segment 40 for the asymmetric total synthesis of 
mycalolides (Scheme 3-4). NHK coupling between (−)-aldehyde 4 and (+)-iodoolefin 27 (E/Z = 5/1)[14] gave allylic 
alcohol 46 as a single E isomer at C5 with a 1:1 diastereomeric mixture of the hydroxy group at C7. The allylic 
alcohol was oxidized with Dess–Martin periodinane and subsequent removal of tert-butyl group in ester afforded 
the C1–C19 segment 40. 
 
 
Scheme 3-4. Synthesis of the C1–C19 segment 40. Reagents and conditions: a) 27 (2.0 eq, E/Z = 5/1), CrCl2–NiCl2 
(99:1 [w/w]), DMSO, rt, 97%; b) Dess–Martin periodinane, pyridine, CH2Cl2, 0 °C, 93%; c) TFA, CH2Cl2, 0 °C, 
100%. 
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3-4. Synthesis of C20-C35 segment 
 
 Next, the author synthesized the C20–C35 segment 41 through the use of Julia–Kocienski olefination as 
a key step. Preparation of PT-sulfone 42 and its use for olefination are shown in Scheme 3-5. Aldol 47 was prepared 
from commercially available methyl (R)-(−)-3-hydroxy-2-methylpropionate ((−)-14, >99%ee) in 8 steps[18a,18b]. 
Methylation of 47 with MeOTf and removal of the chiral auxiliary with LiBH4 gave primary alcohol 48. After 48 
was converted into PT-sulfide 50 with PT-disulfide 49 and nBu3P, oxidation of the sulfide with meta-
chloroperbenzoic acid (mCPBA) afforded PT-sulfone 42. Then, Julia–Kocienski olefination of the PT-sulfone 42 
and known (+)-aldehyde 43[29] was performed. Treatment of 42 with lithium hexamethyldisilazide (LHMDS) 
followed by the addition of aldehyde 43 in 1,2-dimethoxyethane (DME) at −55 °C to rt afforded olefin 51 in 92% 
yield (E/Z = 1/1.5). Although an excess amount of PT-sulfone 42 (2.5 eq) was required to complete the coupling 
reaction, the excess of 42 was quantitatively recovered and reused.  
 
 
Scheme 3-5. Synthesis of olefin 51. Reagents and conditions: a) MeOTf, 2,6-di-tert-butylpyridine, CH2Cl2, rt, 88%; 
b) LiBH4, Et2O, −10 °C, 97%; c) 49, nBu3P, THF, rt, 100%; d) mCPBA, NaHCO3, CH2Cl2, rt, 93%; e) 42 (2.5 eq), 
43 (1.0 eq), LHMDS, DME, −55 °C to rt, 92% (E/Z = 1/1.5). 
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 Further transformation toward the C20–C35 segment 41 is illustrated in Scheme 3-6. Catalytic 
hydrogenation of the double bond and hydrogenolysis of the benzyl group in the E/Z mixture of 51 were completed 
with palladium (II) hydroxide on carbon in single step to give secondary alcohol 52. Protection of the hydroxy group 
in 52 with (3,4-dimethoxybenzyloxy)methyl (DMBOM) chloride afforded the previously reported DMBOM ether 
53.[18a–18c] As a result, the overall yield of 53 from aldol 47 was improved by the use of Julia–Kocienski olefination. 
Selective deprotection of the primary tert-butyldimethylsilyl (TBS) group in 53 and oxidation of the resulting 
primary alcohol with Dess–Martin periodinane provided aldehyde 54. The Grignard reaction of 54 with 
allylmagnesium bromide gave the secondary alcohol 55 as a diastereomeric mixture at C22 (dr = 2.7/1). The desired 
C22-(S) configuration was preferred and their stereoselectivity satisfied the Felkin–Ahn rule. After these 
diastereomers were separated by a column chromatography, methylation of secondary alcohol 55 with methyl iodide 
and sodium hydride followed by the removal of TBS group with TBAF gave the C20–C35 segment 41. 
 
 
Scheme 3-6. Synthesis of the C20–C35 segment 41. Reagents and conditions: a) H2, Pd(OH)2/C (20 mol%), 
NaHCO3, EtOH, rt, 89%; b) DMBOM chloride, 
iPr2NEt, CH2Cl2, rt; c) NH4F, MeOH, 40 °C, 100%; d) Dess–Martin 
periodinane, pyridine, CH2Cl2, rt, 96%; e) CH2=CHCH2MgBr, THF–Et2O (3.4/1 [v/v]), 72% for C22-(S), 27% for 
C22-(R); f) MeI, NaH, THF, rt, 98%; g) nBu4NF, THF, 40 °C, 100%. 
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3-5. Synthesis of the macrolactone though RCM 
 
 With C1–C19 and C20–C35 segments in hand, the author initially made an attempt to assemble these 
segments through the use of esterification/RCM approaches. As shown in Scheme 3-7, condensation of the segments 
40 and 41 using Shiina reagent (2-methyl-6-nitrobenzoic anhydride, MNBA)[30] afforded the RCM precursor 44. 
 
 
Scheme 3-7. Synthesis of the RCM precursor 44. Reagents and condition: a) 40 (1.1 eq), 41 (1.0 eq), MNBA, 
DMAP, Et3N, CH2Cl2, rt, 93%. 
 
 The RCM reaction of the precursor 44 was examined (Table 3-1). Kigoshi et al. reported that treatment 
of 44 with 30 mol% of the second generation Hoveyda–Grubbs catalyst (20a) in refluxing toluene afforded 
macrolactone 39, but undesired 19Z isomer preferred (entry 1).[18d] In the case of the RCM of C1–C24 model 
compound as described in chapter 2, the reaction temperature and solvent polarity were found to affect the 
stereoselectivity. So the author examined the similar reaction conditions for the RCM of 44. First, with the use of 
the catalyst 20a in toluene at 40 °C, the ratio of E isomer slightly increased (entry 2). Next, by using more polar 
solvent, dichloromethane, the E/Z ratio was improved to 2.0/1 (entry 3). But in both cases, the reaction was not 
completed and the starting material 44 was recovered. 
The stereoselectivity of the RCM of 44 was similar with that of C1–C24 model compound, but the 
reactivity of 44 was decreased. This might be due to the steric hindrance of the C25–C35 side-chain moiety in 44. 
To facilitate the initiation of the catalytic cycle at lower temperature, two highly reactive Hoveyda–Grubbs type 
catalysts 20b (Grela catalyst)[31] and 20c (Zhan catalyst 1B)[32] were employed, in which nitro and N,N-
dimethylsulfonamide groups are substituted on the 2-isopropoxybenzylidene ligand, respectively. Because the 
initiation step of the catalytic cycle for the Hoveyda–Grubbs type catalysts includes the cleavage of the O–Ru 
coordination bond, the electron withdrawing groups on the aromatic ring in the catalyst 20b and 20c lower the 
electronic density of the O–Ru bond and enhance their reactivity. In fact, the use of both catalysts increased the 
yield of 39 to 69–75% with similar stereoselectivity as the catalyst 20a (entries 4 and 5). 
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Table 3-1. Synthesis of macrolactone 39 through RCM.  
 
[a] See ref. [18d], [b] Reaction was performed at 40 °C. 
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 A plausible mechanism of the RCM using the second generation Hoveyda–Grubbs catalyst (20a) is shown 
in Scheme 3-8.[33,34] The reaction of catalyst 20a with one olefin in substrate 56 results in the release of O-isopropoxy 
styrene (57) and the formation of carbene complex 58. Subsequent intramolecular reaction of the remaining olefin 
through the ruthenacyclobutane intermediate (trans/cis)-59 provides cyclized product (E/Z)-60 and carbene 
complex 61. The E and Z isomers of 60 are stereospecifically yielded from the corresponding trans- and cis-
ruthenacyclobutane intermediate 59, respectively. Carbene complex 61 reacts with substrate 56 and the propagation 
cycle to generate cyclized product 60 is continued with the release of ethylene.  
Generally, the RCM providing medium and large rings tends to result in a mixture of E and Z isomers.[35] 
The product stereoselectivity is controlled kinetically and thermodynamically, and this is affected by various 
reaction conditions including solvent, temperature, catalyst, and substrate. The E/Z ratio also depends on the product 
reactivity for catalysts due to essentially reversible metathesis reaction. For example, the Z to E isomerization of the 
product was reported during the RCM that provided a 14-membered macrocycle possessing a simple 1,2-
disubstituted olefin.[36] Thus the author examined the isomerization of E and Z isomers of the macrolactone 39 with 
the use of catalyst 20c in refluxing dichloromethane, but isomerization was not observed. It was thought that the 
macrolactone 39 hardly reacts with the catalyst 20c due to the low reactivity of styrene-like electron deficient 
oxazolyl olefin. Then, the author considered that the stereoselectivity of 39 depends on the trans/cis ratio of the 
ruthenacyclobutane intermediates. So, the author tried to modify the steric hinderance and flexibility in 44, such as 
the C3 TBDPS group and the C7 ,-unsaturated ketone moiety. 
 
 
Scheme 3-8. The RCM reaction mechanism of the second generation Hoveyda–Grubbs catalyst (20a). 
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 To enhance flexibility of macrocyclic structures, the C3 TBDPS or the C7 ketone groups in 44 were 
modified (Scheme 3-9). Treatment of 44 with TBAF and acetic acid in THF afforded C3 hydroxy analog 62. 
Acetylation of 62 by the treatment with acetic anhydride afforded C3 acetoxy analog 63. Additionally, Luche 
reduction of 44 followed by the TBS protection of the resulting allylic alcohol gave C7 silyloxy analog 64 with a 
10:1 diastereomeric mixture at C7. 
 
 
Scheme 3-9. Derivatization at C3 and C7 positions of 44. Reagents and conditions: a) nBu4NF–AcOH (1:1), THF, 
rt, 95%; b) Ac2O, DMAP, pyridine, rt, 96%; c) NaBH4, CeCl3·7H2O, MeOH, −20 °C, 91% (dr = 10:1); d) TBSCl, 
imidazole, DMF, rt, 93%. 
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 The RCM reactions for C3 and C7 modified analogs were examined (Scheme 3-10). Treatment of C3 
hydroxy analog 62 with 30 mol% Zhan catalyst 1B (20c) in dichloromethane at reflux gave C3 hydroxy 
macrolactone 65. The stereoselectivity was improved to 3.0/1, but the yield was lower than the case of 44. On the 
other hand, the reaction of C3 acetoxy analog 63 in the same condition proceeded in higher yield, but the 
stereoselectivity was almost the same with the case of 44. The RCM reaction of C7 silyloxy analog 64 also provided 
C7 silyloxy macrolactone 67 with a little improvement of E/Z ratio to 2.2/1, but the yield was low since the C5–C6 
olefin was partially cleaved by the catalyst 20c. 
 As a result, the stereoselectivity was not significantly improved compared with the RCM of 44. 
 
 
Scheme 3-10. RCM of C3 and C7 modified analogs. Reagents and condition: a) 20c (30 mol%), CH2Cl2 (0.9 mM), 
reflux, 24 h. 
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3-6. Synthesis of the macrolactone through CM 
 
 Next, the author attempted CM/macrolactonization approaches to synthesize macrolactone 39. The CM 
of the C1–C19 segment 40 and the C20–C35 segment 41 was examined (Scheme 3-11). However, the yield of seco 
acid 45 was low (18%, E/Z ratio was not determined) and starting materials were recovered (53% for 40, 64% for 
41). 
 
 
Scheme 3-11. CM of the C1–C19 segment 40 and the C20–C35 segment 41. Reagents and condition: a) 20a (30 
mol%), CH2Cl2, reflux, 18% . 
 
 Since polar functional groups in the segments 40 and 41 appeared to quench the metathesis catalyst, then 
the author decided to protect these functional groups (Scheme 3-12). Condensation of 40 with 2,2,2-trichloroethanol 
by using EDC·HCl and DMAP afforded trichloroethyl (TCE) ester 68. The secondary hydroxy group in 41 was 
protected with the use of triethylsilyl (TES) chloride and imidazole to give TES ether 69.  
 
 
Scheme 3-12. Protection of the C1–C19 segment 40 and the C20–C35 segment 41. Reagents and conditions: a) 
2,2,2-trichloroethanol, EDC·HCl, DMAP, CH2Cl2, rt, 89%; b) TESCl, imidazole, DMF, rt, 99%. 
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 The CM of the protected segments 68 and 69 with 20 mol% of catalyst 20a in dichloromethane at reflux 
gave the coupling product 70 in 72% yield with a more E-selective manner (E/Z = 5.5/1.0, Table 3-2, entry 1). An 
E/Z mixture of 70 was separated by a column chromatography. In this reaction, the dimer 71 of segment 69 also 
generated. The terminal olefin in segment 69 is electron rich and more reactive toward metathesis catalysts than that 
of segment 68 which is an electron deficient styrene-like alkene.[37] When a small excess amount of 69 (1.2 eq) was 
used to facilitate coupling reaction, 70 was obtained with the highest yield (77%, entry 2). Additionally, the use of 
Grela catalyst (20b) at the same condition in entry 1 shortened the reaction time (entry 3). The CM using catalyst 
20b partially proceeded at rt (entry 4) and 70 was obtained with the highest stereoselectivity (E/Z = 5.7/1.0).  
  
Table 3-2. Synthesis of coupling product 70 through CM. 
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 Next, the author examined macrolactonization (Scheme 3-13). To remove the C24 TES group, 19E-70 
was treated with acetic acid to give secondary alcohol 72. The TCE group in 72 was removed by the treatment with 
zinc in acetate buffer to afford seco acid 45. Macrolactonization of 45 using Yamaguchi procedure readily proceeded 
to give macrolactone 39. 
 
 
Scheme 3-13. Synthesis of macrolactone 39. Reagents and conditions: a) AcOH–THF–H2O (4/4/1 [v/v/v]), rt, 
100%; b) Zn, 1 M NH4OAc aq., THF, rt, 93%; c) 2,4,6-trichlorobenzoyl chloride, 
iPr2NEt, benzene, rt, then DMAP, 
benzene, rt, 77%. 
 
 As a result, the CM approach to synthesize macrolactone 39 was preferred to the RCM approach with 
respect to the stereoselectivity at the C19 double bond. On the other hand, the overall yields of 39 from the C20–
C35 segment 41 was almost same in both approach (esterification/RCM approach: 44% in 2 steps from 41, 
CM/macrolactonization approach: 45% in 4 steps from 41). These routes have both advantages and disadvantages. 
The esterification/RCM approach enabled the author to access macrolactone 39 in 2 steps but showed moderate 
stereoselectivity at the C19 double bond. Meanwhile, the CM/macrolactonization approach was more selective, but 
additional protection and deprotection steps were needed.  
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3-7. Synthesis of mycalolides A and B 
 
 Synthesis of the key macrolactone 39 was completed, so the author attempted the last functionalization 
toward total syntheses of mycalolides A and B. Acidic hydrolysis of the C35 methyl acetal in 39 afforded hemiacetal 
74 (Scheme 3-14). 
 
 
Scheme 3-14. Synthesis of hemiacetal 73. Reagents and condition: a) 1 M HCl, DME, rt, 94%. 
 
Next, reduction of the five-membered cyclic hemiacetal in 73 using hydride reagents were examined. In 
the previous studies by the collaborator, sodium trimethoxyborohydride was used, and the hemiacetal in 73 was 
completely converted into 1,4-diol. However, 1,4-reduction of the C7 ,-unsaturated ketone in 73 was 
competed.[38] 
 In general, hemiacetals are easily reduced by hydride reagents. However, 5- or 6-membered cyclic 
hemiacetals are relatively stable. Therefore, the author thought the selective reduction of the hemiacetal moiety in 
73 was difficult without the reductions of C7 ,-unsaturated ketone moiety. Then the author planned to 
synthesize mono-protected 1,4-diol 75 through triol 74 (Scheme 3-15). Triol 74 could be synthesize by 1,2-
reduction of the ,-unsaturated ketone and reduction of the hemiacetal in 73. After protection of the primary 
hydroxy group in 74, oxidation of allylic alcohol could afford 75. 
 
 
Scheme 3-15. Synthetic route for mono-protected 1,4-diol 75. 
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 Luche reduction of hemiacetal 73 smoothly proceeded by using cerium(III) chloride heptahydrate and 
sodium borohydride in methanol at –20 °C to rt to give triol 74 quantitatively. The diastereomeric ratio at the C7 
hydroxy group was 10:1. Protection of the primary alcohol in triol 74 with triphenylmethyl (Tr) chloride afforded 
trityl ether 76. Then oxidation of the allylic alcohol in 76 with manganese(IV) oxide yielded ,-unsaturated ketone 
75.  
 
 
Scheme 3-16. Synthesis of ,-unsaturated ketone 75. Reagents and conditions: a) NaBH4, CeCl3·7H2O, MeOH, 
–20 °C to rt, 100%; b) TrCl, pyridine, rt, 82%; c) MnO2, CH2Cl2, rt, 80%. 
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 Next, enamide formation is illustrated in Scheme 3-17. Acetylation of the secondary alcohol in 75 with 
acetic anhydride in pyridine gave acetate 77. Subsequent removal of the trityl group with formic acid in ether gave 
primary alcohol 78, and oxidation of 78 with Dess–Martin periodinane gave aldehyde 79. Dehydrating condensation 
of 79 with N-methylformamide under acidic conditions gave an enamide 80. This reaction was stopped before 
completion due to the competition of enamide formation and elimination of the methoxy, acetoxy, and DMBOM 
ether groups, and unreacted aldehyde 79 were separated from the product. Treatment of the enamide 80 with 2,3-
dichloro-5,6-dicyano-p-benzoquinone (DDQ) afforded secondary alcohol 81. 
 
 
Scheme 3-17. Synthesis of secondary alcohol 81. Reagents and conditions: a) Ac2O, pyridine, rt, 97%; b) HCO2H, 
Et2O, rt, 77%; c) Dess–Martin periodinane, pyridine, CH2Cl2, rt, 99%; d) MeNHCHO, PPTS, hydroquinone, 
benzene, reflux; e) DDQ, tBuOH, 1.0 M phosphate buffer (pH 6.0), CH2Cl2, rt, 29% in 2 steps. 
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 Finally, condensation of 81 with 2,3-di-O-methyl-D-glyceric acid by using Yamaguchi procedure, and the 
subsequent removal of the TBDPS group in 82 by TBAF and acetic acid provided mycalolide B (Scheme 3-18). 
The 1H and 13C NMR spectra were shown in Figures 3-1 and 3-2. The 1H NMR spectrum of synthetic mycalolide 
B was consistent with that of natural one.[6a] The 5.47 ppm proton signal (which was not shown in the literature[6a]) 
was determined as the C3 hydroxyl group based on hydrogen-deuterium exchange experiment. The 13C NMR 
spectrum and optical rotation of synthetic mycalolide B were identical to those of natural product. TLC and HPLC 
analyses also revealed that synthetic and natural mycalolide B were completely identical. 
 
 
Scheme 3-18. Synthesis of mycalolide B. Reagents and conditions: a) 2,3-O-dimethyl-D-glyceric acid, 2,4,6-
trichlorobenzoyl chloride, Et3N, DMAP, benzene, rt, 71%; b) 
nBu4NF–AcOH (1:1), THF, rt, 98%. 
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Figure 3-1. 1H NMR spectra of natural and synthetic mycalolide B (400 MHz, CDCl3). 
 
 
Figure 3-2. 13C NMR spectrum of synthetic mycalolide B (150 MHz, CDCl3). 
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 Additionally, oxidation of secondary alcohol 81 with Dess–Martin periodinane gave TBDPS-protected 
mycalolide A (83)[14](Scheme 3-19), and removal of the TBDPS group in 83 obtained mycalolide A. The 1H NMR 
spectrum was shown in Figure 3-3. The 1H NMR spectrum of synthetic mycalolide A was consistent with that of 
the natural products.[6a] 
 
 
Scheme 3-19. Synthesis of mycalolide A. Reagents and conditions: a) Dess–Martin periodinane, pyridine, CH2Cl2, 
0 °C; b) nBu4NF–AcOH (1:1), THF, rt, 14% in 2 steps. 
 
 
Figure 3-3. 1H NMR spectrum of synthetic mycalolide A (400 MHz, CDCl3).  
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3-8. Conclusion 
 
An asymmetric total synthesis of trisoxazole marine macrolides, mycalolides A and B, is described 
(Scheme 3-20). The assembly of the C1–C19 segment 40 and the C20–C35 segment 41 using esterification/RCM 
or CM/macrolactonization as key steps afforded macrolactone 39, which has all main carbon-chain in mycalolides. 
Subsequent functional group transformation including the installation of terminal enamide and dimethyl glyceric 
ester accomplished the first total synthesis of mycalolide B. Also, oxidation of the C30 hydroxyl group in 81 
followed by the removal of protecting group achieved the second total synthesis of mycalolide A. 
 
 
Scheme 3-20. Total synthesis of mycalolides A and B. 
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4. Conclusion 
 
 In this research, the author described the synthesis and biological activities of the trisoxazole macrolactone 
analogs of mycalolides, and the total synthesis of mycalolides A and B. The author aimed to develop a new synthetic 
route for mycalolides and understand their biological activities. 
In chapter 1, the author mainly outlined the trisoxazole macrolides from the viewpoint of their various 
structures and biological activities. In chapter 2, the synthesis of the trisoxazole macrolactone analogs (19E)- and 
(19Z)-2 was accomplished through the use of NHK coupling and RCM as key steps (Figure 4-1). Both of the analogs 
exhibited moderate cytotoxicity against tumor cells and showed no antifungal and actin-depolymerizing activities. 
In chapter 3, the first total synthesis of (−)-mycalolide B and the second total synthesis of (−)-mycalolide A were 
accomplished through the use of olefin metathesis and esterification as well as NHK coupling, Julia–Kocienski 
olefination and enamide formation as key steps (Figure 4-2). 
Through this research, the author showed that both the macrolactone ring and the side-chain part are 
important for the potent cytotoxicity of mycalolides. The author developed the new synthetic route of mycalolides 
using olefin metathesis. These findings are expected to contribute to the elucidation of the mode of actions of 
mycalolides, and the development of useful artificial molecules for actin-related biochemical studies. 
 
 
Figure 4-1. Structures of the trisoxazole macrolactone analogs 2 and its biological activities. 
 
 
Figure 4-2. Total synthesis of mycalolides A and B. 
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Experimental Section 
 
General experimental 
All chemicals were obtained commercially unless otherwise noted. Organic solvents and reagents for moisture-
sensitive reactions were distilled by the standard procedure. Anhydrous CH2Cl2, THF, Et2O, benzene, pyridine, 
EtOAc, ,,-trifluorotoluene, DMSO, and DMF were obtained commercially. Column chromatography was 
performed using silica gel BW-820MH or FL60D (75–200 or 45–75 m, Fuji Silysia Co., Aichi, Japan) or a 
Yamazen preparative silica gel (40 m). All moisture-sensitive reactions were performed under an atmosphere of 
nitrogen unless otherwise noted, and the starting materials were azeotropically dried with benzene before use. Merck 
precoated silica gel 60 F254 plates were used for TLC. 
 
Spectroscopic analysis 
1H and 13C NMR spectra were recorded on Bruker Biospin AVANCE 600 spectrometer (600 MHz for 1H and 150 
MHz for 13C), AVANCE 500 spectrometer (500 MHz for 1H and 125 MHz for 13C), AVANCE 400 spectrometer 
(400 MHz for 1H and 100 MHz for 13C), or a JEOL EX-270 spectrometer (270 MHz for 1H). Chemical shifts were 
reported in parts per million (ppm) with coupling constants (J) in hertz relative to the solvent peaks, δH 7.26 (residual 
CHCl3) and δC 77.0 for CDCl3, respectively. Optical rotations were measured with a JASCO DIP-1000 polarimeter 
using the sodium D line. IR spectra were recorded on a JASCO FT/IR-230 spectrometer. HR-ESIMS were measured 
on a JEOL AccuTOF CS spectrometer. 
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Synthesis and spectroscopic data 
 
Synthesis and biological activities of trisoxazole macrolactone analogs of mycalolides 
 
 
Amide 11. A mixture of (–)-methyl ether 8[18c] (61. 9 mg, 0.169 mml) and 3.0 M HCl aq. (1.1 mL) in EtOAc (1.1 
mL) was stirred at room temperature for 29 h under air. The mixture was diluted with Et2O (2 mL) and extracted 
with water (2 mL × 3). The combined aqueous layer was concentrated and dried to give crude hydrochloride (50.6 
mg) as a brown solid. The crude solid was used for the next reaction without further purification. 
To a stirred solution of the crude hydrochloride (50.6 mg) in CH2Cl2 (1.7 mL) cooled at 0 °C were added triethyl 
amine (35.3 µL, 0.254 mmol), EDC·HCl (48.6 mg, 0.254 mmol), HOBt (34.3 mg, 0.254 mmol), and 2-
chlorooxazole-4-carboxilic acid (10)[20] (27.4 mg, 0.186 mmol). After being stirred at room temperature for 12 h, 
the reaction mixture was quenched with 10% citric acid aq. (2 mL) and extracted CH2Cl2 (3 mL × 3). The combined 
extracts were washed with sat. NaHCO3 aq. (4 mL) and brine, dried with Na2SO4, and concentrated. The crude oil 
was purified with a SiO2 column chromatography (BW-820MH 2.0 g, hexane / EtOAc = 1/1) to give amide 11 (47.3 
mg, 78%) as a pale yellow solid. 11: Rf 0.55 (CHCl3 / MeOH = 10:1); 1H NMR (270 MHz, CDCl3) δ 8.20 (s, 1H), 
7.63 (d, J = 8.6 Hz, 1H), 7.54 (s, 1H), 5.85 (ddd, J = 7.6, 10.2, 17.5 Hz, 1H), 5.42 (dt, J = 8.6, 7.9 Hz, 1H), 5.04 (d, 
J = 10.2 Hz, 1H), 5.03 (d, J = 17.5 Hz, 1H), 4.26–4.18 (m, 1H), 4.01 (d, J = 6.2 Hz, 1H), 4.01–3.95 (m, 1H), 3.31 
(s, 3H), 3.17 (m, 1H), 2.68 (ddq, J = 6.2, 7.6, 6.9 Hz, 1H), 0.99 (d, J = 6.9 Hz, 3H). 
 
 
Ttisoxaxole 12. To a stirred solution of amide 11 (2.30 g, 6.43 mmol) in CH2Cl2 (64 mL) cooled at –78 °C was 
added DAST (1.9 mL, 14.1 mmol). After the reaction mixture was stirred at –78 °C for 7 h, it was wormed to 0 °C 
and stirred for 12 h additionally. The reaction was quenched with K2CO3 (2.38 g) and sat. NaHCO3 aq. (70 mL), 
and extracted with CH2Cl2 (50 mL × 3). The combined extracts were washed with brine, dried with Na2SO4, and 
concentrated. The crude solid was purified with a SiO2 column chromatography (BW-820MH 90 g, hexane / EtOAc 
= 3/2) to give oxazoline 11a (1.85 g, 85%) as a pale yellow solid. 11a: Rf 0.33 (hexane / EtOAc = 1:1); 1H NMR 
(270 MHz, CDCl3) δ 8.13 (s, 1H), 7.54 (s, 1H), 5.85 (ddd, J = 7.5, 10.8, 16.7 Hz, 1H), 5.51 (dd, J = 8.4, 10.3 Hz, 
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1H), 5.03 (d, J = 10.8 Hz, 1H), 5.02 (d, J = 16.7 Hz, 1H), 4.88–4.71 (m, 2H), 3.99 (d, J = 6.7 Hz, 1H), 3.29 (s, 3H), 
2.67 (ddq, J = 6.7, 7.5, 6.9 Hz, 1H), 1.04 (d, J = 6.9 Hz, 3H). 
To a stirred solution of oxazoline 11a (13.6 mg, 40.3 μmol) in acetonitrile (2.0 mL) cooled at 0 °C were added DBU 
(19.5 μL, 130 μmol) and BrCCl3 (12.0 μL, 122 μmol). After being stirred at room temperature for 48 h, the reaction 
mixture was quenched sat. NH4Cl aq. (3 mL), and extracted with CH2Cl2 (3 mL × 3). The combined extracts were 
washed with brine, dried with Na2SO4, and concentrated. The crude solid was purified with a SiO2 column 
chromatography (FL60D 0.5 g, hexane / EtOAc = 5/1 to 1/1) to give trisoxazole 12 (7.4 mg, 54%) as a colorless 
solid and recovered oxazoline 11a (6.2 mg, 45%) as a pale yellow solid. 12: Rf 0.55 (hexane / EtOAc = 1:1); 1H 
NMR (270 MHz, CDCl3) δ 8.35 (s, 1H), 8.30 (s, 1H), 7.63 (s, 1H), 5.87 (ddd, J = 7.5, 10.8, 16.7 Hz, 1H), 5.06–
4.98 (m, 2H), 4.12 (d, J = 5.7 Hz, 1H), 3.34 (s, 3H), 2.74 (ddq, J = 5.7, 7.5, 7.0 Hz, 1H), 1.04 (d, J = 7.0 Hz, 3H). 
 
 
Diol 13. To a stirred solution of trisoxazole 12 (259.7 mg, 0.774 mmol) in THF (7.8 ml) at room temperature under 
air were added a 0.90 M solution of NMO in water (1.9 mL) and a 0.1 M solution of OsO4 in 
tBuOH (1.55 mL). 
After being stirred for 15 h, the reaction mixture was cooled to 0 °C, diluted with EtOAc (10 mL), quenched sat. 
Na2S2O3 aq. (10 mL), and stirred at room temperature for 1 h. After the reaction mixture was extracted with EtOAc 
(20 mL × 2), the aqueous layer was salted out and extracted with EtOAc (20 mL × 3). The combined extracts were 
washed with brine, dried with Na2SO4, and concentrated, to give crude diol (291.3 mg) as a pale yellow solid. The 
crude solid was used for the next reaction without further purification. 
A mixture of crude diol (291.3 mg), bis(triphenylphospine)palladium (II) dichloride (108.7 mg, 0.155 mmol), and 
tributyl(vinyl)tin (1.1 mL, 3.87 mmol) in 1,4-dioxane (19.0 mL) was stirred at refluxing temperature for 46 h. The 
mixture was cooled to room temperature and concentrated. The crude oil was purified with a SiO2 column 
chromatography (BW-820MH 50 g, CHCl3 / MeOH = 1/0 to 50/1) to give diol 13 (231.4 mg, 83% in 2 steps, ca. 
1:1 diastereomeric mixture at C7) as a pale yellow solid. 13: Rf 0.52 (CHCl3 / MeOH = 10:1); 1H NMR (270 MHz, 
CDCl3) δ 8.33 (s, 1H), 8.31 (s, 1H), 7.69 (s, 1H), 6.68 (dd, J = 11.1, 17.7 Hz, 1H), 6.34 (d, J = 17.7 Hz, 1H), 5.78 
(d, J = 11.1 Hz, 1H), 4.40 [4.30] (d, J = 7.8 [6.5] Hz, 1H), 4.32–4.28 [4.05–3.95] (m, 1H), 3.80–3.55 [3.38–3.36] 
(m, 1H), 3.36 [3.38] (s, 1H), 2.40–2.55 (m, 1H), 1.45–1.25 (m, 1H), 0.78 [0.93] (d, J = 7.2 [7.0] Hz, 1H) Chemical 
shifts of the minor isomers are within parentheses (square brackets). 
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Aldehyde 4. To a stirred solution of diol 13 (29.7 mg, 82.2 mol) in EtOH (2.1 mL) at room temperature under air 
was added a 0.14 M NaIO4 in water (2.0 mL). After being stirred for 10 minutes, the reaction mixture was diluted 
with CHCl3 (5 mL), quenched sat. Na2S2O3 aq. (5 mL), and extracted with CHCl3 (5 mL × 3). The combined extracts 
were washed with brine, dried with Na2SO4, and concentrated. The crude solid was purified with a SiO2 column 
chromatography (BW-820MH 0.6 g, CHCl3 only) to give aldehyde 4 (26.6 mg, 98%) as a pale yellow solid. 4: Rf 
0.60 (CHCl3 / MeOH = 10:1); 1H NMR (270 MHz, CDCl3) δ 9.86 (d, J = 2.0 Hz, 1H), 8.34 (s, 1H), 8.32 (s, 1H), 
7.71 (s, 1H), 6.68 (dd, J = 11.0, 17.6 Hz, 1H), 6.34 (d, J = 17.6 Hz, 1H), 5.78 (d, J = 11.0 Hz, 1H), 4.46 (d, J = 7.3 
Hz, 1H), 3.35 (s, 3H), 3.04 (ddq, J = 2.0, 7.3, 7.0 Hz, 1H), 1.03 (d, J = 7.0 Hz, 3H). 
 
 
Methyl ether 16. To a stirred solution of (–)-homoallylic alcohol 15[22] (787 mg, 2.14 mmol, >99%ee, syn/anti = 
93/7) and in CH2Cl2 (4.8 mL) cooled at 0 °C were added MeOTf (0.72 mL, 6.4 mmol) and 2,6-di-tert-butylpyridine 
(1.5 mL, 6.4 mmol). After the reaction mixture was stirred at room temperature for 20 h, the reaction was quenched 
with sat. NaHCO3 aq. (15 mL) at 0°C, stirred for 45 min at room temperature, and extracted with CH2Cl2 (5 mL × 
4). The combined extracts were washed with water and brine, dried with Na2SO4, and concentrated. The crude oil 
was purified with a Yamazen preparative SiO2 column (30 g, hexane / EtOAc = 100/0 to 95/5) to give methyl ether 
16 (737 mg, 90%, syn/anti = 93/7) as a colorless oil. 16: Rf 0.41 (hexane / EtOAc = 9:1); [α]D25 +9.0 (c 1.09 CHCl3); 
1H NMR (600 MHz, CDCl3) δ 7.72–7.65 (m, 4H), 7.46–7.36 (m, 6H), 5.81 (ddt, J = 17.2, 10.2, 7.0 Hz, 1H), 5.08 
(d, J = 17.2 Hz, 1H), 5.05 (d, J = 10.2 Hz, 1H), 3.69 (dd, J = 10.0, 7.2 Hz, 1H), 3.54 (dd, J = 10.0, 6.1 Hz, 1H), 3.45 
(dt, J = 3.9, 6.8 Hz, 1H), 3.36 (s, 3H), 2.36 (dddt, J = 13.9, 7.0, 6.8, 1.2 Hz, 1H), 2.23 (dddt, J = 13.9, 7.0, 6.8, 1.0 
Hz, 1H), 1.87 (dddq, J = 7.8, 6.1, 3.9, 7.0 Hz, 1H), 1.08 (s, 9H), 0.89 (d, J = 7.0 Hz, 3H); 13C NMR (150 MHz, 
CDCl3) δ 135.6 (d, 4C), 135.5 (d), 134.0 (s), 133.9 (s), 129.5 (d, 2C), 127.6 (d, 4C), 116.5 (t), 80.6 (d), 65.9 (t), 57.9 
(q), 38.7 (d), 35.6 (t), 26.9 (q, 3C), 19.3 (s), 10.9 (q); IR (CHCl3) 3073, 3009, 2962, 2932, 2859, 1640, 1589, 1472, 
1428, 1389, 1362, 1217, 1112, 1088, 998, 918, 824, 705 cm–1; HRMS (ESI) m/z 405.2207 (calcd for C24H34NaO2Si 
[M+Na]+, Δ –1.9 mmu). 
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Primary alcohol 7. To a stirred solution of methyl ether 16 (1.01 g, 2.64 mmol, syn/anti = 93/7) in dry THF (18 
mL) cooled at 0 °C was added a 1.0 M solution of TBAF in THF (3.2 mL, 3.2 mmol). After being stirred for 4 h at 
room temperature, the reaction was quenched with sat. NH4Cl aq. (10 mL), and extracted with Et2O (10 mL × 3). 
The combined extracts were washed with brine, dried with Na2SO4, and concentrated. The crude material was 
purified with a SiO2 column chromatography (BW-820MH 40 g, hexane / Et2O = 9/1 to 1/1) to give primary alcohol 
7 (366 mg, 96%, syn/anti = 93/7) as a colorless oil. 7: Rf 0.15 (hexane / Et2O = 7:3); [α]D25 +17.2 (c 1.31, CHCl3); 
1H NMR (600 MHz, CDCl3) δ 5.81 (ddt, J = 17.0, 10.7, 7.2 Hz, 1H), 5.10 (d, J = 17.0 Hz, 1H), 5.04 (d, J = 10.7 
Hz, 1H), 3.65 (dd, J = 10.7, 7.1 Hz, 1H), 3.58 (dd, J = 10.7, 4.6 Hz, 1H), 3.38 (s, 3H), 3.36 (dt, J = 3.4, 6.6 Hz, 1H), 
2.56 (br s, 1H), 2.38 (dddt, J = 14.0, 7.2, 6.6, 1.3 Hz, 1H), 2.20 (dddt, J = 14.0, 7.2, 6.6, 1.1 Hz, 1H), 1.95 (m, 1H), 
0.89 (d, J = 7.1 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ 135.2 (d), 116.8 (t), 83.8 (d), 66.3 (t), 57.6 (q), 37.0 (d), 
34.6 (t), 11.1 (q); IR (CHCl3) 3632, 3484, 3081, 3009, 2979, 2935, 2832, 1641, 1460, 1428, 1380, 1361, 1236, 1192, 
1083, 1032, 918, 780, 773, 726 cm–1; HRMS (ESI) m/z 167.1050 (calcd for C8H16NaO2 [M+Na]+, Δ +0.2 mmu).  
 
 
Carboxylic acid 6. To a stirred solution of (+)-methyl ester 17[18d] (302 mg, 0.593 mmol, 99%ee, E/Z = 6.7/1) in 
THF (3 mL) cooled at 0 °C was added 1 M lithium hydroxide aq. (3.6 mL, 3.6 mmol). After being stirred for 23 h 
at 40 °C, the reaction mixture was acidified with 1 M HCl aq. (5 mL) and extracted with Et2O (5 mL × 4). The 
combined extracts were washed with brine, dried with Na2SO4, and concentrated. The crude material was purified 
with a SiO2 column chromatography (BW-820MH 10 g, hexane / EtOAc = 9/1 to 5/1) to give carboxylic acid 6 
(234 mg, 80%, E/Z = 6.7/1) as a colorless oil. 6: Rf 0.42 (hexane / EtOAc =2:1); [α]D25 +33.7 (c 1.22, CHCl3); 1H 
NMR (270 MHz, CDCl3) δ 7.75–7.64 (m, 4H), 7.50–7.35 (m, 6H), 6.38 (dt, J = 14.4, 7.6 Hz, 1H), 5.98 (d, J = 14.4 
Hz, 1H), 4.18 (tt, J = 5.9, 5.9 Hz, 1H), 2.49 (dd, J = 6.7, 6.5 Hz, 2H), 2.30–2.16 (m, 2H), 1.06 (s, 9H). COOH signal 
was not observed; 13C NMR (150 MHz, CDCl3) δ 177.1 (s), 141.5 (d), 135.9 (d, 4C), 133.4 (s, 2C), 129.9 (d), 129.8 
(d), 127.7 (d, 4C), 78.2 (d), 68.8 (d), 43.1 (t), 41.2 (t), 26.9 (q, 3C), 19.3 (s); IR (CHCl3) 3073, 3054, 3010, 2961, 
2933, 2897, 2860, 1712, 1606, 1589, 1472, 1428, 1363, 1221, 1111, 951, 822, 786, 704 cm–1; HRMS (ESI) m/z 
517.0701 (calcd for C22H27INaO3Si [M+Na]+, Δ +2.9 mmu).  
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Iodoolefin 5. To a stirred solution of carboxylic acid 6 (234 mg, 0.473 mmol) in dry THF (8.6 mL) were added 
triethylamine (72 μL, 0.52 mmol) and 2,4,6-trichlorobenzoyl chloride (81 μL, 0.52 mmol). After the mixture was 
stirred for 5 h at room temperature, the precipitate was removed by centrifugation. After the precipitate was washed 
with dry THF (4 mL), the combined filtrates and washings were concentrated in vacuo and dissolved in dry benzene 
(11.8 mL). To the activated ester solution was added a solution of primary alcohol 7 (75.3 mg, 0.522 mmol, syn/anti 
= 93/7) and N,N-dimethyl-4-aminopyridine (124 mg, 1.02 mmol) in dry benzene (4 mL). After being stirred for 2 h 
at room temperature, the reaction mixture was quenched with sat. NaHCO3 aq. (10 mL), and extracted with EtOAc 
(3 mL × 5). The combined extracts were washed with brine, dried with Na2SO4, and concentrated. The crude oil 
was purified with a SiO2 column chromatography (FL60D, 9 g, hexane / EtOAc = 49/1 to 4/1) to give iodoolefin 5 
(269 mg, 92%, syn/anti = 99/1, E/Z = 6.1/1) as a colorless oil. 5: Rf 0.60 (hexane / EtOAc = 5:1); [α]D25+26.8 (c 
1.31, CHCl3); 1H NMR (600 MHz, CDCl3) δ 7.68–7.64 (m, 4H), 7.46–7.37 (m, 6H), 6.38 (dt, J = 14.5, 7.4 Hz, 1H), 
5.95 (d, J = 14.5 Hz, 1H), 5.76 (ddt, J = 17.2, 10.1, 7.1 Hz, 1H), 5.10 (d, J = 17.2 Hz, 1H), 5.06 (d, J = 10.1 Hz, 
1H), 4.20 (tt, J = 5.9, 5.9 Hz, 1H), 3.99 (dd, J = 10.7, 6.8 Hz, 1H), 3.87 (dd, J = 10.7, 6.8 Hz, 1H), 3.31 (s, 3H), 3.16 
(dt, J = 3.7, 6.5 Hz, 1H), 2.45 (dd, J = 6.5, 5.9 Hz, 2H), 2.34 (m, 1H), 2.27–2.15 (m, 3H), 1.90 (m, 1H), 1.04 (s, 
9H), 0.87 (d, J = 6.9 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ 170.9 (s), 141.8 (d), 135.9 (d, 2C), 135.8 (d, 2C), 
134.9 (d), 133.6 (s), 133.5 (s), 129.8 (d, 2C), 127.7 (d, 2C), 127.6 (d, 2C), 117.1 (t), 80.9 (d), 77.8 (d), 69.0 (d), 66.8 
(t), 58.0 (q), 43.1 (t), 41.5 (t), 35.4 (d), 35.3 (t), 26.9 (q, 3C), 19.2 (s), 11.0 (q); IR (CHCl3) 3074, 3054, 3010, 2962, 
2933, 2897, 2860, 2829, 1729, 1641, 1472, 1428, 1363, 1233, 1190, 1105, 998, 952, 920, 822, 735, 704 cm–1; 
HRMS (ESI) m/z 643.1729 (calcd for C30H41INaO4Si [M+Na]+, Δ +1.3 mmu). 
 
 
Allylic alcohol 18. To a stirred solution of aldehyde 4 (23.3 mg, 70.8 μmol) and iodoolefin 5 (65.9 mg, 106 μmol, 
E/Z = 6.1/1) in degassed dry THF / DMF (3:1, 1.3 mL) under an argon atmosphere was added a 99:1 (w/w) mixture 
of chromium chloride (II) – nickel chloride (II) (56.5 mg, CrCl2 455 μmol and NiCl2 4.36 μmol). After being stirred 
for 14 h, the reaction mixture was diluted with EtOAc (4 mL), sat. NH4Cl aq. (4 mL), and water (1 mL), and 
extracted with EtOAc (4 mL × 3). The combined extracts were washed with brine, dried with Na2SO4, and 
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concentrated. The crude oil was purified with a SiO2 column chromatography (BW-820MH 3.1 g, hexane / CHCl3 
/ EtOAc = 1/1/0, 3/7/0, 0/1/0, 0/4/1 and 0/3/1) to give allylic alcohol 18 (42.7 mg, 73%, 5E-isomer only, ca. 3:2 
diastereomeric mixture at C7) as a colorless oil. 18: Rf 0.50 (hexane / acetone = 7:3); [α]D25 +5.7 (c 0.93, CHCl3); 
1H NMR (600 MHz, CDCl3) δ 8.32 (s, 0.4H), 8.32 (s, 0.6H), 8.31 (s, 0.6H), 8.30 (s, 0.4H), 7.72–7.61 (m, 5H), 7.44–
7.32 (m, 6H), 6.67 (dd, J = 17.7, 11.2 Hz, 1H), 6.34 (d, J = 17.7 Hz, 1H), 5.77 (d, J = 11.2 Hz, 1H), 5.74 (m, 1H), 
5.55 (m, 1H), 5.39 (m, 1H), 5.08 (d, J = 17.2 Hz, 1H), 5.03 (d, J = 10.2 Hz, 1H), 4.30–4.26 (m, 0.4H), 4.26 (d, J = 
7.9 Hz, 0.6H), 4.25–4.19 (m, 0.6H), 4.17 (d, J = 7.8 Hz, 0.4H), 4.01 (m, 1H), 3.97 (m, 1H), 3.84 (m, 1H), 3.30 (s, 
1.2H), 3.30 (s, 1.8H), 3.29 (s, 1.8H), 3.28 (s, 1.2H), 3.16 (m, 1H), 2.51–2.43 (m, 2H), 2.36–2.12 (m, 6H), 1.89 (m, 
1H), 1.02 (s, 9H), 0.87 (d, J = 6.8 Hz, 1.2H), 0.86 (d, J = 6.8 Hz, 1.8H), 0.75 (d, J = 7.1 Hz, 1.2H), 0.65 (d, J = 6.9 
Hz, 1.8H); 13C NMR (150 MHz, CDCl3) δ 171.34 [171.27], 161.90 [161.89], 156.0, 155.3 [155.0], 141.0 [140.6], 
138.96 [138.95], 138.43 [138.39], 136.7 [136.5], 135.8 (4C), 134.9 [134.8], 134.3, 134.0 [133.9], 133.7 (2C), 131.54 
[131.50], 130.7, 129.7 [129.6], 127.8, 127.5 (4C), 126.4 [124.2], 122.5, 117.0, 80.9, 80.1 [79.9], 75.7 [73.0], 70.2 
[70.1], 66.6, 58.0 [57.5], 57.2 [56.9], 42.5, 42.1, 41.5 [41.4], 40.0, 39.8, 35.3, 26.9, 19.2, 12.0, 11.4, 11.02 [11.01] 
(sprit signals derived from the C7 diastereomer were shown in parenthesis); IR (CHCl3) 3673, 3462, 3167, 3072, 
3029, 3009, 2966, 2933, 2899, 2859, 2828, 1729, 1651, 1542, 1462, 1428, 1380, 1308, 1238, 1218, 1191, 1111, 
980, 942, 918, 822 cm–1; HRMS (ESI) m/z 846.3741 (calcd for C46H57N3NaO9Si [M+Na]+, Δ –2.1 mmu). 
 
 
RCM precursor diene 3. To a stirred solution of allylic alcohol 18 (26.1 mg, 28.3 μmol) in dry CH2Cl2 (0.63 mL) 
cooled at 0 °C were added pyridine (26 μL) and Dess–Martin periodinane (20.2 mg, 47.6 μmol). After being stirred 
for 2.5 h at 0 °C, the reaction mixture was quenched with a 1:1:1 mixture of sat. Na2S2O3 aq. – sat. NaHCO3 aq. – 
water (5 mL), and extracted with CH2Cl2 (2 mL × 4). The combined extracts were washed with brine, dried with 
Na2SO4, and concentrated. The crude oil was purified with a SiO2 column chromatography (FL60D 2 g, hexane / 
CHCl3 = 1/1 to 0/1) to give RCM precursor diene 3 (24.6 mg, 94%) as a colorless oil. 3: Rf 0.42 (CHCl3 / EtOAc = 
4:1); [α]D25 –5.5 (c 0.54, CHCl3); 1H NMR (600 MHz, CDCl3) δ 8.332 (s, 1H), 8.327 (s, 1H), 7.70 (s, 1H), 7.70–
7.65 (m, 4H), 7.44–7.35 (m, 6H), 6.83 (dt, J = 15.8, 7.6 Hz, 1H), 6.67 (dd, J = 17.7, 11.3 Hz, 1H), 6.34 (d, J = 17.7 
Hz, 1H), 6.12 (d, J = 15.8 Hz, 1H), 5.78 (d, J = 11.3 Hz, 1H), 5.75 (ddt, J = 17.2, 10.2, 7.1 Hz, 1H), 5.07 (d, J = 
17.2 Hz, 1H), 5.04 (d, J = 10.2 Hz, 1H), 4.40 (d, J = 9.7 Hz, 1H), 4.32 (tt, J = 6.1, 5.9 Hz, 1H), 4.01 (dd, J = 10.8, 
6.8 Hz, 1H), 3.86 (dd, J = 10.8, 6.9 Hz, 1H), 3.44 (dq, J = 9.7, 7.1 Hz, 1H), 3.31 (s, 3H), 3.21–3.13 (m, 1H), 3.17 
(s, 3H), 2.51 (dd, J = 15.1, 6.1 Hz, 1H), 2.46 (dd, J = 15.1, 6.1 Hz, 1H), 2.47–2.35 (m, 2H), 2.32 (m, 1H), 2.19 (m, 
1H), 1.90 (m, 1H), 1.04 (s, 9H), 0.87 (d, J = 6.9 Hz, 3H), 0.84 (d, J = 7.1 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ 
201.7 (s), 170.9 (s), 161.9 (s), 156.0 (s), 155.5 (s), 142.8 (d), 140.0 (s), 139.0 (d), 138.5 (d), 137.2 (d), 135.9 (d, 2C), 
135.8 (d, 2C), 134.8 (d), 133.5 (s), 133.4 (s), 132.9 (d), 131.6 (s), 130.7 (s), 129.9 (d), 129.8 (d), 127.7 (d, 4C), 
124.2 (t), 122.6 (d), 117.1 (t), 80.9 (d), 77.6 (d), 69.2 (d), 66.8 (t), 58.0 (q), 57.0 (q), 47.0 (d), 41.6 (t), 40.0 (t), 35.3 
(d), 35.3 (t), 26.9 (q, 3C), 19.2 (s), 14.1 (q), 11.0 (q); IR (CHCl3) 3163, 3027, 3010, 2933, 2859, 1729, 1694, 1665, 
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1637, 1542, 1462, 1428, 1376, 1308, 1111, 978, 943, 919, 823, 703 cm–1; HRMS (ESI) m/z 844.3618 (calcd for 
C46H55N3NaO9Si [M+Na]+, Δ +1.3 mmu). 
 
 
C3 hydroxy RCM precursor 19. To a stirred solution of RCM precursor diene 3 (22.7 mg, 27.6 μmol) in THF 
(10.2 mL) cooled at 0 °C were added a 1.0 M solution of TBAF/AcOH (1:1) in THF (0.91 mL, 0.91 mmol) [prepared 
by adding AcOH (114.5 μL, 2.0 mmol) to a 1.0 M solution of TBAF in THF (2.0 mL, 2.0 mmol)]. After being 
stirred for 18 h at room temperature, the reaction mixture was diluted with sat. NaHCO3 aq. (10 mL) and extracted 
with EtOAc (5 mL × 4). The combined extracts were washed with brine, dried with Na2SO4, and concentrated. The 
crude oil was purified with two SiO2 column chromatographies (FL60D 1.2 g, CHCl3 / EtOAc = 4/1 to 1/1; FL60D 
0.4 g, EtOAc) to give C3 hydroxy RCM precursor 19 (11.6 mg, 72%) as a colorless oil. 19: Rf 0.66 (CHCl3 / MeOH 
= 10:1);[α]D25 –39.7 (c 0.46, CHCl3); 1H NMR (600 MHz, CDCl3) δ 8.34 (s, 1H), 8.33 (s, 1H), 7.71 (s, 1H), 6.97 
(dt, J = 15.8, 7.3 Hz, 1H), 6.67 (dd, J = 17.7, 11.5 Hz, 1H), 6.34 (d, J = 17.7 Hz, 1H), 6.29 (d, J = 15.8 Hz, 1H), 
5.78 (d, J = 11.5 Hz, 1H), 5.77 (ddt, J = 17.8, 10.0, 7.3 Hz, 1H), 5.11 (d, J = 17.8 Hz, 1H), 5.06 (d, J = 10.0 Hz, 
1H), 4.42 (d, J = 9.6 Hz, 1H), 4.21 (m, 1H), 4.12 (dd, J = 10.9, 7.0 Hz, 1H), 4.05 (dd, J = 10.9, 6.5 Hz, 1H), 3.56 
(dq, J = 9.6, 7.1 Hz, 1H), 3.35 (s, 3H), 3.34 (m, 1H), 3.23 (dt, J = 3.5, 6.5 Hz, 1H), 3.19 (s, 3H), 2.55 (dd, J = 16.6, 
3.1 Hz, 1H), 2.48 (dd, J = 16.6, 9.2 Hz, 1H), 2.52–2.40 (m, 2H), 2.36 (m, 1H), 2.21 (m, 1H), 2.04 (m, 1H), 0.93 (d, 
J = 7.0 Hz, 3H), 0.90 (d, J = 7.1 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ 202.0 (s), 172.4 (s), 161.9 (s), 156.0 (s), 
155.6 (s), 142.8 (d), 139.8 (s), 139.0 (d), 138.6 (d), 137.2 (d), 134.8 (d), 132.9 (d), 131.6 (s), 130.7 (s), 124.2 (t), 
122.6 (d), 117.6 (t), 81.3 (d), 77.7 (d), 67.1 (d), 66.8 (t), 58.0 (q), 57.0 (q), 46.8 (d), 41.0 (t), 39.4 (t), 35.2 (d), 35.1 
(t), 14.2 (q), 11.1 (q); IR (CHCl3) 3674, 3481, 3168, 3079, 3010, 2934, 2826, 1720, 1665, 1628, 1542, 1459, 1377, 
1233, 1222, 1210, 1187, 1092, 980, 943, 919, 787, 771, 756, 741, 731 cm–1; HRMS (ESI) m/z 606.2411 (calcd for 
C30H37N3NaO9 [M+Na]+, Δ –1.6 mmu). 
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Macrocycle 21. To a stirred solution of RCM precursor diene 3 (7.8 mg, 9.5 μmol) in dry CH2Cl2 (8.8 mL) was 
added 2 mM solution of the 2nd generation Hoveyda–Grubbs catalyst (20a) in dry CH2Cl2 (1.4 mL, 2.8 μmol). After 
being stirred for 9 h at refluxing temperature, the reaction mixture was concentrated. The crude material was purified 
with a SiO2 column chromatography (FL60D 0.5 g, hexane / EtOAc = 2/1 to 1/1) to give macrocycle (19E)-21 (4.0 
mg, 53%), its stereoisomer (19Z)-21 (2.2 mg, 29%), and its dimer (0.8 mg, 5%) as colorless oils. (19E)-21: Rf 0.16 
(CHCl3 / EtOAc = 4:1); [α]D25 –38.1 (c 0.63, CHCl3); 1H NMR (600 MHz, CDCl3) δ 8.13 (s, 1H), 8.08 (s, 1H), 
7.71–7.66 (m, 4H), 7.66 (s, 1H), 7.44–7.35 (m, 6H), 7.07 (td, J = 7.6, 15.8 Hz, 1H), 6.94 (td, J = 7.2, 16.2 Hz, 1H), 
6.35 (d, J = 15.8 Hz, 1H), 5.97 (d, J = 16.2 Hz, 1H), 4.45 (m, 1H), 4.36 (d, J = 9.6 Hz, 1H), 4.13 (qd, J = 7.0, 9.6 
Hz, 1H), 4.00 (dd, J = 6.8, 10.4 Hz, 1H), 3.92 (dd, J = 6.8, 10.4 Hz, 1H), 3.39 (m, 1H), 3.35 (s, 3H), 3.09 (s, 3H), 
2.77 (m, 1H), 2.72 (dd, J = 5.6, 15.6 Hz, 1H), 2.66 (dd, J = 6.8, 15.6 Hz, 1H), 2.45 (m, 2H), 2.42 (m, 1H), 2.06 
(ddtq, J = 2.0, 6.8, 6.8, 6.8 Hz, 1H), 1.02 (s, 9H), 0.88 (d, J = 6.8 Hz, 3H), 0.81 (d, J = 7.0 Hz, 3H); 13C NMR (150 
MHz, CDCl3) δ 203.2 (s), 171.1 (s), 162.7 (s), 156.5 (s), 155.6 (s), 143.3 (d), 139.6 (d), 139.0 (s), 137.4 (d), 137.3 
(d), 137.2 (d), 135.9 (d, 2C), 135.83 (d, 2C), 135.0 (d), 133.7 (s), 133.6 (s), 131.5 (s), 130.3 (s), 129.9 (d), 129.7 (d), 
127.7 (d, 2C), 127.6 (d, 2C), 116.3 (d), 79.7 (d), 76.7 (d), 68.7 (d), 67.5 (t), 57.7 (q), 56.2 (q), 42.6 (d), 41.7 (t), 40.3 
(t), 35.0 (d), 32.4 (t), 26.9 (t, 3C), 19.2 (s), 14.9 (q), 9.3 (q); IR (CHCl3) 3160, 3005, 2932, 2856, 1731, 1662, 1560, 
1485, 1424, 1220, 1209, 1181, 1104, 997, 979, 909, 821, 790, 721, 703 cm–1; HRMS (ESI) m/z 816.3320 (calcd for 
C44H51N3O9SiNa [M+Na]+, Δ +2.8 mmu). 
(19Z)-21: Rf 0.21 (CHCl3 / EtOAc = 4:1); [α]D25 –67.8 (c 0.57, CHCl3); 1H NMR (600 MHz, CDCl3) δ 8.13 (s, 1H), 
8.10 (s, 1H), 7.69–7.62 (m, 4H), 7.61 (s, 1H), 7.44–7.35 (m, 6H), 6.84 (td, J = 6.8, 16.0 Hz, 1H), 6.43 (td, J = 7.6, 
11.8 Hz, 1H), 6.33 (d, J = 11.8 Hz, 1H), 6.01 (d, J = 16.0 Hz, 1H), 4.38–4.29 (m, 1H), 4.35 (d, J = 8.4 Hz, 1H), 4.16 
(dd, J = 5.2, 10.8 Hz, 1H), 3.95 (m, 1H), 3.94 (dd, J = 7.6, 10.8 Hz, 1H), 3.50–3.41 (m, 2H), 3.37 (s, 3H), 3.16 (s, 
3H), 2.88 (m, 1H), 2.60 (dd, J = 6.4, 15.8 Hz, 1H), 2.53 (dd, J = 6.4, 15.8 Hz, 1H), 2.40 (m, 2H), 2.19 (m, 1H), 1.07 
(d, J = 6.8 Hz, 3H), 1.02 (s, 9H), 0.93 (d, J = 6.8 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ 202.5 (s), 170.9 (s), 161.7 
(s), 156.6 (s), 155.7 (s), 142.7 (d), 141.1 (d), 139.3 (s), 137.6 (d), 137.4 (d), 137.0 (d), 135.80 (d, 2C), 135.79 (d, 
2C), 134.7 (d), 133.7 (s), 133.5 (s), 131.6 (s), 130.7 (s), 129.83 (d), 129.78 (d), 127.71 (d, 2C), 127.67 (d, 2C), 114.3 
(d), 81.7 (d), 77.6 (d), 69.0 (d), 66.9 (t), 58.3 (q), 56.9 (q), 44.0 (d), 41.0 (t), 39.4 (t), 36.8 (d), 31.9 (t), 26.9 (q, 3C), 
19.2 (s), 14.0 (q), 12.6 (q); IR (CHCl3) 3162, 3005, 2932, 2856, 1730, 1663, 1558, 1458, 1424, 1179, 1103, 980, 
917, 820, 790, 758, 739, 702 cm–1; HRMS (ESI) m/z 816.3318 (calcd for C44H51N3O9SiNa [M+Na]+, Δ +2.4 mmu). 
 
 
RCM of C3 hydroxy precursor 19. To a stirred solution of C3 hydroxy RCM precursor 19 (5.8 mg, 9.9 μmol) in 
dry CH2Cl2 (9.2 mL) was added a 2.0 mM solution of the 2nd generation Hoveyda–Grubbs catalyst (20a) in dry 
CH2Cl2 (1.5 mL, 3.0 μmol). After being stirred for 37 h at refluxing temperature, the reaction mixture was 
concentrated. The crude material was purified with two SiO2 column chromatographies (FL60D 0.5 g, CHCl3 / 
MeOH = 100/1 to 10/1; FL60D 0.5 g, hexane / EtOAc = 3/7 to 1/9) to give macrolactone (19E)-2 (2.9 mg, 72%), 
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its stereoisomer (19Z)-2 (1.1 mg, 20%), and its dimer (0.8 mg, 7%) as colorless oils. (19E)-2: Rf 0.30 (hexane/EtOAc 
= 1/9); [α]D25 –54 (c 0.38, CHCl3); 1H NMR (600 MHz, CDCl3) δ 8.12 (s, 1H), 8.08 (s, 1H), 7.66 (s, 1H), 7.05 (dt, 
J = 15.8, 7.7 Hz, 1H), 7.04 (dt, J = 15.9, 7.5 Hz, 1H), 6.35 (dt, J = 15.8, 1.6 Hz, 1H), 6.23 (dt, J = 15.9, 1.3 Hz, 1H), 
4.40 (d, J = 8.9 Hz, 1H), 4.34 (m, 1H), 4.16 (dd, J = 10.7, 8.2 Hz, 1H), 4.10 (m, 1H), 4.04 (dd, J = 10.7, 5.9 Hz, 
1H), 4.00 (dt, J = 8.9, 7.0 Hz, 1H), 3.53 (ddd, J = 10.2, 4.7, 2.6 Hz, 1H), 3.39 (s, 3H), 3.15 (s, 3H), 2.78 (dddd, J = 
14.8, 7.7, 4.7, 1.6 Hz, 1H), 2.71 (dd, J = 15.8, 2.9 Hz, 1H), 2.61 (dd, J = 15.8, 10.0 Hz, 1H), 2.57–2.54 (m, 2H), 
2.41 (dddd, J = 14.8, 10.2, 7.7, 1.6 Hz, 1H), 2.05 (m, 1H), 0.93 (d, J = 6.9 Hz, 3H), 0.88 (d, J = 7.0 Hz, 3H); 13C 
NMR (150 MHz, CDCl3) δ 202.6, 172.3, 162.7, 156.5, 155.5, 143.6, 139.8, 139.2, 137.4, 137.3, 137.2, 134.2, 131.3, 
130.1, 116.3, 79.2, 77.1, 67.2, 66.9, 57.9, 56.6, 43.6, 41.5, 40.4, 35.7, 33.2, 13.8, 9.5; IR (CHCl3) 3690, 3167, 3026, 
3003, 2929, 2846, 1719, 1661, 1609, 1563, 1458, 1386, 1261, 1215, 1091, 1100, 1023, 977, 918 cm–1; HRMS (ESI) 
m/z 578.2087 (calcd for C28H33N3NaO9 [M+Na]+, Δ –2.7 mmu). 
(19Z)-2: Rf 0.39 (hexane/EtOAc = 1/9); [α]D25 –71 (c 0.36, CHCl3); 1H NMR (600 MHz, CDCl3) δ 8.17 (s, 1H), 
8.14 (s, 1H), 7.63 (s, 1H), 6.91 (dt, J = 16.1, 6.7 Hz, 1H), 6.42 (dt, J = 11.7, 7.5 Hz, 1H), 6.35 (d, J = 11.7 Hz, 1H), 
6.18 (d, J = 16.1 Hz, 1H), 4.37 (d, J = 7.5 Hz, 1H), 4.18 (m, 1H), 4.16 (dd, J = 10.9, 5.3 Hz, 1H), 4.09 (dd, J = 10.9, 
5.6 Hz, 1H), 3.89 (qd, J = 7.1, 7.5 Hz, 1H), 3.75 (br s, 1H), 3.51 (dt, J = 4.7, 6.6 Hz, 1H), 3.40 (s, 3H), 3.36 (dddd, 
J = 16.2, 7.5, 4.7, 1.4 Hz, 1H), 3.24 (s, 3H), 3.08 (dddd, J = 16.2, 7.5, 6.6, 1.4 Hz, 1H), 2.60 (dd, J = 16.0, 3.2 Hz, 
1H), 2.51 (dd, J = 16.0, 9.5 Hz, 1H), 2.46–2.41 (m, 2H), 2.15 (m, 1H), 1.08 (d, J = 7.0 Hz, 3H), 1.01 (d, J = 7.1 Hz, 
3H); 13C NMR (150 MHz, CDCl3) δ 202.2, 172.2, 161.8, 156.6, 155.6, 143.4, 140.4, 139.7, 137.9, 137.7, 136.8, 
133.9, 131.4, 130.6, 114.6, 81.0, 78.2, 67.0, 66.8, 58.1, 57.3, 44.3, 41.2, 39.6, 37.0, 31.4, 13.5, 12.7; IR (CHCl3) 
3675, 3167, 3026, 3007, 2931, 2846, 1724, 1663, 1557, 1459, 1377, 1279, 1261, 1220, 1182, 1100, 1013, 975, 918 
cm–1; HRMS (ESI) m/z 578.2091 (calcd for C28H33N3NaO9 [M+Na]+, Δ –2.3 mmu). 
 
 
Removal of the TBDPS group of (19E)-21. To a stirred solution of macrocycle (19E)-21 (7.7 mg, 9.7 μmol) in 
THF (3.7 mL) cooled at 0 °C were added a 1.0 M solution of TBAF/AcOH (1:1) in THF (0.29 mL, 0.29 mmol) 
[prepared by adding AcOH (114.5 μL, 2.0 mmol) to a 1.0 M solution of TBAF in THF (2.0 mL, 2.0 mmol)]. After 
being stirred for 60 h at room temperature, the reaction mixture was diluted with sat. NaHCO3 aq. (5 mL), and 
extracted with EtOAc (5 mL × 3). The combined extracts were washed with brine, dried with Na2SO4, and 
concentrated. The crude oil was purified with a SiO2 column chromatography (FL60D 0.5 g, hexane / EtOAc = 3/7 
to 1/9) to give macrolactone (19E)-2 (4.7 mg, 87%) as a colorless oil.  
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Removal of the TBDPS group of (19Z)-21. To a stirred solution of macrocycle (19Z)-21 (3.3 mg, 4.2 μmol) in 
THF (1.6 mL) under a nitrogen atmosphere at 0 °C were added a 1.0 M solution of TBAF/AcOH (1:1) in THF 
(0.14 mL, 0.14 mmol) [prepared by adding AcOH (114.5 μL, 2.0 mmol) to a 1.0 M solution of TBAF in THF (2.0 
mL, 2.0 mmol)]. After being stirred for 48 h at room temperature, the reaction mixture was diluted with sat. 
NaHCO3 aq. (5 mL), and extracted with EtOAc (5 mL × 4). The combined extracts were washed with brine, dried 
with Na2SO4, and concentrated. The crude oil was purified with a SiO2 column chromatography (FL60D 0.5 g, 
hexane / EtOAc = 1/9) to give macrolactone (19Z)-2 (2.1 mg, 91%) as a colorless oil. 
  
Bioassay of mycalolide B and its synthetic analogs. The cytotoxicities of mycalolide B and its synthetic analogs 
were measured by the MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) method. The actin-
depolymerizing activities of the compounds were measured based on their ability to attenuate the fluorescence of 
pyrene-conjugated actin, as previously described.[39] Antimycotic assays against several fungi were conducted at 
Ricerca Biosciences Inc. (Taipei, Taiwan). 
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Total synthesis of mycalolides A and B 
 
 
Allylic alcohol 46. To a stirred solution of (−)-aldehyde 4 (31.2 mg, 94.7 µmol) and (+)-iodoolefin 27[14] (104.3 mg, 
189 µmol, E/Z = 5/1) in degassed dry DMSO (1.9 mL) under an argon atmosphere was added a 99:1 (w/w) mixture 
of chromium chloride (II)–nickel chloride (II) (69.9 mg, CrCl2 563 µmol and NiCl2 5.39 µmol). After being stirred 
for 12 h, the reaction mixture was diluted with EtOAc (4 mL) and sat. NH4Cl aq. (4 mL), and extracted with EtOAc 
(4 mL × 3). The combined extracts were washed with brine, dried with Na2SO4, and concentrated. The crude oil 
was purified with a SiO2 column chromatography (FL60D 3.8 g, hexane / EtOAc = 4/1 to 2/1) to give allylic alcohol 
46 (59.0 mg, 83%, 5E-isomer only, ca. 1:1 diastereomeric mixture at C7) as a colorless oil. 46: Rf 0.38 (hexane / 
EtOAc = 1:1); [α]D25 +7.7 (c 1.09, CHCl3); 1H NMR (400 MHz, CDCl3) δ 8.32 (s, 1H), 8.31 (s, 1H), 7.70–7.63 (m, 
5H), 7.43–7.33 (m, 6H), 6.67 (dd, J = 11.2, 17.8 Hz, 1H), 6.34 (d, J = 17.8 Hz, 1H), 5.78 (d, J = 11.2 Hz, 1H), 5.57 
(m, 1H), 5.39 (m, 1H), 4.30–4.25 (m, 1H), 4.21–4.15 (m, 1.5H), 3.97 (m, 0.5H), 3.50 (m, 0.5H), 3.29 (s, 1.5H), 3.28 
(s, 1.5H), 3.17 (m, 0.5H), 2.45–2.13 (m, 5H), 1.39 (s, 4.5H), 1.38 (s, 4.5H), 1.03 (s, 9H), 0.75 (d, J = 7.2 Hz, 1.5H), 
0.66 (d, J = 6.8 Hz, 1.5H); 13C NMR (100 MHz, CDCl3) δ 170.6 [170.5], 161.9, 156.0, 155.3 [155.0], 141.0 [140.6], 
139.0, 138.5 [138.4], 136.7 [136.6], 135.9 (4C), 134.2 [134.10], 134.07, 133.9, 133.5, 131.6 [131.5], 130.7, 129.6 
(2C), 127.5 (4C), 124.2, 122.6, 80.3 [80.2], 80.1 [80.0], 77.2 [75.8], 73.1, 70.3 [70.2], 57.2 [56.9], 42.4 [42.1], 39.7 
[39.5], 28.1 (3C), 26.9 (3C), 19.3, 12.0 [11.5] (sprit signals derived from the C7 diastereomer were shown in 
parenthesis); IR (CHCl3) 3511, 3168, 3073, 3052, 3033, 3009, 2983, 2966, 2933, 2860, 1720, 1651, 1542, 1472, 
1428, 1368, 1308, 1221, 1216, 1211, 1153, 1112, 979, 909, 822, 726 cm–1; HRMS (ESI) m/z 776.3334 (calcd for 
C42H51N3NaO8Si [M+Na]+, Δ –0.9 mmu). 
 
 
C1–C19 segment 40. To a stirred solution of the allylic alcohol 46 (517.2 mg, 0.686 mmol) in dry CH2Cl2 (13.7 
mL) cooled at 0 °C were added pyridine (0.55 mL) and Dess–Martin periodinane (581.9 mg, 1.37 mmol). After 
being stirred for 1 h at 0 °C, the reaction mixture was warmed to room temperature and stirred for 1 h. The reaction 
mixture was quenched with a 1:1:1 mixture of sat. Na2S2O3 aq. – sat. NaHCO3 aq. – water (30 mL), and extracted 
with CH2Cl2 (20 mL × 3). The combined extracts were washed with brine, dried with Na2SO4, and concentrated. 
The crude oil was purified with a SiO2 column chromatography (FL60D 15 g, hexane / EtOAc = 4/1 to 2/1) to give 
ketone 46a (470.4 mg, 91%) as a colorless oil. 46a: Rf 0.55 (hexane / EtOAc = 1:1); 1H NMR (400 MHz, CDCl3) δ 
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8.34 (s, 2H), 7.70 (s, 1H), 7.70–7.67 (m, 4H), 7.44–7.36 (m, 6H), 6.85 (dt, J = 15.8, 7.6 Hz, 1H), 6.68 (dd, J = 11.2, 
17.6 Hz, 1H), 6.35 (d, J = 17.6 Hz, 1H), 6.12 (d, J = 15.8 Hz, 1H), 5.78 (d, J = 11.2 Hz, 1H), 4.41 (d, J = 9.6 Hz, 
1H), 4.27 (m, 1H), 3.44 (dq, J = 9.6, 6.8 Hz, 1H), 3.18 (s, 3H), 2.49–2.34 (m, 4H), 1.39 (s, 9H), 1.05 (s, 9H), 0.85 
(d, J = 6.8 Hz, 3H).  
To a stirred solution of ketone 46a (189.8 mg, 0.252 mmol) in dry CH2Cl2 (5.0 mL) cooled at 0 °C was added 
trifluoroacetic acid (2.8 mL). After being stirred for 3 h at 0 °C, the reaction mixture was neutralized (pH = 7.0) 
with sat. NaHCO3 aq. (30 mL), and extracted with EtOAc (20 mL × 3). The combined extracts were washed with 
brine, dried with Na2SO4, and concentrated. The crude oil was purified with a SiO2 column chromatography (FL60D 
5 g, hexane / EtOAc = 2/1 to 1/1) to give the C1–C19 segment 40 (170.5 mg, 100%) as a colorless oil. 40: Rf 0.55 
(hexane / EtOAc = 1:1); 1H NMR (400 MHz, CDCl3) δ 8.33 (s, 1H), 8.32 (s, 1H), 7.70–7.67 (m, 4H), 7.69 (s, 1H), 
7.45–7.36 (m, 6H), 6.78 (dt, J = 15.8, 7.6 Hz, 1H), 6.68 (dd, J = 11.8, 18.0 Hz, 1H), 6.35 (d, J = 18.0 Hz, 1H), 6.12 
(d, J = 15.8 Hz, 1H), 5.79 (d, J = 11.8 Hz, 1H), 4.45 (d, J = 9.2 Hz, 1H), 4.31(m, 1H), 3.44 (dq, J = 9.2, 7.0 Hz, 
1H), 3.20 (s, 3H), 2.58 (dd, J = 5.6, 15.2 Hz, 1H), 2.51 (dd, J = 6.8, 15.2 Hz, 1H), 2.47–2.43 (m, 2H), 1.06 (s, 9H), 
0.86 (d, J = 7.0 Hz, 3H) [COOH signal was not observed]. 
 
 
Primary alcohol 48. To a stirred solution of aldol 47[18a,18b] (2.66 g, 4.48 mmol) in dry CH2Cl2 (9.9 mL) cooled at 
0 °C were added 2,6-di-tert-butylpyridine (3.3 mL, 15 mmol) and MeOTf (1.34 mL, 11.6 mmol). After being stirred 
for 43 h at room temperature, the reaction mixture was quenched with 10% NaHCO3 aq. (80 mL) at 0°C, and 
extracted with CH2Cl2 (20 mL × 3). The combined extracts were washed with water and brine, dried with Na2SO4, 
and concentrated. The crude material was purified with a SiO2 column chromatography (FL60D 100 g, hexane / 
EtOAc = 49/1 to 19/1) to give methyl ether 47a (2.40 g, 88%) as a colorless oil. 47a: Rf 0.58 (hexane / EtOAc = 
5/1); [α]D24 –63 (c 0.88, CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.35–7.21 (m, 5H), 4.61 (ddt, J = 3.2, 10.0, 4.8 Hz, 
1H), 4.27 (dq, J = 4.8, 6.8 Hz, 1H), 4.14 (d, J = 4.8 Hz, 2H), 4.02 (ddd, J = 2.0, 2.4, 10.0 Hz, 1H), 3.54 (ddd, J =1.6, 
4.8, 9.6 Hz, 1H), 3.43 (dd, J = 7.2, 10.0 Hz, 1H), 3.40 (dd, J = 6.8, 10.0 Hz, 1H), 3.35 (s, 3H), 3.30 (dd, J = 3.2, 
13.2 Hz, 1H), 2.77 (dd, J = 10.0, 13.2 Hz, 1H), 1.98–1.89 (m, 1H), 1.51 (ddd, J = 2.0, 9.6, 14.0 Hz, 1H), 1.41 (ddd, 
J = 1.6, 10.0, 14.0 Hz, 1H), 1.20 (d, J = 6.8 Hz, 3H), 0.90 (s, 9H), 0.88 (s, 9H), 0.83 (d, J = 7.2 Hz, 3H), 0.08 (s, 
6H), 0.02 (s, 3H), 0.01 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 175.6, 153.6, 135.8, 129.8 (2C), 129.3 (2C), 127.6, 
80.5, 69.9, 66.2, 65.6, 58.1, 56.3, 42.5, 39.8, 38.1, 34.2, 26.3 (3C), 26.2 (3C), 18.5 (2C), 13.4, 10.8, –3.5, –4.2, –
5.1, –5.2; IR (CHCl3) 2956, 2929, 1779, 1697, 1471, 1251, 1220, 1210, 1086, 730, 670 cm–1; HRMS (ESI) m/z 
630.3629 (calcd for C32H57NNaO6Si2 [M+Na]+, Δ +0.7 mmu). 
To a stirred solution of methyl ether 47a (27.9 mg, 45.9 μmol) in dry Et2O (0.9 mL) cooled at –10 °C were added 
dry EtOH (5 μL, 90 μmol) and a 2.0 M solution of lithium borohydride in THF (28 μL, 56 μmol). After being stirred 
at –10 °C for 1.5 h, the reaction mixture was quenched by addition of 1 M NaOH aq. (1 mL) and sat. Na2S2O3 aq. 
(1 mL), and extracted with Et2O (5 mL × 3). The combined extracts were washed with brine, dried with Na2SO4, 
and concentrated. The crude material was purified with a SiO2 column chromatography (0.5 g, hexane / EtOAc = 
24/1) to give primary alcohol 48 (19.3 mg, 97%) as a colorless oil. 48: Rf 0.60 (hexane / EtOAc = 3/1); [α]D24 –22 
(c 0.86, CHCl3); 1H NMR (400 MHz, CDCl3) δ 4.07 (ddd, J = 2.6, 2.6, 9.2 Hz, 1H), 3.66 (dd, J = 9.2, 10.6 Hz, 1H), 
3.51 (dd, J = 4.8, 10.6 Hz, 1H), 3.47-3.35 (m, 3H), 3.39 (s, 3H), 2.28 (m, 1H), 1.94 (m, 1H), 1.47 (ddd, J = 2.6, 9.2, 
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14.2 Hz, 1H), 1.40 (ddd, J = 2.6, 9.2, 14.2 Hz, 1H), 0.89 (s, 18H), 0.81 (d, J = 7.2 Hz, 3H), 0.79 (d, J = 7.2 Hz, 3H), 
0.072 (s, 3H), 0.067 (s, 3H), 0.03 (s, 6H) [OH signal was not observed]; 13C NMR (100 MHz, CDCl3) δ 83.1, 70.2, 
66.5, 65.5, 57.4, 42.4, 35.4, 31.8, 26.3 (3C), 26.2 (3C), 18.5, 18.4, 13.1, 10.8, –3.6, –4.2, –5.1, –5.2; IR (CHCl3) 
3471, 1471, 1463, 1388, 1256, 1220, 1082, 1038, 837, 668 cm–1; HRMS (ESI) m/z 457.3152 (calcd for 
C22H50NaO4Si2 [M+Na]+, Δ –0.7 mmu). 
 
 
PT-sulfide 50. To a stirred solution of primary alcohol 48 (1.73 g, 3.98 mmol) and 5,5’-dithiobis(1-phenyl-1H-
tetrazole) (49) (2.82 g, 7.96 mmol) in dry THF (13.2 mL) cooled at 0 °C was added tri-n-butylphosphine (2.2 mL, 
8.8 mmol). After being stirred for 17 h at room temperature, the reaction mixture was diluted with water (15 mL), 
and extracted with EtOAc (10 mL × 3). The combined extracts were washed with sat. NaHCO3 aq. and brine, dried 
with Na2SO4, and concentrated. The crude material was purified with a SiO2 column chromatography (BW-820MH 
50 g, hexane / EtOAc = 10/1) and a Yamazen preparative silica gel column (90 g, hexane / EtOAc = 20/1) to give 
PT-sulfide 50 (2.44 g, quant.) as a light yellow oil. 50: Rf 0.65 (hexane / EtOAc = 5/1); [α]D25 –30 (c 0.79, CHCl3); 
1H NMR (400 MHz, CDCl3) δ 7.61–7.51 (m, 5H), 4.04 (ddd, J = 3.2, 3.2, 8.8 Hz, 1H), 3.60 (dd, J = 6.0, 12.8 Hz, 
1H), 3.45 (dd, J = 8.0, 10.0 Hz, 1H), 3.41 (m, 1H), 3.40 (dd, J = 6.0, 10.0 Hz, 1H), 3.37 (s, 3H), 3.20 (dd, J = 8.4, 
12.8 Hz, 1H), 2.32 (m, 1H), 1.91 (m, 1H), 1.43 (ddd, J = 3.2, 8.4, 14.0 Hz, 1H), 1.37 (ddd, J = 2.8, 8.8, 14.0 Hz, 
1H), 1.01 (d, J = 6.8 Hz, 3H), 0.88 (s, 9H), 0.87 (s, 9H), 0.81 (d, J = 6.8 Hz, 3H), 0.06 (s, 3H), 0.05 (s, 3H), 0.03 (s, 
6H); 13C NMR (100 MHz, CDCl3) δ 155.1, 134.2, 130.4, 130.1 (2C), 124.2 (2C), 80.7, 70.4, 65.5, 57.7, 42.4, 36.4, 
35.4, 33.0, 26.3 (3C), 26.2 (3C), 18.5, 18.4, 15.3, 11.0, –3.6, –4.2, –5.1, –5.1; IR (CHCl3) 2957, 2929, 2884, 2857, 
1598, 1500, 1471, 1463, 1388, 1255, 1089, 837, 686, 666 cm–1; HRMS (ESI) m/z 617.3332 (calcd for 
C29H54N4NaO3Si2 [M+Na]+, Δ–2.2 mmu). 
 
 
PT-sulfone 42. To a stirred solution of PT-sulfide 50 (92 mg, 0.16 mmol) in dry CH2Cl2 (3.1 mL) cooled at 0 °C 
were added NaHCO3 (69 mg, 0.82 mmol) and mCPBA (134 mg, 0.78 mmol). After being stirred for 18 h at room 
temperature, the reaction was quenched with sat. Na2S2O3 aq. (10 mL) at 0 °C. The resulting mixture was stirred 
for 1 h at 0 °C, and extracted with CH2Cl2 (10 mL × 3). The combined extracts were washed with brine, dried with 
Na2SO4, and concentrated. The crude material was purified with a SiO2 column chromatography (FL60D 3.6 g, 
hexane / EtOAc = 99/1) to give PT-sulfone 42 (88 mg, 91%) as a light yellow oil. 42: Rf 0.70 (toluene / Et2O = 
20/1); [α]D25 –34 (c 0.79, CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.69–7.58 (m, 5H), 4.04 (ddd, J = 2.0, 3.2, 9.6 Hz, 
1H), 3.98 (dd, J = 2.4, 14.0 Hz, 1H), 3.43 (dd, J = 10.0, 14.0 Hz, 1H), 3.42-3.40 (m, 2H), 3.36 (ddd, J = 2.0, 3.6, 
9.6 Hz, 1H), 3.30 (s, 3H), 2.81 (m, 1H), 1.93 (m, 1H), 1.35 (ddd, J = 2.0, 9.6, 13.6 Hz, 1H), 1.19 (ddd, J = 2.0, 9.6, 
13.6 Hz, 1H), 1.12 (d, J = 6.8 Hz, 3H), 0.90 (s, 9H), 0.88 (s, 9H), 0.80 (d, J = 7.2 Hz, 3H), 0.07 (s, 3H), 0.051 (s, 
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3H), 0.046 (s, 6H); 13C NMR (100 MHz, CDCl3) δ 154.4, 133.4, 131.8, 130.0 (2C), 125.6 (2C), 80.6, 69.8, 65.5, 
57.7, 57.1, 42.4, 31.9, 29.1, 26.3 (3C), 26.2 (3C), 18.5, 18.4, 16.3, 10.7, –3.6, –4.2, –5.1, –5.2; IR (CHCl3) 3031, 
2956, 2930, 1596, 1498, 1339, 1256, 1154, 1063, 1007, 744, 736, 688, 539 cm–1; HRMS (ESI) m/z 649.3277 (calcd 
for C29H54N4NaO5Si2 [M+Na]+, Δ +2.6 mmu). 
 
 
Olefin 51. To a stirred solution of PT-sulfone 42 (139 mg, 0.222 mmol) in dry DME (1.2 mL) cooled at –55 °C was 
added a 1.0 M solution of lithium hexamethyldisilazide in THF (0.22 mL, 0.22 mmol) dropwise under a nitrogen 
stream. The mixture was stirred at –55 °C for 30 min, then a solution of (+)-aldehyde 43[28] (26 mg, 89 μmol) in 
DME (0.6 mL) was added dropwise, and the resulting mixture was stirred at –55 °C for 2 h and allowed to warm to 
room temperature for 8 h. The reaction was quenched by addition of brine (5 mL) at 0 °C and extracted with Et2O 
(5 mL × 3). The combined extracts were washed with brine, dried with Na2SO4, and concentrated. The crude 
material was purified with a SiO2 column chromatography (FL60D 4.5 g, hexane / acetone = 50/1) to give olefin 51 
(56.4 mg, 92%, E/Z = 1/1.5) and recovered PT-sulfone 42 (86 mg) as light yellow oils. A part of the E/Z-
stereoisomers of 51 was separated by the same SiO2 column chromatography as above. (E)-51: Rf 0.70 (hexane / 
Et2O = 4/1); 1H NMR (400 MHz, CDCl3) δ 7.35–7.22 (m, 5H), 5.64 (dd, J = 7.5, 15.6 Hz, 1H), 5.47 (dd, J = 7.4, 
15.6 Hz, 1H), 4.91 (d, J = 4.4 Hz, 1H), 4.61–4.35 (AB quart, J = 12.0 Hz, 2H), 4.21 (dd, J = 2.6, 7.5 Hz, 1H), 4.03 
(m, 1H), 3.70 (dd, J = 7.0, 9.0 Hz, 1H), 3.44–3.26 (m, 3H), 3.32 (s, 3H), 3.29 (s, 3H), 2.56 (m, 1H), 2.23 (m, 1H), 
2.08 (dd, J = 7.2, 12.4 Hz, 1H), 1.90 (m, 1H), 1.68–1.59 (m, 1H), 1.66 (dd, J = 4.8, 12.4 Hz, 1H), 1.42–1.38 (m, 
1H), 1.32–1.24 (m, 1H), 1.09 (d, J = 7.2 Hz, 3H), 0.98 (d, J = 7.2 Hz, 3H), 0.94 (d, J = 7.2 Hz, 3H), 0.89 (s, 9H), 
0.88 (s, 9H), 0.79 (d, J = 6.8 Hz, 3H), 0.07 (s, 6H), 0.01 (s, 6H). 
(Z)-51: Rf 0.75 (hexane / Et2O = 4/1); [α]D24 +7.6 (c 0.79, CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.37–7.22 (m, 
5H), 5.52 (dd, J = 8.4, 11.2 Hz, 1H), 5.42 (dd, J = 10.6, 11.2 Hz, 1H), 4.92 (dd, J = 1.3, 5.0 Hz, 1H), 4.61–4.59 (m, 
1H), 4.59–4.39 (AB quart, J = 12.0 Hz, 2H), 4.03 (ddd, J = 3.0, 3.0, 9.6 Hz, 1H), 3.74 (dd, J = 6.8, 10.0 Hz, 1H), 
3.43 (dd, J = 7.4, 10.2 Hz, 1H), 3.37 (dd, J = 6.8, 10.2 Hz, 1H), 3.32 (s, 3H), 3.31 (s, 3H), 3.22 (ddd, J = 2.4, 6.6, 
9.5 Hz, 1H), 2.70 (ddq, J = 6.6, 10.6, 7.2 Hz, 1H), 2.20 (dddq, J = 6.8, 7.4, 8.8, 6.8 Hz, 1H), 2.05 (ddd, J = 1.3, 7.4, 
12.6 Hz, 1H), 1.91 (dddq, J = 3.0, 6.8, 7.4, 7.2 Hz, 1H), 1.68 (ddd, J = 5.0, 8.8, 12.6 Hz, 1H), 1.71–1.63 (m, 1H), 
1.40 (ddd, J = 2.4, 9.6, 14.2 Hz, 1H), 1.33 (ddd, J = 3.0, 9.6, 14.2 Hz, 1H), 1.09 (d, J = 6.8 Hz, 3H), 0.98 (d, J = 7.2 
Hz, 3H), 0.96 (d, J = 7.2 Hz, 3H), 0.90 (s, 9H), 0.89 (s, 9H), 0.79 (d, J = 7.2 Hz, 3H), 0.08 (s, 3H), 0.07 (s, 3H), 
0.033 (s, 3H), 0.029 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 139.8, 135.1, 130.7, 128.4 (2C), 127.7 (2C), 127.4, 
105.2, 87.8, 81.4, 75.2, 70.8, 70.0, 65.7, 55.3, 57.1, 46.5, 42.7, 42.5, 36.14, 36.10, 34.2, 26.4 (3C), 26.2 (3C), 20.3, 
18.5, 18.5, 17.6, 10.8, 10.1, –3.6, –4.1, –5.10, –5.14; IR (CHCl3) 2957, 2930, 1471, 1463, 1256, 1221, 1188, 1094, 
1065, 785, 767, 758, 669 cm–1; HRMS (ESI) m/z 715.4784 (calcd for C39H72NaO6Si2 [M+Na]+, Δ +1.9 mmu). 
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Secondary alcohol 52. A mixture of olefin 51 (44.8 mg, 64.7 µmol, E/Z = 1/1.5), NaHCO3 (10.9 mg, 0.129 mmol), 
and 20% Pd(OH)2 on carbon (9.1 mg) in dry EtOH (0.65 mL) was stirred under a hydrogen atmosphere for 45 h at 
room temperature. The mixture was filtered through a pad of Celite, and the residue was washed with EtOAc. The 
filtrate and the washings were combined and concentrated. The crude oil was purified with a SiO2 column 
chromatography (FL60D 0.8 g, hexane / EtOAc = 20/1 to 10/1) to give secondary alcohol 52 (28.8 mg, 74%) as a 
colorless oil. 52: Rf 0.52 (hexane / EtOAc = 3:1); 1H NMR (400 MHz, CDCl3) δ 4.91 (d, J = 5.0 Hz, 1H), 3.99 (m, 
1H), 3.86 (m, 1H), 3.57 (t, J = 7.5 Hz, 1H), 3.48 (dd, J = 7.5, 10.2 Hz, 1H), 3.37 (dd, J = 6.6, 10.2 Hz, 1H), 3.33 (s, 
3H), 3.31 (s, 3H), 3.23 (m, 1H), 2.74 (br d, J = 4.1 Hz, 1H), 2.34–2.22 (m, 1H), 2.08 (dd, J = 7.0, 12.7 Hz, 1H), 
1.94–1.84 (m, 1H), 1.82–1.57 (m, 4H), 1.56–1.39 (m, 2H), 1.33 (m, 2H), 1.06 (d, J = 6.5 Hz, 3H), 0.95 (d, J = 7.0 
Hz, 3H), 0.88 (s, 18H), 0.86 (d, J = 7.0 Hz, 3H), 0.81 (d, J = 6.8 Hz, 3H), 0.06 (s, 6H), 0.02 (s, 6H). 
 
 
DMBOM ether 53. To a stirred solution of secondary alcohol 52 (28.8 mg, 47.6 µmol) in dry CH2Cl2 (0.48 mL) 
cooled at 0 °C were added diisopropylethylamine (0.33 mL, 1.9 mmol) and a 1.1 M solution of (3,4-
dimethoxybenzyloxy)methyl chloride in CH2Cl2 (0.43 mL, 0.47 mmol). After being stirred at 0 °C for 18 h, the 
reaction was quenched by addition of MeOH (2 mL) and NaHCO3 (50 mg). The resulting mixture was stirred at 
room temperature for 1 h, diluted with water (5 mL) at 0 °C, and extracted with hexane (5 mL × 3). The combined 
extracts were washed with sat. NaHCO3 aq., water, and brine, successively, dried with Na2SO4, and concentrated. 
The crude oil was purified with a SiO2 column chromatography (FL60D 1.5 g, hexane / Et2O = 20/1 to 7/1) to give 
DMBOM ether 53 (36.5 mg, 98%) as a colorless oil. 53: Rf 0.61 (benzene / Et2O = 6:1); 1H NMR (400 MHz, CDCl3) 
δ 6.91 (m, 2H), 6.82 (d, J = 8.0 Hz, 1H), 4.89 (d, J = 4.6 Hz, 1H), 4.85 (d, J = 7.3 Hz, 1H), 4.82 (d, J = 7.3 Hz, 1H), 
4.59 (s, 2H), 4.07 (m, 1H), 3.99 (m, 1H), 3.89 (s, 3H), 3.87 (s, 3H), 3.58 (dd, J = 6.5, 9.7 Hz, 1H), 3.44 (dd, J = 7.6, 
10.0 Hz, 1H), 3.36 (dd, J = 6.5, 10.0 Hz, 1H), 3.28 (s, 6H), 3.21 (m, 1H), 2.28–2.19 (m, 1H), 2.09 (dd, J = 7.6, 12.7 
Hz, 1H), 1.93–1.85 (m, 1H), 1.78–1.69 (m, 1H), 1.68–1.55 (m, 5H), 1.54–1.43 (m, 1H), 1.36–1.23 (m, 2H), 1.10 (d, 
J = 6.8 Hz, 3H), 0.89 (s, 18H), 0.88 (d, J = 7.2 Hz, 3H), 0.86 (d, J = 6.8 Hz, 3H), 0.81 (d, J = 7.0 Hz, 3H), 0.06 (s, 
6H), 0.02 (s, 6H). 
 
 
Aldehyde 54. DMBOM ether 53 (963 mg, 1.23 mmol) was dissolved in a 0.5 M solution of NH4F in dry MeOH 
(24.6 mL, 12.3 mmol). The resulting mixture was stirred for 20 h at 40 °C, SiO2 (0.8 g) was added, and concentrated. 
The residue was suspended in EtOAc, filtered through a small plug of cotton, and washed with EtOAc. After the 
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filtrate and washings were concentrated, the crude material was purified with a SiO2 column chromatography (BW-
820MH 12 g, hexane / EtOAc = 3/1 to 1/1) to give primary alcohol 53a (828 mg, quant.) as a colorless oil. 53a: Rf 
0.43 (hexane / EtOAc = 1/1); [α]D21 –0.70 (c 1.1, CHCl3); 1H NMR (270 MHz, CDCl3) δ 6.94–6.80 (m, 3H), 4.88 
(d, J = 4.6 Hz, 1H), 4.83 (s, 2H), 4.58 (s, 2H), 4.05 (m, 1H), 3.88 (s, 3H), 3.87 (s, 3H), 3.87 (m, 1H), 3.68 (dd, J = 
4.6, 11.1 Hz, 1H), 3.56 (dd, J = 6.8, 10.1 Hz, 1H), 3.47 (dd, J = 6.5, 11.1 Hz, 1H), 3.29 (s, 3H), 3.28 (s, 3H), 3.15 
(m, 1H), 2.65 (br s, 1H), 2.21 (m, 1H), 2.09 (dd, J = 7.6, 12.7 Hz, 1H), 1.89–1.79 (m, 3 H), 1.79–1.38 (m, 7H), 1.10 
(d, J = 6.5 Hz, 3H), 0.94 (d, J = 7.3 Hz, 3H), 0.89 (s, 9H), 0.88 (d, J = 6.5 Hz, 3H), 0.86 (d, J = 7.3 Hz, 3H), 0.08 
(s, 3H), 0.08 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 149.0, 148.6, 130.7, 120.5, 111.4, 110.9, 104.7, 94.5, 87.2, 
82.5, 78.5, 73.0, 69.4, 64.9, 56.8, 55.9, 55.8, 54.5, 43.5, 42.4, 40.1, 35.9, 34.5, 34.1, 30.6, 27.1, 25.9 (3C), 20.1, 
18.0, 15.4, 12.9, 8.8, –4.3, –4.4; IR (CHCl3) 3448, 1606, 1512, 1464, 1383, 1259, 1032, 955, 935, 835 cm–1; HRMS 
(ESI) m/z 693.4366 (calcd for C36H66NaO9Si [M+Na]+, Δ –0.8 mmu). 
To a stirred solution of primary alcohol 53a (194 mg, 0.289 mmol) in dry CH2Cl2 (2.9 mL) were added dry pyridine 
(0.23 mL, 2.9 mmol) and Dess–Martin periodinane (194 mg, 0.46 mmol). After being stirred for 2 h at room 
temperature, the resulting mixture was diluted with a mixture of sat. Na2S2O3 aq. – sat. NaHCO3 aq. – water (10 
mL, 1:1:1 [v/v/v]) at 0 °C and extracted with EtOAc (10 mL × 2). The combined extracts were washed with water 
and brine, dried with Na2SO4, and concentrated. The crude material was purified with a SiO2 column 
chromatography (BW-820MH 5 g, hexane / EtOAc = 5/1) to give aldehyde 54 (184 mg, 96%) as a light yellow oil. 
54: Rf 0.70 (hexane / EtOAc = 1/1); [α]D20 +18 (c 1.0, CHCl3); 1H NMR (270 MHz, CDCl3) δ 9.70 (d, J = 1.6 Hz, 
1H), 6.93–6.81 (m, 3H), 4.88 (d, J = 4.6 Hz, 1H), 4.83 (AB quart, J = 6.8 Hz, 2H), 4.58 (s, 2H), 4.20 (dt, J = 8.4, 
3.5 Hz, 1H), 4.05 (m, 1H), 3.89 (s, 3H), 3.87 (s, 3H), 3.56 (dd, J = 6.8, 10.0 Hz, 1H), 3.28 (s, 3H), 3.27 (s, 3H), 
3.23–3.17 (m, 1H), 2.53 (m, 1H), 2.24 (m, 1H), 2.09 (dd, J = 7.6, 12.4 Hz, 1H), 1.79 (m, 1H), 1.65–1.21 (m, 8H), 
1.10 (d, J = 7.0 Hz, 6H), 0.90–0.86 (m, 12H), 0.85 (d, J = 7.0 Hz, 3H), 0.10 (s, 3H), 0.08 (s, 3H); 13C NMR (100 
MHz, CDCl3) δ 204.1, 148.9, 148.5, 130.8, 120.5, 111.3, 110.9, 104.7, 94.5, 87.1, 81.4, 78.5, 70.2, 69.4, 56.5, 55.9, 
55.8, 54.5, 52.6, 43.5, 42.5, 35.9, 35.1, 34.4, 30.7, 27.0, 25.8 (3C), 20.1, 18.0, 15.4, 9.2, 8.8, –4.3, –4.4; IR (CHCl3) 
3690, 3447, 3025, 3020, 2957, 2935, 1718, 1602, 1516, 1465, 1382, 1260, 1224, 1158, 1140, 1095, 1029, 938, 852, 
840, 800, 793, 770 cm–1; HRMS (ESI) m/z 691.4221 (calcd for C36H64NaO9Si [M+Na]+, Δ +0.4 mmu). 
 
 
Secondary alcohol 55. To a stirred solution of aldehyde 54 (179 mg, 0.268 mmol) in dry THF (2.7 mL) cooled at 
–78 °C was added a 1.0 M allylmagnesium bromide in Et2O (0.8 mL, 0.8 mmol). After being stirred for 1 h at –
78 °C, a 1.0 M allylmagnesium bromide in Et2O (0.8 mL, 0.8 mmol) was added, stirred for 1 h, a 1.0 M 
allylmagnesium bromide in Et2O (0.8 mL, 0.8 mmol) was added, and stirred for 2 h. The resulting mixture was 
quenched with sat. NH4Cl aq. (20 mL) and extracted with EtOAc (10 mL × 3). The combined extracts were washed 
with water and brine, dried with Na2SO4, and concentrated. The crude material was purified with a SiO2 column 
chromatography (FL60D 7 g, hexane / EtOAc = 6/1 to 4/1) to give secondary alcohol 55 (137 mg, 72%) and its 22R 
isomer (52 mg, 27%) as colorless oils. (22S)-55: Rf 0.28 (hexane / EtOAc = 2/1); [α]D26 +4.2 (c 1.0, CHCl3); 1H 
NMR (270 MHz, CDCl3) δ 6.93–6.81 (m, 3H), 5.79 (m, 1H), 5.13–5.03 (m, 2H), 4.89 (d, J = 4.6 Hz, 1H), 4.83 (AB 
quart, J = 7.3 Hz, 2H), 4.59 (s, 2H), 4.11–4.02 (m, 2H), 3.94–3.81 (m, 1H), 3.89 (s, 3H), 3.87 (s, 3H), 3.57 (dd, J = 
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6.5, 10.0 Hz, 1H), 3.48 (br s, 1H), 3.29 (s, 3H), 3.26 (s, 3H), 3.06 (m, 1H), 2.36–2.06 (m, 3H), 2.10 (dd, J = 7.8, 
13.5 Hz, 1H), 1.79–1.42 (m, 10H), 1.11 (d, J = 6.5 Hz, 3H), 1.01 (d, J = 7.0 Hz, 3H), 0.89–0.88 (m, 12H), 0.87 (d, 
J = 7.3 Hz, 3H), 0.10 (s, 3H), 0.09 (s, 3H); 13C NMR (150 MHz, CDCl3) δ 149.0, 148.6, 135.5, 130.8, 120.5, 116.9, 
111.4, 110.9, 104.7, 94.5, 87.2, 82.1, 78.7, 76.8, 70.5, 69.5, 56.8, 56.2, 55.9, 54.5, 43.9, 42.6, 39.6, 39.5, 35.9, 35.2, 
34.7, 30.7, 27.6, 26.3, 20.1, 18.0, 15.0, 10.9, 8.9, –4.2, –4.4; IR (CHCl3) 3460, 3025, 3019, 3010, 2934, 1596, 1516, 
1465, 1421, 1382, 1262, 1225, 1158, 1140, 1095, 1028, 837, 797, 781, 771 cm–1; HRMS (ESI) m/z 733.4686 (calcd 
for C39H70NaO9Si [M+Na]+, Δ –0.1 mmu). 
(22R)-55: Rf 0.20 (hexane / EtOAc = 2/1); [α]D26 –12 (c 0.86, CHCl3); 1H NMR (400 MHz, CDCl3) δ 6.93–6.81 (m, 
3H), 5.86 (m, 1H), 5.14–5.07 (m, 2H), 4.88 (d, J = 4.9 Hz, 1H), 4.83 (s, 2H), 4.58 (s, 2H), 4.13 (m, 1H), 4.06 (br t, 
J = 6.4 Hz, 1H), 3.88 (s, 3H), 3.87 (s, 3H), 3.57 (dd, J = 6.8, 10.0 Hz, 1H), 3.40-3.14 (m, 2H), 3.32 (s, 3H), 3.28 (s, 
3H), 2.86 (br s, 1H), 2.39 (m, 1H), 2.23 (m, 1H), 2.15–2.01 (m, 2H), 1.89–1.21 (m, 10H), 1.10 (d, J = 6.8 Hz, 3H), 
0.884 (s, 9H), 0.878 (d, J = 6.8 Hz, 3H), 0.86 (d, J = 6.8 Hz, 3H), 0.81 (d, J = 7.0 Hz, 3H), 0.07 (s, 3H), 0.06 (s, 
3H); 13C NMR (150 MHz, CDCl3) δ 148.9, 148.5, 135.4, 130.8, 120.5, 117.3, 111.4, 110.9, 104.6, 94.4, 87.1, 83.4, 
78.4, 72.9, 70.3, 69.4, 56.9, 55.9, 55.8, 54.5, 44.7, 43.4, 42.5, 39.5, 35.8, 34.5, 32.7, 30.5, 26.7, 25.9 (3C), 20.1, 
18.0, 15.7, 10.2, 8.9, –4.1, –4.6; IR (CHCl3) 3464 (br), 1593, 1518, 1464, 1381, 1261, 1032, 993, 955, 935 cm–1; 
HRMS (ESI) m/z 733.4677 (calcd for C39H70NaO9Si [M+Na]+, Δ –1.0 mmu). 
 
 
C20–C35 segment 41. To a stirred solution of secondary alcohol (22S)-55 (2.16 g, 3.04 mmol) in dry THF (30 mL) 
cooled at 0 °C were added iodomethane (5.7 mL, 91 mmol) and sodium hydride (1.34 g of 60% dispersion in mineral 
oil, 33 mmol). After being stirred for 14 h at room temperature, the resulting mixture was quenched with cold water 
(50 mL) and extracted with Et2O (25 mL × 3). The combined extracts were washed with sat. Na2S2O3 aq., water, 
and brine, successively, dried with Na2SO4, and concentrated. The crude material was purified with a Yamazen 
preparative silica gel column (90 g, hexane / EtOAc = 10/1) to give methyl ether 55a (2.14 g, 97%) as a colorless 
oil. 55a: Rf 0.55 (hexane / EtOAc = 2/1); [α]D25 –4.0 (c 0.73, CHCl3); 1H NMR (600 MHz, CDCl3) δ 6.93–6.81 (m, 
3H), 5.84 (m, 1H), 5.16–5.04 (m, 2H), 4.88 (d, J = 4.6 Hz, 1H), 4.83 (s, 2H), 4.59 (s, 2H), 4.06 (m, 1H), 3.93–3.85 
(m, 1H), 3.89 (s, 3H), 3.87 (s, 3H), 3.57 (dd, J = 6.8, 10.0 Hz, 1H), 3.32 (s, 6H), 3.28 (s, 3H), 3.19 (m, 1H), 2.93 
(m, 1H), 2.40–2.18 (m, 3H), 2.11 (m, 1H), 1.82–1.15 (m, 10H), 1.10 (d, J = 6.8 Hz, 3H), 0.93–0.84 (m, 9H), 0.88 
(s, 9H), 0.04 (s, 3H), 0.02 (s, 3H); 13C NMR (150 MHz, CDCl3) δ 149.2, 148.8, 134.8, 131.1, 120.7, 117.3, 111.6, 
111.2, 104.8, 94.6, 87.4, 83.0, 82.2, 78.7, 70.4, 69.6, 57.5, 57.3, 56.1, 56.0, 54.6, 43.6, 42.7 (2C), 36.1, 35.1, 34.9, 
33.0, 30.8, 27.3, 26.1 (3C), 20.3, 18.2, 15.9, 9.0, 8.9, -3.7, -4.5; IR (CHCl3) 1518, 1464, 1381, 1257, 1095, 1032, 
993, 935, 835 cm–1; HRMS (ESI) m/z 747.4858 (calcd for C40H72NaO9Si [M+Na]+, Δ +1.5 mmu). 
To a stirred solution of methyl ether 55a (14.0 mg, 19.3 μmol) in dry THF (0.36 mL) was added a 1.0 M solution 
of TBAF in THF (97 μL, 97 μmol). After being stirred for 14 h at room temperature and for 10 h at 40 °C, the 
reaction mixture was quenched with sat. NH4Cl aq. (2 mL) and water (1 mL), and extracted with EtOAc (5 mL × 
3). The combined extracts were washed with brine, dried with Na2SO4, and concentrated. The crude material was 
purified with a SiO2 column chromatography (FL60D 0.5 g, hexane / EtOAc = 5/1 to 2/1) to give the C20–C35 
segment 41 (11.8 mg, quant.) as a colorless oil. 41: Rf 0.43 (hexane / EtOAc = 1/1); [α]D24 +4.1 (c 0.71, CHCl3); 1H 
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NMR (270 MHz, CDCl3) δ 6.93–6.81 (m, 3H), 5.79 (m, 1H), 5.14–5.03 (m, 2H), 4.89 (d, J = 4.6 Hz, 1H), 4.84 (AB 
quart, J = 6.8 Hz, 2H), 4.59 (s, 2H), 4.06 (m, 1H), 3.89 (s, 3H), 3.87 (s, 3H), 3.75 (m, 1H), 3.62 (m, 1H), 3.57 (dd, 
J = 6.5, 10.0 Hz, 1H), 3.54 (dt, J = 2.7, 7.0 Hz, 1H), 3.38 (s, 3H), 3.37 (m, 1H), 3.36 (s, 3H), 3.29 (s, 3H), 2.44 (m, 
1H), 2.29-2.12 (m, 2H), 2.09 (dd, J = 7.6, 12.4 Hz, 1H), 1.80–1.35 (m, 10H), 1.11 (d, J = 6.5 Hz, 3H), 0.92–0.87 
(m, 9H); 13C NMR (150 MHz, CDCl3) δ 149.2, 148.8, 135.4, 131.1, 120.7, 117.0, 111.6, 111.2, 104.9, 94.8, 87.4, 
83.0, 82.4, 78.7, 71.5, 69.6, 58.2, 57.6, 56.1, 56.0, 54.7, 43.7, 42.6 (2C), 40.1, 36.5, 36.1, 34.9, 30.7, 28.1, 20.3, 
15.5, 11.7, 9.0; IR (CHCl3) 3481, 2934, 1516, 1457, 1380, 1265, 1095, 1030 cm–1; HRMS (ESI) m/z 633.3980 
(calcd for C34H58NaO9 [M+Na]+, Δ +0.1 mmu). 
 
 
RCM precursor 44. To a stirred solution of the C1–C19 segment 40 (7.2 mg, 10 μmol) and the C20–C35 segment 
41 (5.2 mg, 8.7 μmol) in dry CH2Cl2 (0.12 mL) cooled at 0 °C were added triethylamine (5 μL, 36 μmol), 2-methyl-
6-nitrobenzoic anhydride (MNBA) (4.5 mg, 13 μmol), and a 0.5 M solution of N,N-dimethyl-4-aminopyridine in 
dry CH2Cl2 (4.5 μL, 2.3 μmol). After being stirred for 34 h at room temperature, the reaction mixture was quenched 
with sat. NaHCO3 aq. (2 mL) and extracted with EtOAc (3 mL × 3). The combined extracts were washed with brine, 
dried with Na2SO4, and concentrated. The crude oil was purified with a SiO2 column chromatography (FL60D 0.6 
g, hexane / acetone = 10/1 to 9/1) to give the RCM precursor 44 (10.5 mg, 93%) as a colorless oil. 44: Rf 0.52 
(hexane / EtOAc = 1/1); [α]D25 –8.3 (c 1.26, CHCl3); 1H NMR (600 MHz, CDCl3) δ 8.33 (s, 2H), 7.71 (s, 1H), 7.70–
7.65 (m, 4H),7.42–7.33 (m, 6H), 6.97–6.80 (m, 4H), 6.68 (dd, J = 11.2, 17.8 Hz, 1H), 6.34 (d, J = 17.8 Hz, 1H), 
6.14 (d, J = 15.9 Hz, 1H), 5.78 (d, J = 11.2 Hz, 1H), 5.72 (m, 1H), 5.10–5.01 (m, 3H), 4.87 (d, J = 4.6 Hz, 1H), 4.82 
(s, 2H), 4.57 (s, 2H), 4.42 (d, J = 9.7 Hz, 1H), 4.32 (m, 1H), 4.05 (m, 1H), 3.88 (s, 3H), 3.87 (s, 3H), 3.56 (m, 1H), 
3.46 (m, 1H), 3.26 (s, 3H), 3.22 (s, 3H), 3.21 (s, 3H), 3.17 (s, 3H), 3.03 (m, 1H), 2.80 (m, 1H), 2.54–2.04 (m, 8H), 
1.79–1.37 (m, 10H), 1.09 (d, J = 6.2 Hz, 3H), 1.04 (s, 9H), 0.88–0.79 (m, 12H); 13C NMR (150 MHz, CDCl3) δ 
201.6, 170.1, 161.9, 156.0, 155.4, 149.0, 148.6, 143.2, 140.0, 139.0, 138.5, 137.2, 135.8 (4C), 134.6, 133.5 (2C), 
132.9, 131.7, 130.8 (2C), 129.9 (2C), 127.7 (4C), 124.2, 122.6, 120.5, 117.2, 111.4, 110.9, 104.7, 94.4, 87.2, 81.8, 
81.1, 78.4, 77.6, 73.6, 69.4, 69.0, 57.8, 57.5, 57.0, 55.9, 55.8, 54.5, 47.0, 43.5, 42.5, 41.6, 39.7 (2C), 35.9, 35.6, 
35.2, 31.5, 30.6, 27.04, 27.00 (3C), 20.1, 19.3, 15.6, 14.2, 8.9, 8.8; IR (CHCl3) 2931, 1730, 1669, 1627, 1516, 1462, 
1380, 1264, 1103, 1029, 755, 704 cm–1; HRMS (ESI) 1310.6534 (calcd for C72H97N3NaO16Si [M+Na]+, Δ –0.2 
mmu). 
 
63 
 
 
Macrolactone 39. To a stirred solution of the RCM precursor 44 (137 mg, 0.106 mmol) in dry CH2Cl2 (101 mL) 
was added a 6.4 mM solution of Zhan catalyst 1B (20c) in dry CH2Cl2 (5 mL, 32 μmol). After being stirred for 24 
h at reflux temperature, the reaction mixture was concentrated. The crude material was purified with two SiO2 
column chromatographies (FL60D 6 g, hexane / EtOAc = 3/1 to 1/1; FL60D 0.6 g, hexane / EtOAc = 3/1 to 1/1) to 
give macrolactone (19E)-39 (62.5 mg, 47%) and its stereoisomer (19Z)-39 (37.1 mg, 28%) as colorless oils. (19E)-
39: Rf 0.21 (hexane / EtOAc = 2/3); [α]D25 –33 (c 1.15, CHCl3); 1H NMR (400 MHz, CDCl3) δ 8.11 (s, 1H), 8.06 
(s, 1H), 7.74–7.62 (m, 4H), 7.67 (s, 1H), 7.45–7.32 (m, 4H), 7.18–7.03 (m, 2H), 6.91 (s, 1H), 6.90 (d, J = 8.4 Hz, 
1H), 6.81 (d, J = 8.4 Hz, 1H), 6.32 (d, J = 16.0 Hz, 1H), 5.90 (d, J = 16.4 Hz, 1H), 5.13 (m, 1H), 4.86 (d, J = 4.4 
Hz, 1H), 4.81 (d, J = 6.8 Hz, 1H), 4.79 (d, J = 6.8 Hz, 1H), 4.56 (s, 2H), 4.41 (ddt, J = 3.2, 5.2, 5.2 Hz, 1H), 4.37 
(d, J = 9.6 Hz, 1H), 4.19 (dq, J = 9.6, 6.8 Hz, 1H), 4.02 (m, 1H), 3.87 (s, 3H), 3.86 (s, 3H), 3.54 (dd, J = 10.0, 6.8 
Hz, 1H), 3.29 (m, 1H), 3.26 (s, 3H), 3.24 (s, 3H), 3.22 (s, 3H), 3.10 (s, 3H), 2.99 (m, 1H), 2.79–2.61 (m, 3H), 2.42 
(ddd, J = 8.8, 8.8, 14.8 Hz, 1H), 2.27 (m, 1H), 2.20 (m, 1H), 2.06 (dd, J = 7.4, 12.6 Hz, 1H), 1.83–1.22 (m, 11H), 
1.08 (d, J = 6.8 Hz, 3H), 1.03 (s, 9H), 0.85 (m, 6H), 0.84 (d, J = 6.8 Hz, 3H), 0.78 (d, J = 6.8 Hz, 3H); 13C NMR 
(100 MHz, CDCl3) δ 203.0, 170.4, 162.5, 156.5, 155.5, 148.9, 148.5, 143.7, 139.6, 139.1, 137.2, 136.9 (2C), 135.9 
(4C), 135.1, 133.7, 133.5, 131.5, 130.8, 130.2, 128.8, 129.7, 127.6 (4C), 120.5, 116.4, 111.3, 110.9, 104.6, 94.4, 
87.1, 81.7, 79.8, 78.4, 77.1, 73.6, 69.4, 68.8, 57.6, 57.4, 56.2, 55.9, 55.8, 54.4, 43.4, 42.8, 42.4, 40.9, 39.7, 39.5, 
35.8, 35.0, 32.7, 32.6, 30.7, 27.1 (3C), 26.9, 20.1, 19.2, 15.6, 14.7, 8.8, 8.1; IR (CHCl3) 3008, 2961, 2934, 1729, 
1659, 1609, 1593, 1561, 1427, 1263, 1240, 1177, 1158, 1138, 1097, 1029, 980, 918, 840, 728, 704 cm–1; HRMS 
(ESI) m/z 1282.6223 (calcd for C70H93N3NaO16Si [M+Na]+, Δ –2.0 mmu). 
(19Z)-39: Rf 0.33 (hexane / EtOAc = 2/3); [α]D25 –35 (c 0.037, CHCl3); 1H NMR (500 MHz, CDCl3) δ 8.10 (s, 1 H), 
8.09 (s, 1 H), 7.67–7.65 (m, 4 H), 7.61 (s, 1 H), 7.44–7.34 (m, 6 H), 7.00–6.94 (m, 1 H), 6.92–6.81 (m, 3 H), 6.38–
6.30 (m, 2 H), 5.82 (d, J = 16.1 Hz, 1 H), 5.26 (m, 1 H), 4.88 (d, J = 4.7 Hz, 1 H), 4.82 (d, J = 6.8 Hz, 1 H), 4.80 (d, 
J = 6.8 Hz, 1 H), 4.57 (s, 2 H), 4.35 (d, J = 8.9 Hz, 1 H), 4.04–3.98 (m, 2 H), 3.88 (s, 3 H), 3.87 (s, 3 H), 3.58–3.51 
(m, 3 H), 3.37 (s, 3 H), 3.29 (s, 3 H), 3.25 (s, 3 H), 3.23–3.18 (m, 2 H), 3.14 (s, 3 H), 2.83 (m, 1 H), 2.61 (m, 2 H), 
2.23 (m, 2 H), 2.10–2.03 (m, 2 H), 1.70–1.20 (m, 7 H), 1.15–1.12 (m, 1 H), 1.09 (d, J = 6.6 Hz, 3 H), 1.03 (s, 9 H), 
1.01 (d, J = 6.9 Hz, 3 H), 0.95 (m, 1 H), 0.89 (m, 1 H), 0.87 (d, J = 7.0 Hz, 3 H), 0.85 (d, J = 7.0 Hz, 3 H), 0.76 (d, 
J = 6.9 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ 202.7, 170.2, 161.8, 156.5, 155.7, 149.0, 148.6, 143.6, 141.0, 139.3, 
137.4, 137.3, 136.9, 135.8 (4C), 134.7, 133.6, 133.5, 131.5, 130.8, 130.7, 129.9 (2C), 127.7 (4C), 120.5, 114.1, 
111.4, 110.9, 104.7, 94.5, 87.2, 81.8, 81.1, 78.4, 76.6, 74.2, 70.6, 69.8, 69.4, 58.2, 58.0, 56.8, 55.9, 55.8, 54.5, 43.5, 
43.4, 42.5, 41.5, 40.3, 39.0, 35.9, 35.2, 33.3, 31.8, 30.7, 27.0 (3C), 20.1, 19.2, 15.5, 14.3, 9.7, 8.8; IR (CHCl3) 2929, 
1726, 1670, 1516, 1458, 1379, 1263, 1099, 1029, 754, 703 cm–1; HRMS (ESI) m/z 1282.6224 (calcd for 
C70H93N3NaO16Si [M+Na]+, Δ –1.9 mmu). 
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C3 hydroxy analog 62. To a stirred solution of the RCM precursor 44 (9.7 mg, 7.53 μmol) in dry THF (1.0 mL) 
was added a 1.0 M solution of TBAF/AcOH (1:1) in THF (0.23 mL, 0.23 mmol) [prepared by adding AcOH (114.5 
μL, 2.0 mmol) to a 1.0 M solution of TBAF in THF (2.0 mL, 2.0 mmol)]. After being stirred for 21 h at room 
temperature, the reaction mixture was diluted with sat. NaHCO3 aq. (7 mL), and extracted with EtOAc (4 mL × 3). 
The combined extracts were washed with brine, dried with Na2SO4, and concentrated. The crude oil was purified 
with a SiO2 column chromatography (FL60D 0.4 g, hexane / acetone = 5/1 to 3/1) to give C3 hydroxy analog 62 
(7.5 mg, 95%) as a colorless oil. 62: Rf 0.19 (hexane / acetone = 2:3); [α]D25 –26 (c 0.58, CHCl3); 1H NMR (400 
MHz, CDCl3) δ 8.34 (s, 1H), 8.33 (s, 1H), 7.71 (s, 1H), 6.98 (dt, J = 12.7, 5.8 Hz, 1H), 6.92 (s, 1H), 6.90 (d, J = 6.7 
Hz, 1H), 6.82 (d, J = 6.7 Hz, 1H), 6.67 (dd, J = 9.1, 14.1 Hz, 1H), 6.34 (d, J = 14.1 Hz, 1H), 6.28 (d, J = 12.7 Hz, 
1H), 5.77 (d, J = 9.1 Hz, 1H), 5.74 (m, 1H), 5.20 (m, 1H), 5.11 (d, J = 13.7 Hz, 1H), 5.06 (d, J = 8.1 Hz, 1H), 4.88 
(d, J = 3.8 Hz, 1H), 4.83 (d, J = 5.5 Hz, 1H), 4.81 (d, J = 5.5 Hz, 1H), 4.57 (s, 2H), 4.42 (d, J = 7.7 Hz, 1H), 4.18 
(m, 1H), 4.05 (m, 1H), 3.88 (s, 3H), 3.86 (s, 3H), 3.55 (m, 3H), 3.29 (s, 6H), 3.27 (s, 3H), 3.19 (s, 3H), 2.96 (m, 
1H), 2.55–2.38 (m, 5H), 2.27–2.14 (m, 2H), 2.08 (dd, J = 5.9, 10.2 Hz, 1H), 1.88–1.81 (m, 1H), 1.80–1.65 (m, 3H), 
1.65–1.45 (m, 6H), 1.09 (d, J = 5.2 Hz, 3H), 0.89 (d, J = 5.9 Hz, 3H), 0.88 (d, J = 5.5 Hz, 3H), 0.87 (d, J = 4.8 Hz, 
3H), 0.85 (d, J = 5.1 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 202.0, 171.7, 161.9, 156.0, 155.5, 148.9, 148.5, 143.0, 
139.8, 139.0, 138.6, 137.3 (2C), 134.6, 132.8, 131.6, 130.7, 124.2, 122.5, 120.5, 117.3, 111.3, 110.9, 104.7, 94.5, 
87.1, 81.7, 80.7, 78.4, 77.2, 74.0, 69.4, 66.9, 57.8, 57.5, 57.0, 55.9, 55.8, 54.5, 46.8, 43.4, 42.4, 41.5, 39.6, 39.3, 
35.9, 35.4, 35.3, 32.3, 30.5, 27.4, 20.1, 15.5, 14.2, 9.4, 8.8; IR (CHCl3) 3632, 3009, 2937, 2836, 1721, 1665, 1630, 
1516, 1464, 1420, 1380, 1264, 1222, 1216, 1211, 1157, 1139, 1096, 1029, 980, 945, 919, 788, 784, 774 cm–1; 
HRMS (ESI) m/z 1072.5383 (calcd for C56H79N3NaO16 [M+Na]+, Δ +2.5 mmu). 
 
 
C3 acetoxy analog 63. To a stirred solution of C3 hydroxy analog 62 (4.7 mg, 4.48 μmol) in dry pyridine (0.45 
mL) cooled at 0 °C were added acetic anhydride (130 μL, 1.4 mmol) and N,N-dimethyl-4-aminopyridine (1.2 mg, 
9.0 μmol). After being stirred for 8 h at room temperature, the reaction was quenched with sat. NaHCO3 aq. (3 mL) 
at 0 °C, and extracted with EtOAc (3 mL × 3). The combined extracts were washed with brine, dried with Na2SO4, 
and concentrated. The crude material was purified with a SiO2 column chromatography (FL60D 0.4 g, hexane / 
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EtOAc = 1/1 to 2/3) to give C3 acetoxy analog 63 (4.7 mg, 96%) as a colorless oil. 63: Rf 0.40 (hexane / EtOAc = 
2/3); 1H NMR (400 MHz, CDCl3) δ 8.35 (s, 1H), 8.33 (s, 1H), 7.72 (s, 1H), 6.94–6.80 (m, 4H), 6.67 (dd, J = 11.4, 
17.7 Hz, 1H), 6.34 (d, J = 17.7 Hz, 1H), 6.27 (d, J = 15.6 Hz, 1H), 5.83–5.71 (m, 1H), 5.78 (d, J = 11.4 Hz, 1H), 
5.38 (m, 1H), 5.16 (m, 1H), 5.09 (d, J = 17.5 Hz, 1H), 5.06 (d, J = 10.5 Hz, 1H), 4.88 (d, J = 4.7 Hz, 1H), 4.83 (d, 
J = 7.0 Hz, 1H), 4.81 (d, J = 7.0 Hz, 1H), 4.58 (s, 2H), 4.42 (d, J = 9.7 Hz, 1H), 4.05 (m, 1H), 3.88 (s, 3H), 3.87 (s, 
3H), 3.59–3.47 (m, 3H), 3.29 (s, 3H), 3.27 (s, 6H), 3.18 (s, 3H), 3.13 (m, 1H), 2.88 (m, 1H), 2.70–2.51 (m, 4H), 
2.45–2.35 (m, 1H), 2.28–2.15 (m, 2H), 2.08 (dd, J = 7.5, 12.6 Hz, 1H), 2.03 (s, 3H), 1.86–1.44 (m, 9H), 1.09 (d, J 
= 6.6 Hz, 3H), 0.89–0.84 (m, 12H); HRMS (ESI) m/z 1114.5444 (calcd for C58H81N3NaO17 [M+Na]+, Δ −2.0 mmu). 
 
 
C7 silyloxy analog 64. To a stirred solution of the RCM precursor 44 (18.3 mg, 14.2 μmol) in dry MeOH (2.8 mL) 
cooled at –20 °C was added cerium (III) chloride heptahydrate (95.2 mg, 0.26 mmol). The mixture was stirred for 
5 min, and sodium borohydride (8.1 mg, 0.21 mmol) was added. After being stirred at –20 °C for 1 h, the reaction 
was quenched with acetone (130 μL), and stirred for 5 min. The resulting mixture was diluted with EtOAc (2 mL) 
and sat. NH4Cl aq. (7 mL), and extracted with EtOAc (5 mL × 3). The combined extracts were washed with brine, 
dried with Na2SO4, and concentrated. The crude material was purified with a SiO2 column chromatography (BW-
820MH 0.5 g, hexane / acetone = 3/1) to give C7 hydroxy analog 44a (16.6 mg, 91%, a 10:1 diastereomeric mixture 
at C7) as a colorless oil. 44a: Rf 0.45 (hexane / acetone = 2/1); [α]D25 +2.0 (c 1.35, CHCl3); 1H NMR (400 MHz, 
CDCl3) δ 8.32 (s, 1H), 8.31 (s, 1H), 7.71–7.63 (m, 4H), 7.65 (s, 1H), 7.44–7.31 (m, 6H), 6.92 (s, 1H), 6.91 (d, J = 
8.1 Hz, 1H), 6.82 (d, J = 8.1 Hz, 1H), 6.67 (dd, J = 11.3, 17.7 Hz, 1H), 6.34 (d, J = 17.7 Hz, 1H), 5.77 (d, J = 11.3 
Hz, 1H), 5.78–5.60 (m, 2H), 5.43 (dd, J = 5.7, 15.5 Hz, 1H), 5.05 (m, 3H), 4.88 (d, J = 4.7 Hz, 1H), 4.83 (d, J = 6.9 
Hz, 1H), 4.80 (d, J = 6.9 Hz, 1H), 4.58 (s, 2H), 4.31 (m, 1H), 4.24 (m, 1H), 4.18 (d, J = 8.0 Hz, 1H), 4.04 (m, 1H), 
3.87 (s, 3H), 3.86 (s, 3H), 3.56 (dd, J = 6.7, 9.8 Hz, 1H), 3.30–3.13 (m, 3H), 3.28 (s, 3H), 3.27 (s, 3H), 3.23 (s, 6H), 
3.05 (m, 1H), 2.83 (m, 1H), 2.55–2.40 (m, 2H), 2.39–2.30 (m, 2H), 2.30–2.13 (m, 4H), 2.08 (dd, J = 7.4, 12.6 Hz, 
1H), 1.84–1.38 (m, 9H), 1.09 (d, J = 6.6 Hz, 3H), 1.03 (s, 9H), 0.87 (d, J = 7.0 Hz, 3H), 0.83 (d, J = 7.0 Hz, 3H), 
0.81 (d, J = 6.9 Hz, 3H), 0.74 (d, J = 7.1 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ 170.5, 162.0 [160.4], 156.0, 155.3, 
149.0, 148.6, 141.0 [140.7], 139.0, 138.4 [138.1], 136.6, 135.9 (2C), 135.8 (2C), 134.6, 134.0, 133.9, 133.8, 131.6, 
130.8, 130.7 [130.6], 129.7, 129.6, 127.6 (2C), 127.5 (2C), 126.5, 124.2, 122.6 [121.8], 120.5, 117.2, 111.4, 111.0, 
104.7, 94.4, 87.2, 81.8, 81.2, 79.8, 78.4, 73.4, 73.0, 69.9 [69.7], 69.4, 57.9, 57.5, 57.1, 55.9, 55.8, 54.5, 43.5, 42.4, 
42.1, 41.2, 39.7, 39.4, 35.9, 35.7, 35.4, 31.6, 30.6, 27.3, 27.0 (3C), 20.1, 19.3 [19.0], 15.5, 11.4, 8.9, 8.8. Chemical 
shifts of the minor isomers are within parentheses (square brackets); IR (CHCl3) 3492, 3008, 2962, 2934, 2860, 
1724, 1641, 1592, 1516, 1465, 1427, 1382, 1308, 1264, 1240, 1223, 1217, 1210, 1190, 1157, 1139, 1103, 1029, 
980, 942, 918, 822, 774, 766, 744 cm–1; HRMS (ESI) m/z 1312.6681 (calcd for C72H99N3NaO16Si [M+Na]+, Δ –1.1 
mmu). 
To a stirred solution of C7 hydroxy analog 44a (5.5 mg, 4.26 μmol) in dry DMF (0.10 mL) were added 1.0 M 
solution of tert-butyldimethylsilyl chloride in DMF (43 μL, 43 μmol) and imidazole (5.8 mg, 85 μmol). After being 
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stirred for 24 h at room temperature, the resulting mixture was diluted with EtOAc (0.5 mL) and sat. NaHCO3 aq. 
(2 mL), and extracted with EtOAc (2 mL × 3). The combined extracts were washed with water and brine, dried with 
Na2SO4, and concentrated. The crude material was purified with a SiO2 column chromatography (FL60D 0.4 g, 
hexane / acetone = 5/1) to give C7 silyloxy analog 64 (5.6 mg, 93%) as a colorless oil. 64: Rf 0.51 (hexane / acetone 
= 2/1); 1H NMR (400 MHz, CDCl3) δ 8.32 (s, 2H), 7.71–7.66 (m, 4H), 7.64 (s, 1H), 7.42–7.33 (m, 6H), 6.92 (s, 
1H), 6.91 (d, J = 8.2 Hz, 1H), 6.82 (d, J = 8.2 Hz, 1H), 6.67 (dd, J = 11.3, 17.7 Hz, 1H), 6.34 (d, J = 17.7 Hz, 1H), 
5.77 (d, J = 11.3 Hz, 1H), 5.76–5.68 (m, 1H), 5.61 (dt, J = 15.2, 7.6 Hz, 1H), 5.42 (dd, J = 6.4, 15.2 Hz, 1H), 5.09–
5.01 (m, 3H), 4.87 (d, J = 4.7 Hz, 1H), 4.82 (d, J = 6.9 Hz, 1H), 4.80 (d, J = 6.9 Hz, 1H), 4.73 (d, J = 6.1 Hz, 1H), 
4.57 (s, 2H), 4.23 (m, 1H), 4.04 (m, 3H), 3.87 (s, 3H), 3.86 (s, 3H), 3.56 (dd, J = 6.7, 9.8 Hz, 1H), 3.26 (s, 3H), 3.22 
(s, 3H), 3.21 (s, 3H), 3.06 (m, 1H), 2.82 (m, 1H), 2.56–1.95 (m, 9H), 1.82–1.38 (m, 9H), 1.09 (d, J = 6.6 Hz, 3H), 
1.04 (s, 9H), 0.91 (s, 9H), 0.86 (d, J = 6.6 Hz, 3H), 0.83 (d, J = 7.0 Hz, 3H), 0.79 (d, J = 6.8 Hz, 3H), 0.62 (d, J = 
6.8 Hz, 3H), 0.06 (s, 3H), −0.01 (s, 3H). 
 
 
RCM of C3 hydroxy analog 62. To a stirred solution of C3 hydroxy analog 62 (7.2 mg, 6.86 μmol) in dry CH2Cl2 
(7.1 mL) was added a 4.1 mM solution of Zhan catalyst 1B (20c) in dry CH2Cl2 (0.5 mL, 2.1 μmol). After being 
stirred for 24 h at reflux temperature, the reaction mixture was concentrated. The crude material was purified with 
a SiO2 column chromatography (FL60D 0.4 g, hexane / EtOAc = 1/1 to 1/3) to give an E/Z mixture of C3 hydroxy 
macrolactone 65 (4.4 mg, 63%, E/Z = 3.0/1.0) as a colorless oil. 65: Rf 0.30 (hexane / EtOAc = 1/3); 1H NMR (400 
MHz, CDCl3) δ 8.10 [8.16] (s, 1H), 8.04 [8.13] (s, 1H), 7.65 [7.63] (s, 1H), 7.25 [7.02] (dt, J = 15.8, 7.2 Hz, 1H), 
7.14 [6.36] (dt, J = 16.0, 7.5 Hz, 1H), 6.94–6.80 (m, 3H), 6.35 [6.33] (d, J = 15.8 Hz, 1H), 6.23 [6.15] (d, J = 16.0 
Hz, 1H), 5.41 (m, 1H), 5.27 (m, 1H), 4.88 [4.87] (d, J = 4.5 Hz, 1H), 4.83 [4.81] (m, 2H), 4.58 [4.57] (s, 2H), 4.44 
[4.27] (m, 1H), 4.35 (d, J = 8.4 Hz, 1H), 4.08–3.89 (m, 2H), 3.88 (s, 3H), 3.87 (s, 3H), 3.56 [3.63] (m, 1H), 3.34 
[3.44] (s, 3H), 3.33–3.25 (m, 1H), 3.31 [3.30] (s, 3H), 3.28 [3.27] (s, 3H), 3.19 [3.21] (s, 3H), 2.98 (m, 1H), 2.72–
2.38 (m, 4H), 2.28–2.16 (m, 2H), 2.12–1.86 (m, 3H), 1.77–1.45 (m, 9H), 1.09 [1.088] (d, J = 6.7 [6.3] Hz, 3H), 
1.01–0.81 (m, 12H). Chemical shifts of the Z isomers are within parentheses (square brackets). 
 
 
RCM of C3 acetoxy analog 63. To a stirred solution of C3 acetoxy analog 63 (4.7 mg, 4.30 μmol) in dry CH2Cl2 
(4.3 mL) was added a 2.6 mM solution of Zhan catalyst 1B (20c) in dry CH2Cl2 (0.5 mL, 1.3 μmol). After being 
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stirred for 24 h at reflux temperature, the reaction mixture was concentrated. The crude material was purified with 
a SiO2 column chromatography (FL60D 0.5 g, hexane / EtOAc = 1/1 to 1/3) to give C3 acetoxy macrolactone (19E)-
66 (2.6 mg, 57%) and its stereoisomer (19Z)-66 (1.4 mg, 31%) as colorless oils. (19E)-66: Rf 0.28 (hexane / EtOAc 
= 1/3); 1H NMR (400 MHz, CDCl3) δ 8.10 (s, 1H), 8.06 (s, 1H), 7.65 (s, 1H), 7.18 (dt, J = 15.9, 7.4 Hz, 1H), 7.07 
(dt, J = 16.1, 6.8 Hz, 1H), 6.92 (s, 1H), 6.91 (d, J = 7.8 Hz, 1H), 6.82 (d, J = 7.8 Hz, 1H), 6.32 (d, J = 15.9 Hz, 1H), 
6.17 (d, J = 16.1 Hz, 1H), 5.48 (m, 1H), 5.26 (m, 1H), 4.88 (d, J = 4.8 Hz, 1H), 4.84 (d, J = 6.5 Hz, 1H), 4.81 (d, J 
= 6.5 Hz, 1H), 4.58 (s, 2H), 4.33 (d, J = 8.7 Hz, 1H), 4.05 (m, 2H), 3.88 (s, 3H), 3.87 (s, 3H), 3.56 (dd, J = 6.5, 9.6 
Hz, 1H), 3.34–3.22 (m, 1H), 3.31 (s, 3H), 3.28 (s, 6H), 3.13 (s, 3H), 3.02–2.80 (m, 3H), 2.73–2.51 (m, 2H), 2.48–
2.38 (m, 1H), 2.28–2.17 (m, 1H), 2.13 (s, 3H), 2.12–2.00 (m, 3H), 1.93–1.45 (m, 9H), 1.09 (d, J = 6.5 Hz, 3H), 
0.92–0.84 (m, 12H); HRMS (ESI) m/z 1086.5144 (calcd for C56H77N3NaO17 [M+Na]+, Δ –0.6 mmu). 
(19Z)-67: Rf 0.40 (hexane / EtOAc = 1/3); 1H NMR (400 MHz, CDCl3) δ 8.17 (s, 1H), 8.11 (s, 1H), 7.63 (s, 1H), 
6.94–6.80 (m, 4H), 6.45–6.36 (m, 1H), 6.32 (d, J = 11.5 Hz, 1H), 6.13 (d, J = 16.1 Hz, 1H), 5.34–5.21 (m, 2H), 
4.87 (d, J = 4.3 Hz, 1H), 4.83 (d, J = 6.9 Hz, 1H), 4.80 (d, J = 6.9 Hz, 1H), 4.57 (s, 2H), 4.35 (d, J = 8.6 Hz, 1H), 
4.08–3.91 (m, 2H), 3.88 (s, 3H), 3.87 (s, 3H), 3.61–3.46 (m, 2H), 3.41 (s, 3H), 3.28 (s, 3H), 3.26 (s, 3H), 3.20 (s, 
3H), 2.99 (m, 1H), 2.86–2.67 (m, 2H), 2.62–2.47 (m, 3H), 2.30–1.94 (m, 4H), 2.06 (s, 3H), 1.75–1.46 (m, 9H), 1.09 
(d, J = 6.3 Hz, 3H), 1.00 (d, J = 7.5 Hz, 3H), 0.95 (d, J = 6.9 Hz, 3H), 0.86 (d, J = 6.9 Hz, 3H), 0.83 (d, J = 6.9 Hz, 
3H); HRMS (ESI) m/z 1086.5167 (calcd for C56H77N3NaO17 [M+Na]+, Δ +1.6 mmu). 
 
 
RCM of C7 silyloxy analog 64. To a stirred solution of C7 silyloxy analog 64 (5.6 mg, 3.99 μmol) in dry CH2Cl2 
(3.9 mL) was added a 2.4 mM solution of Zhan catalyst 1B (20c) in dry CH2Cl2 (0.5 mL, 1.2 μmol). After being 
stirred for 24 h at reflux temperature, the reaction mixture was concentrated. The crude material was purified with 
two SiO2 column chromatographies (FL60D 0.4 g, hexane / EtOAc = 3/1 to 1/2; FL60D 0.4 g, hexane / EtOAc = 
3/1 to 1/1) to give C7 silyloxy macrolactone (19E)-67 (1.8 mg, 33%) and its stereoisomer (19Z)-67 (0.8 mg, 15%) 
as a colorless oils. (19E)-67: Rf 0.50 (hexane / EtOAc = 1/1); 1H NMR (400 MHz, CDCl3) δ 8.07 (s, 1H), 8.03 (s, 
1H), 7.77–7.62 (m, 4H), 7.56 (s, 1H), 7.42–7.31 (m, 6H), 7.11 (m, 1H), 6.92 (s, 1H), 6.90 (d, J = 7.2 Hz, 1H), 6.81 
(d, J = 7.2 Hz, 1H), 6.31 (d, J = 15.4 Hz, 1H), 5.68 (dt, J = 15.8, 7.1 Hz, 1H), 5.38 (dd, J = 6.7, 15.8 Hz, 1H), 5.15 
(m, 1H), 4.87 (d, J = 4.6 Hz, 1H), 4.81 (d, J = 6.9 Hz, 1H), 4.79 (d, J = 6.9 Hz, 1H), 4.57 (s, 2H), 4.36 (m, 1H), 4.21 
(m, 1H), 4.07 (d, J = 7.1 Hz, 1H), 4.04 (m, 1H), 3.87 (s, 3H), 3.86 (s, 3H), 3.55 (m, 1H), 3.33–3.17 (m, 2H), 3.27 
(s, 3H), 3.25 (s, 6H), 3.19 (s, 3H), 3.02 (m, 1H), 2.76–1.87 (m, 9H), 1.74–1.44 (m, 9H), 1.09 (d, J = 6.6 Hz, 3H), 
1.04 (s, 9H), 0.90–0.83 (m, 6H), 0.84 (s, 9H), 0.77 (d, J = 7.4 Hz, 3H), 0.71 (d, J = 6.6 Hz, 3H), −0.05 (s, 3H), −0.11 
(s, 3H). 
(19Z)-67: Rf 0.55 (hexane / EtOAc = 1/1); 1H NMR (400 MHz, CDCl3) δ 8.08 (s, 1H), 8.06 (s, 1H), 7.72–7.66 (m, 
4H), 7.56 (s, 1H), 7.43–7.33 (m, 6H), 6.92 (s, 1H), 6.91 (d, J = 7.5 Hz, 1H), 6.81 (d, J = 7.5 Hz, 1H), 6.40–6.32 (m, 
1H), 6.29 (d, J = 11.5 Hz, 1H), 5.51–5.40 (m, 2H), 5.20 (m, 1H), 4.87 (d, J = 4.1 Hz, 1H), 4.81 (d, J = 7.0 Hz, 1H), 
4.79 (d, J = 7.0 Hz, 1H), 4.57 (s, 2H), 4.53 (m, 1H), 4.17 (m, 1H), 4.04 (m, 1H), 4.02 (d, J = 8.5 Hz, 1H), 3.87 (s, 
3H), 3.86 (s, 3H), 3.55 (dd, J = 6.6, 9.5 Hz, 1H), 3.46 (m, 1H), 3.33 (s, 3H), 3.29–3.19 (m, 1H), 3.24 (s, 6H), 3.17 
68 
 
(s, 3H), 2.97 (m, 1H), 2.64–2.30 (m, 5H), 2.26–2.01 (m, 4H), 1.72–1.46 (m, 9H), 1.09 (d, J = 6.4 Hz, 3H), 1.06 (d, 
J = 7.0 Hz, 3H), 1.03 (s, 9H), 0.88 (s, 9H), 0.85 (d, J = 7.0 Hz, 3H), 0.76 (d, J = 6.8 Hz, 3H), 0.69 (d, J = 6.8 Hz, 
3H), −0.01 (s, 3H), −0.08 (s, 3H). 
 
 
TCE ester 68. To a stirred solution of the C1–C19 segment 40 (10.0 mg, 14 μmol) and 2,2,2-trichloroethanol (6 
μL, 57 μmol) in dry CH2Cl2 (0.7 mL) cooled at 0 °C were added N,N-dimethyl-4-aminopyridine (3.5 mg, 29 μmol) 
and EDC·HCl (6.1 mg, 32 μmol). After being stirred at room temperature for 11.5 h, the reaction mixture was 
diluted with 5% citric acid aq. (4 mL) and extracted with EtOAc (3 mL × 3). The combined extracts were washed 
with water and brine, dried with Na2SO4, and concentrated. The crude oil was purified with a SiO2 column 
chromatography (FL60D 1.5 g, hexane / EtOAc = 6/1 to 4/1) to give TCE ester 68 (10.6 mg, 89%) as a colorless 
oil. 68: Rf 0.63 (hexane / EtOAc = 1/1); [α]D23 –10 (c 0.32, CHCl3); 1H NMR (600 MHz, CDCl3) δ 8.332 (s, 1H), 
8.330 (s, 1H), 7.73–7.70 (m, 4H), 7.70 (s, 1H), 7.48–7.34 (m, 6H), 6.83 (dt, J = 15.9, 7.6 Hz, 1H), 6.68 (dd, J = 
11.1, 17.7 Hz, 1H), 6.35 (d, J = 17.7 Hz, 1H), 6.15 (d, J = 15.9 Hz, 1H), 5.78 (d, J = 11.1 Hz, 1H), 4.69–4.55 (AB 
quart, J = 12.0 Hz, 2H), 4.40 (d, J = 9.9 Hz, 1H), 4.36 (m, 1H), 3.45 (dq, J = 9.9, 7.0 Hz, 1H), 3.18 (s, 3H), 2.66–
2.41 (m, 4H), 1.05 (s, 9H), 0.85 (d, J = 7.0 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ 201.9, 169.4, 162.1, 156.1, 
155.7, 142.5, 140.0, 139.1, 138.7, 137.4, 136.0 (2C), 136.0 (2C), 133.5, 133.4, 133.3, 131.8, 130.9, 130.1, 130.1, 
127.9 (2C), 127.9 (2C), 124.4, 122.7, 94.9, 77.8, 74.1, 69.1, 57.1, 47.2, 41.3, 40.1, 27.1 (3C), 19.4, 14.3; IR (CHCl3) 
3167, 3032, 3007, 2933, 2859, 1752, 1693, 1665, 1628, 1541, 1462, 1428, 1377, 1308, 1269, 1223, 1209, 1112, 
978, 942 cm–1; HRMS (ESI) m/z 848.1715 (calcd for C40H4235Cl3N3NaO8Si [M+Na]+, Δ +1.1 mmu).  
 
 
TES ether 69. To a stirred solution of the C20–C35 segment 41 (88.0 mg, 0.144 mmol) in dry DMF (1.4 mL) 
cooled at 0 °C were added imidazole (196 mg, 2.88 mmol) and chlorotriethylsilane (0.24 mL, 1.4 mmol). After 
being stirred for 21 h at 40 °C, the reaction mixture was diluted with sat. NaHCO3 aq. (10 mL) and extracted with 
EtOAc (10 mL × 2). The combined extracts were washed with water and brine, dried with Na2SO4, and concentrated. 
The crude material was purified with a SiO2 column chromatography (FL60D 6 g, hexane / EtOAc = 9/1 to 0/1) to 
give TES ether 69 (104 mg, 99%) as a colorless oil. 69: Rf 0.83 (hexane / EtOAc = 1/1); [α]D25 –6.2 (c 0.80, CHCl3); 
1H NMR (600 MHz, CDCl3) δ 6.93–6.90 (m, 2H), 6.82 (d, J = 8.6 Hz, 1H), 5.82 (ddt, J = 9.7, 17.0, 7.3 Hz, 1H), 
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5.15–5.04 (m, 2H), 4.88 (d, J = 4.9 Hz, 1H), 4.83 (s, 2H), 4.59 (s, 2H), 4.06 (m, 1H), 3.90 (m, 1H), 3.89 (s, 3H), 
3.87 (s, 3H), 3.57 (dd, J = 6.8, 9.7 Hz, 1H), 3.31 (s, 3H), 3.31 (s, 3H), 3.28 (s, 3H), 3.20 (m, 1H), 2.96 (dt, J = 5.8, 
5.8 Hz, 1H), 2.33–2.17 (m, 3H), 2.09 (dd, J = 7.8, 12.4 Hz, 1H), 1.82–1.44 (m, 8H), 1.38–1.21 (m, 2H), 1.10 (d, J 
= 6.5 Hz, 3H), 0.95 (t, J = 7.7 Hz, 9H), 0.91 (d, J = 6.8 Hz, 3H), 0.88 (d, J = 7.0 Hz, 3H), 0.86 (d, J = 6.8 Hz, 3H), 
0.58 (q, J = 7.7 Hz, 6H); 13C NMR (150 MHz, CDCl3) δ 149.2, 148.8, 134.8, 131.1, 120.7, 117.2, 111.6, 111.2, 
104.8, 94.6, 87.4, 82.8, 82.3, 78.7, 70.9, 69.6, 57.5, 57.2, 56.1, 56.0, 54.6, 43.6, 43.0, 42.7, 36.1, 35.3, 35.2, 33.3, 
30.8, 27.4, 20.3, 15.8, 9.0, 8.8, 7.2 (3C), 5.5 (3C); IR (CHCl3) 3510, 3091, 3072, 3037, 3008, 2960, 2937, 2911, 
2877, 2832, 1516, 1465, 1420, 1382, 1264, 1239, 1157, 1139, 1094, 1029, 855, 681 cm–1; HRMS (ESI) m/z 
747.4841 (calcd for C40H72NaO9Si [M+Na]+, Δ –0.2 mmu). 
 
 
Coupling product 70. To a stirred solution of TCE ester 68 (10.4 mg, 12.6 μmol) and TES ether 69 (11.0 mg, 15.2 
μmol) was added a solution of the 2nd generation Hoveyda–Grubbs catalyst (20a) (1.6 mg, 2.6 μmol) in dry CH2Cl2 
(0.97 mL). After being stirred for 20 h at reflux temperature, the reaction mixture was concentrated. The crude 
material was purified with a SiO2 column chromatography (FL60D 1 g, hexane / EtOAc = 9/1, 4/1, 2/1, 1/1 to 1/2) 
to give the coupling product 70 (14.8 mg, 77%, E/Z = 5.0/1.0), and TES ether homodimer 71 (4.0 mg, 19%, E/Z = 
2/1) as colorless oils, and to recover 68 (1.7 mg) and 69 (1.5 mg). (19E)-70: Rf 0.13 (hexane / EtOAc = 2/1); [α]D25 
–8.1 (c 0.28, CHCl3); 1H NMR (400 MHz, CDCl3) δ 8.32 (s, 1H), 8.28 (s, 1H), 7.71–7.65 (m, 4H), 7.70 (s, 1H), 
7.47–7.37 (m, 6H), 6.95–6.87 (m, 2H), 6.91 (ddd, J = 6.8, 7.6, 16.0 Hz, 1H), 6.82 (d, J = 8.0 Hz, 1H), 6.82 (dt, J = 
15.8, 7.6 Hz, 1H), 6.44 (d, J = 16.0 Hz, 1H), 6.15 (d, J = 15.8 Hz, 1H), 4.89 (d, J = 4.4 Hz, 1H), 4.85–4.81 (AB 
quart, J = 6.8 Hz, 2H), 4.67–4.56 (AB quart, J = 12.0 Hz, 2H), 4.59 (s, 2H), 4.39 (d, J = 9.8 Hz, 1H), 4.35 (m, 1H), 
4.07 (m, 1H), 3.91 (m, 1H), 3.88 (s, 3H), 3.87 (s, 3H), 3.57 (dd, J = 6.6, 9.6 Hz, 1H), 3.44 (dq, J = 9.8, 7.2 Hz, 1H), 
3.35 (s, 3H), 3.33 (s, 3H), 3.30 (s, 3H), 3.19 (m, 1H), 3.17 (s, 3H), 3.06 (m, 1H), 2.65 (dd, J = 6.4, 15.2 Hz, 1H), 
2.60 (dd, J = 6.0, 15.2 Hz, 1H), 2.59–2.40 (m, 4H), 2.23 (m, 1H), 2.09 (dd, J = 7.2, 12.4 Hz, 1H), 1.84–1.72 (m, 
2H), 1.64–1.46 (m, 5H), 1.61 (ddd, J = 4.8, 7.6, 12.4 Hz, 1H), 1.36–1.16 (m, 2H), 1.10 (d, J = 6.4 Hz, 3H), 1.05 (s, 
9H), 0.95 (d, J = 7.2 Hz, 3H), 0.89 (t, J = 7.8 Hz, 9H), 0.884 (d, J = 6.8 Hz, 3H), 0.877 (d, J = 6.8 Hz, 3H), 0.84 (d, 
J = 7.2 Hz, 3H), 0.53 (q, J = 7.8 Hz, 6H); 13C NMR (100 MHz, CDCl3) δ 202.1, 169.6, 162.3, 156.5, 155.9, 149.3, 
148.9, 142.7, 140.2, 139.0, 139.0, 138.8, 137.5, 136.24 (2C), 136.16 (2C), 133.6, 133.6, 133.5, 131.9, 131.1, 130.9, 
130.32, 130.28, 128.13 (2C), 128.08 (2C), 120.9, 118.3, 111.7, 111.2, 105.0, 95.1, 94.7, 87.5, 82.7, 82.4, 78.8, 77.9, 
74.3, 70.4, 69.8, 69.3, 57.9, 57.5, 57.3, 56.3, 56.1, 54.8, 47.4, 43.8, 42.8, 41.4, 40.3, 36.2, 35.1, 34.3, 33.4, 31.0, 
30.0, 27.3, 27.2 (3C), 20.5, 19.6, 16.1, 14.5, 9.5, 9.2, 7.3 (3C), 5.6 (3C); IR (CHCl3) 3021, 3006, 2958, 2934, 1751, 
1696, 1664, 1628, 1592, 1544, 1517, 1464, 1427, 1380, 1263, 1239, 1156, 1138, 1096, 1029, 919 cm–1; HRMS 
(ESI) m/z 783.8092 (calcd for (C78H11035Cl3N3Na2O17Si2)/2 [M+2Na]2+, Δ –2.5 mmu). 
(19Z)-70: Rf 0.20 (hexane / EtOAc = 2/1); [α]D26 –5.1 (c 0.49, CHCl3); 1H NMR (400 MHz, CDCl3) δ 8.35 (s, 1H), 
8.33 (s, 1H), 7.71–7.66 (m, 4H), 7.70 (s, 1H), 7.47–7.37 (m, 6H), 6.93–6.90 (m, 2H), 6.83 (dt, J = 15.8, 7.5 Hz, 1H), 
6.82 (d, J = 7.6 Hz, 1H), 6.44 (d, J = 11.8 Hz, 1H), 6.25 (dt, J = 11.8, 7.2 Hz, 1H), 6.15 (d, J = 15.8 Hz, 1H), 4.88 
(d, J = 5.2 Hz, 1H), 4.85– 4.81 (AB quart, J = 7.0 Hz, 2H), 4.68–4.56 (AB quart, J = 11.8 Hz, 2H), 4.59 (s, 2H), 
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4.40 (d, J = 9.6 Hz, 1H), 4.35 (m, 1H), 4.06 (br t, J = 6.4 Hz, 1H), 3.88 (s, 3H), 3.87 (m, 1H), 3.87 (s, 3H), 3.57 (dd, 
J = 6.6, 9.8 Hz, 1H), 3.44 (dq, J = 9.6, 7.2 Hz, 1H), 3.36 (s, 3H), 3.28 (s, 3H), 3.23 (s, 3H), 3.17 (s, 3H), 3.05–3.02 
(m, 2H), 2.65 (dd, J = 6.0, 15.6 Hz, 1H), 2.60 (dd, J = 6.4, 15.6 Hz, 1H), 2.55–2.40 (m, 2H), 2.23 (m, 1H), 2.09 (dd, 
J = 7.6, 12.8 Hz, 1H), 1.83–1.73 (m, 2H), 1.67–1.45 (m, 6H), 1.38–1.16 (m, 4H), 1.10 (d, J = 7.2 Hz, 3H), 1.05 (s, 
9H), 0.95 (d, J = 6.8 Hz, 3H), 0.91 (t, J = 7.8 Hz, 9H), 0.88 (d, J = 6.0 Hz, 3H), 0.854 (d, J = 6.8 Hz, 3H), 0.847 (d, 
J = 7.2 Hz, 3H), 0.54 (q, J = 7.8 Hz, 6H); 13C NMR (100 MHz, CDCl3) δ 202.0, 169.6, 162.5, 156.5, 155.9, 149.3, 
148.9, 142.7, 140.3, 139.1, 138.9, 138.8, 137.5, 136.25 (2C), 136.17 (2C), 133.7, 133.4, 131.9, 131.1, 130.9, 130.33, 
130.29, 128.14 (2C), 128.09 (2C), 120.9, 119.1, 116.0, 111.7, 111.2, 105.0, 95.1, 94.7, 87.5, 82.3 (2C), 78.8, 78.0, 
74.3, 71.0, 69.7, 69.3, 57.7, 57.35, 57.33, 56.3, 56.2, 54.8, 47.5, 44.0, 42.8, 41.5, 40.3, 36.3, 35.3, 33.6, 31.3, 31.0, 
30.0, 27.5, 27.3 (3C), 20.5, 19.6, 16.0, 14.5, 9.25, 9.19, 7.4 (3C), 5.6 (3C); IR (CHCl3) 3007, 2958, 2934, 1750, 
1696, 1663, 1628, 1517, 1464, 1427, 1381, 1263, 1240, 1220, 1156, 1139, 1096, 1029, 952, 785, 767, 758, 747, 
731 cm–1; HRMS (ESI) m/z 1544.6328 (calcd for C78H11035Cl3N3NaO17Si2 [M+Na]+, Δ –0.9 mmu). 
TES ether homodimer 71: Rf 0.34 (hexane / acetone = 4/1); [α]D25 –7.4 (c 1.60, CHCl3); 1H NMR (400 MHz, CDCl3) 
δ 6.93–6.90 (m, 4H), 6.82 (d, J = 8.4 Hz, 2H), 5.51–5.47 (m, 2H), 4.88 (d, J = 4.4 Hz, 2H), 4.83 (AB quart, J = 7.2 
Hz, 4H), 4.58 (s, 4H), 4.08–4.04 (m, 2H), 3.91–3.83 (m, 2H), 3.88 (s, 6H), 3.87 (s, 6H), 3.57 (dd, J = 6.6, 9.8 Hz, 
2H), 3.31 [3.30] (s, 6H), 3.290 [3.3295] (s, 6H), 3.27 (s, 6H), 3.22–3.17 (m, 2H), 2.93 [3.00] (dt, J = 5.6, 5.4 Hz, 
2H), 2.35–2.18 (m, 6H), 2.08 (dd, J = 7.6, 12.8 Hz, 2H), 1.83–1.56 (m, 14H), 1.55–1.46 (m, 2H), 1.37–1.20 (m, 
4H), 1.10 (d, J = 6.8 Hz, 6H), 0.94 (t, J = 7.8 Hz, 18H), 0.89 (d, J = 7.2 Hz, 6H), 0.88 (d, J = 6.8 Hz, 6H), 0.86 (d, 
J = 6.8 Hz, 6H), 0.57 (q, J = 8.0 Hz, 12H); 13C NMR (100 MHz, CDCl3) δ 148.9 [148.5], 130.8, 128.8 [127.3], 
120.5, 111.3, 110.9, 104.6, 94.3, 87.1, 82.8 [82.6], 82.0 [81.9], 78.4, 77.2, 71.0 [71.4], 69.3, 57.2, 57.0 [56.9], 55.9, 
55.8, 54.4, 43.3, 42.6 [42.9], 42.4, 35.9, 35.01 [34.96], 33.8, 33.1 [33.3], 30.5, 27.2 [28.7], 20.1, 15.6, 8.8, 8.14 
[8.10], 7.0, 5.2 [5.3]. Chemical shifts of the Z-isomer are within parentheses (square blankets); IR (CHCl3) 3092, 
3072, 3037, 3011, 2959, 2937, 2912, 2878, 2832, 1961, 1819, 1594, 1517, 1479, 1465, 1420, 1382, 1264, 1240, 
1157, 1139, 1095, 1030, 855, 810, 758, 740, 723, 666 cm–1; HRMS (ESI) m/z 1443.9495 (calcd for C78H140NaO18Si2 
[M+Na]+, Δ +1.7 mmu). 
 
 
Secondary alcohol 72. A solution of coupling product (19E)-70 (35.9 mg, 23.6 μmol) in a mixture of AcOH–THF–
H2O (4.5 mL, 4:4:1 [v/v/v]) was stirred for 3 h at room temperature. The resulting mixture was quenched with sat. 
NaHCO3 aq. (20 mL) at 0 °C and extracted with EtOAc (10 mL × 4). The combined extracts were washed with sat. 
NaHCO3 aq., water, and brine, successively, dried with Na2SO4, and concentrated. The crude oil was purified with 
a SiO2 column chromatography (FL60D 1.7 g, hexane / EtOAc = 1/1 to 1/2) to give secondary alcohol 72 (33.3 mg, 
quant.) as a colorless oil. 72: Rf 0.15 (hexane / EtOAc = 2/3); [α]D26 –11 (c 0.20, CHCl3); 1H NMR (400 MHz, 
CDCl3) δ 8.32 (s, 1H), 8.29 (s, 1H), 7.70–7.65 (m, 4H), 7.69 (s, 1H), 7.46–7.36 (m, 6H), 6.92–6.90 (m, 2H), 6.88 
(m, 1H), 6.83 (dt, J = 15.8, 7.6 Hz, 1H), 6.82 (d, J = 7.6 Hz, 1H), 6.44 (d, J = 16.4 Hz, 1H), 6.15 (d, J = 15.8 Hz, 
1H), 4.88 (d, J = 5.0 Hz, 1H), 4.85–4.81 (AB quart, J = 6.8 Hz, 2H), 4.68–4.55 (AB quart, J = 12.0 Hz, 2H), 4.58 
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(s, 2H), 4.39 (d, J = 9.6 Hz, 1H), 4.35 (ddt, J = 5.2, 6.4, 6.4 Hz, 1H), 4.06 (br t, J = 6.4 Hz, 1H), 3.88 (s, 3H), 3.86 
(s, 3H), 3.76 (br t, J = 8.4 Hz, 1H), 3.70–3.64 (m, 2H), 3.57 (dd, J = 6.6, 9.8 Hz, 1H), 3.44 (dq, J = 9.6, 7.2 Hz, 1H), 
3.42 (s, 3H), 3.37 (m, 1H), 3.35 (s, 3H), 3.28 (s, 3H), 3.17 (s, 3H), 2.68 (m, 1H), 2.64 (dd, J = 5.8, 15.6 Hz, 1H), 
2.60 (dd, J = 6.0, 15.6 Hz, 1H), 2.55–2.40 (m, 3H), 2.23 (m, 1H), 2.09 (dd, J = 7.8, 12.8 Hz, 1H), 1.81–1.40 (m, 
9H), 1.62 (ddd, J = 5.0, 10.0, 12.8 Hz, 1H), 1.10 (d, J = 6.4 Hz, 3H), 1.04 (s, 9H), 0.90 (d, J = 7.2 Hz, 3H), 0.89 (d, 
J = 7.2 Hz, 3H), 0.88 (d, J = 6.8 Hz, 3H), 0.84 (d, J = 7.2 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 202.0, 169.5, 
162.3, 156.4, 155.9, 149.3, 148.9, 142.7, 140.2, 139.3, 139.0, 138.8, 137.5, 136.23 (2C), 136.15 (2C), 133.6, 133.5, 
133.4, 131.9, 131.1, 130.9, 130.30, 130.26, 128.11 (2C), 128.07 (2C), 120.9, 117.9, 111.7, 111.2, 105.0, 95.1, 94.9, 
87.5, 82.7, 82.6, 78.8, 77.9, 74.3, 71.3, 69.8, 69.3, 58.3, 58.2, 57.3, 56.3, 56.1, 54.9, 47.4, 43.8, 42.8, 41.4, 40.8, 
40.3, 36.3, 36.05, 35.95, 34.5, 30.7, 28.0, 27.2 (3C), 20.5, 19.6, 15.8, 14.4, 11.9, 9.2; IR (CHCl3) 3459, 3029, 3006, 
2934, 2361, 1752, 1665, 1592, 1517, 1465, 1427, 1381, 1263, 1240, 1212, 1156, 1139, 1096, 1029, 992, 952, 919 
cm–1; HRMS (ESI) m/z 1430.5455 (calcd for C72H9635Cl3N3NaO17Si [M+Na]+, Δ –1.7 mmu). 
 
 
Seco acid 45. To a stirred solution of secondary alcohol 72 (72.7 mg, 51.6 μmol) in THF (5.2 mL) were added an 
activated Zn powder (1.52 g, 23.2 mmol) and a 1.0 M solution of NH4OAc aq. (0.39 mL). After being stirred for 6 
h at room temperature, the mixture was filtered through a pad of Celite, and the residue was washed with EtOAc 
(50 mL). The filtrate and the washings were combined and concentrated. The crude material was purified with a 
SiO2 column chromatography (FL60D 3 g, CHCl3 / MeOH = 200/1 to 100/1) to give seco acid 45 (61.2 mg, 93%) 
as a colorless oil. 45: Rf 0.03 (hexane / EtOAc = 1/5); [α]D25 –19 (c 0.15, CHCl3); 1H NMR (400 MHz, CDCl3) δ 
8.32 (s, 1H), 8.28 (s, 1H), 7.70–7.65 (m, 5H), 7.46-7.34 (m, 6H), 6.92–6.90 (m, 2H), 6.86 (m, 1H), 6.82 (d, J = 8.0 
Hz, 1H), 6.79 (dt, J = 15.4, 7.5 Hz, 1H), 6.44 (d, J = 16.4 Hz, 1H), 6.12 (d, J = 15.4 Hz, 1H), 4.88 (d, J = 4.8 Hz, 
1H), 4.85–4.81 (AB quart, J = 6.8 Hz, 2H), 4.62–4.56 (AB quart, J = 12.2 Hz, 2H), 4.44 (d, J = 8.8 Hz, 1H), 4.29 
(m, 1H), 4.06 (br t, J = 6.4 Hz, 1H), 3.88 (s, 3H), 3.87 (s, 3H), 3.77 (m, 1H), 3.66 (m, 1H), 3.57 (dd, J = 6.8, 10.0 
Hz, 1H), 3.49–3.33 (m, 3H), 3.42 (s, 3H), 3.35 (s, 3H), 3.28 (s, 3H), 3.19 (s, 3H), 2.67 (m, 1H), 2.60–2.40 (m, 5H), 
2.23 (m, 1H), 2.09 (dd, J = 7.2, 12.6 Hz, 1H), 1.81–1.69 (m, 2H), 1.67–1.39 (m, 7H), 1.62 (ddd, J = 4.8, 9.6, 12.6 
Hz, 1H), 1.10 (d, J = 6.4 Hz, 3H), 1.05 (s, 9H), 0.90 (d, J = 6.8 Hz, 3H), 0.89 (d, J = 6.8 Hz, 3H), 0.88 (d, J = 6.8 
Hz, 3H), 0.86 (d, J = 7.2 Hz, 3H) [COOH signal was not observed.]; 13C NMR (150 MHz, CDCl3) δ 201.7, 170.3, 
162.3, 156.4, 155.8, 149.2, 148.8, 142.9, 140.0, 139.3, 139.0, 138.9, 137.5, 136.2 (2C), 136.1 (2C), 133.7, 133.6, 
133.1, 131.7, 131.1, 130.8, 130.24, 130.23, 128.1 (2C), 128.0 (2C), 120.8, 117.9, 111.6, 111.1, 105.0, 94.8, 87.5, 
82.7, 82.6, 78.8, 77.8, 71.3, 69.8, 69.5, 58.24, 58.16, 57.3, 56.2, 56.1, 54.8, 47.3, 43.8, 42.8, 40.8, 40.7, 36.2, 36.0, 
35.9, 34.5, 30.7, 30.0, 28.0, 27.2 (3C), 20.5, 19.6, 15.7, 13.9, 11.9, 9.1; IR (CHCl3) 3566, 3502, 3026, 3007, 2935, 
1715, 1664, 1517, 1464, 1427, 1264, 1220, 1210, 1157, 1139, 1097, 1029, 991, 822, 549 cm–1; HRMS (ESI) m/z 
1300.6322 (calcd for C70H95N3NaO17Si [M+Na]+, Δ –0.6 mmu). 
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Macrolactonization of seco acid 45. To a stirred solution of seco acid 45 (21.8 mg, 17.0 μmol) in dry benzene (3.5 
mL) under a nitrogen stream were added diisopropylethylamine (0.14 mL, 0.77 mmol) and 2,4,6-trichlorobenzoyl 
chloride (66 μL, 0.41 mmol). After being stirred for 12 h at room temperature, the reaction mixture was diluted with 
dry benzene (14 mL) and loaded in a syringe. The activated ester solution was slowly added using a syringe pump 
over 13.5 h to a stirred solution of N,N-dimethyl-4-aminopyridine (48 mg, 0.39 mmol) in dry benzene (23 mL) 
under a nitrogen stream. The remaining activated ester in syringe was rinsed with dry benzene (7 mL) to the above 
reaction mixture over 1 h. After being stirred for 11 h at room temperature, the reaction mixture was quenched with 
sat. NH4Cl aq. (40 mL) and extracted with EtOAc (20 mL × 3). The combined extracts were washed with brine, 
dried with Na2SO4, and concentrated. The crude material was purified with a SiO2 column chromatography (FL60D 
2.2 g, hexane / EtOAc = 5/1, 1/1 to 0/1) to give macrolactone 39 (16.5 mg, 77%) as a colorless oil.  
 
 
Hemiacetal 73. A mixture of macrolactone 39 (147 mg, 0.116 mmol) in 1,2-dimethoxyethane (23 mL) and 1 M 
HCl aq. (7 mL) was stirred for 7 h at 25 °C. The resulting mixture was neutralized with sat. NaHCO3 aq. (25 mL) 
at 0 °C, and extracted with EtOAc (20 mL × 3). The combined extracts were washed with brine, dried with Na2SO4, 
and concentrated. The crude material was purified with a SiO2 column chromatography (FL60D 4 g, hexane / 
acetone = 9/2 to 7/3) to give hemiacetal 73 (145 mg, quant., a 1.8:1 diastereomeric mixture at C35) as a colorless 
oil. 73: Rf 0.40 (CHCl3 / MeOH = 20/1); [α]D25 –44 (c 0.92, CHCl3); 1H NMR (400 MHz, CDCl3) δ 8.12 (s, 1H), 
8.06 (s, 1H), 7.72–7.65 (m, 4H), 7.67 (s, 1H), 7.44–7.30 (m, 6H), 7.16–7.03 (m, 2H), 6.92–6.87 (m, 2H), 6.80 [6.81] 
(d, J = 8.0 Hz, 1H), 6.33 (d, J = 15.6 Hz, 1H), 5.91 (d, J = 16.8 Hz, 1H), 5.42 [5.40] (dd, J = 1.6, 4.4 Hz, 1H), 5.12 
(m, 1H), 4.76 (s, 2H), 4.58–4.50 [4.62–4.53] (AB quart, J = 11.6 Hz, 2H), 4.42 (m, 1H), 4.37 (d, J = 9.6 Hz, 1H), 
4.24 (m, 1H), 3.94 (m, 1H), 3.86 (s, 3H), 3.85 (s, 3H), 3.48 [3.37] (dd, J = 6.8, 9.6 Hz, 1H), 3.32 (s, 3H), 3.29 (m, 
1H), 3.23 (s, 3H), 3.10 (s, 3H), 2.99 (m, 1H), 2.80–2.63 (m, 3H), 2.43 (m, 1H), 2.35–2.18 (m, 2H), 2.08 (dd, J = 
7.6, 12.4 Hz, 1H), 1.81–1.23 (m, 12H), 1.09 [1.17] (d, J = 6.4 Hz, 3H), 1.03 (s, 9H), 0.94–0.84 (m, 9H), 0.76 [0.78] 
(d, J = 6.8 Hz, 3H). Chemical shifts of the minor isomers are within parentheses (square brackets); 13C NMR (100 
MHz, CDCl3) δ 203.0, 170.6, 162.5, 156.5, 155.6, 148.9 [149.0], 148.5, 143.9, 139.7, 139.1, 137.3, 137.0 (2C), 
135.9 (4C), 135.0, 133.8, 133.5, 131.4, 130.7 [130.8], 130.2, 129.8, 129.7, 127.65 (2C), 127.59 (2C), 120.5 [120.2], 
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116.4, 111.3 [111.2], 110.87 [110.93], 98.2 [98.1], 93.9 [94.2], 87.9 [85.9], 82.5 [81.8], 79.8, 77.2, 73.5 [73.6], 69.3 
[69.4], 68.8, 57.7 [57.6], 57.5, 56.3, 55.9, 55.78 [55.83], 43.5, 43.1, 42.8, 42.0, 41.2, 40.9 [41.0], 39.7, 39.46 [39.54], 
36.0 [36.2], 34.1 [34.5], 32.7 [32.5], 32.1, 30.0 [30.2], 27.1 [26.1] (3C), 20.0 [21.1], 19.3, 16.2 [15.6], 14.7 [14.2], 
9.8 [9.3], 8.09 [8.14]; IR (CHCl3) 3167, 3007, 2961, 2936, 2860, 1729, 1661, 1517, 1464, 1378, 1263, 1219, 1157, 
1103, 1028, 981, 918, 822, 761, 703, 666, 611 cm–1; HRMS (ESI) m/z 1268.6042 (calcd for C69H91N3NaO16Si 
[M+Na]+, Δ –2.4 mmu). 
 
 
Triol 74. To a stirred solution of hemiacetal 73 (11.9 mg, 9.6 μmol) in dry MeOH (2.3 mL) cooled at –20 °C was 
added cerium (III) chloride heptahydrate (64 mg, 0.17 mmol). The mixture was stirred for 10 min, and sodium 
borohydride (5.4 mg, 0.14 mmol) was added. After being stirred at –20 °C for 1 h and at 0 °C for 5.5 h, the resulting 
mixture was quenched with acetone (0.1 mL), diluted with sat. NH4Cl aq. (10 mL), and extracted with EtOAc (5 
mL × 3). The combined extracts were washed with brine, dried with Na2SO4, and concentrated. The crude material 
was purified with a SiO2 column chromatography (BW-820MH 0.4 g, hexane / acetone = 4/1, 2/1, 1/1) to give triol 
74 (12.0 mg, 100%, a 10:1 diastereomeric mixture at C7) as a colorless oil. 74: Rf 0.55 (hexane / acetone = 1/1); 
[α]D25 –18 (c 0.66, CHCl3); 1H NMR (400 MHz, CDCl3) δ 8.08 (s, 1H), 8.05 (s, 1H), 7.74–7.68 [7.80–7.74] (m, 
4H), 7.59 [7.55] (s, 1H), 7.39–7.29 [7.43–7.35] (m, 6H), 7.13 (ddd, J = 5.7, 9.5, 15.6 Hz, 1H), 6.91–6.79 (m, 3H), 
6.32 (d, J = 15.6 Hz, 1H), 5.74 (dt, J = 15.5, 7.4 Hz, 1H) [5.81 (dt, J = 15.3, 7.5Hz)], 5.47 (dd, J = 15.5, 6.1 Hz, 1H) 
[5.37 (dd, J = 15.3, 6.5 Hz)], 5.11 (t, J = 7.8 Hz, 1H) [5.15 (t, J = 8.9 Hz)], 4.76 (AB quart, J = 6.9 Hz, 2H), 4.56 
(AB quart, J = 11.6 Hz, 2H), 4.45–4.43 (m, 1H), 4.34 (d, J = 3.0 Hz, 1H), 4.30–4.25 (m, 1H), 4.01 (br s, 1H), 3.89–
3.81 (m, 1H), 3.87 (s, 3H), 3.86 (s, 3H), 3.75–3.66 (m, 1H), 3.59–3.49 (m, 1H), 3.48–3.37 (m, 1H), 3.39 (s, 3H), 
3.36–3.25 (m, 1H), 3.290 (s, 3H), 3.286 (s, 3H), 3.18 (br s, 2H), 3.03–2.95 (m, 1H), 2.74–2.30 (m, 5H), 2.28–2.18 
(m, 1H), 2.15–2.06 (m, 1H), 2.00–1.78 (m, 4H), 1.74–1.38 (m, 8H), 1.04 (d, J = 8.0 Hz, 3H), 1.01 (s, 9H), 0.99 (d, 
J = 7.0 Hz, 3H), 0.89 (d, J = 6.9 Hz, 3H), 0.84 (d, J = 7.0 Hz, 3H), 0.77 (d, J = 6.8 Hz, 3H). Chemical shifts of the 
minor isomers are within parentheses (square brackets); 13C NMR (100 MHz, CDCl3) δ 170.7, 162.5, 156.5, 154.9, 
149.1, 148.8, 141.0, 139.6, 137.2, 137.1, 136.3, 136.0 (4C), 135.0, 134.4, 134.0, 131.5, 130.4, 129.8, 129.53, 129.47, 
127.5 (2C), 127.4 (2C), 127.2, 120.4, 116.7, 111.1, 111.0, 94.3, 81.5, 80.7, 80.6, 80.2, 77.2, 73.0, 72.0, 70.3, 70.2, 
59.6, 58.1, 57.9, 57.5, 55.9, 55.8, 42.2, 40.7, 39.5, 39.3, 37.6, 35.3, 33.1, 32.5, 32.2, 29.6, 27.6, 27.11, 27.07 (3C), 
19.3, 17.2, 15.5, 11.2, 9.4, 8.5; IR (CHCl3) 3168, 3073, 3008, 2963, 2936, 1731, 1655, 1594, 1560, 1517, 1464, 
1427, 1383, 1263, 1210, 1158, 1105, 1028, 977, 916, 856, 822, 771, 749, 739, 705, 668, 612 cm–1; HRMS (ESI) 
m/z 1272.6355 (calcd for C69H95N3NaO16Si [M+Na]+, Δ –2.4 mmu). 
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Trityl ether 76. To a stirred solution of triol 74 (12.6 mg, 10.1 μmol) in dry pyridine (1.3 mL) was added trityl 
chloride (108 mg, 0.39 mmol) at room temperature. After being stirred for 48 h at room temperature, the resulting 
mixture was diluted with EtOAc (3 mL), quenched with sat. NaHCO3 aq. (10 mL), and extracted with EtOAc (5 
mL × 3). The combined extracts were washed with brine, dried with Na2SO4, and concentrated. The crude material 
was purified with two SiO2 column chromatographies (BW-820MH 1 g, CHCl3 / MeOH = 1/0 to 10/1; FL60D 0.5 
g, hexane / acetone = 4/1, 3/1 to 1/1) to give trityl ether 76 (12.4 mg, 82%, a 10:1 diastereomeric mixture at C7) as 
a colorless oil. 76: Rf 0.65 (hexane / acetone = 2/1); [α]D25 –7.6 (c 0.63, CHCl3); 1H NMR (400 MHz, CDCl3) δ 8.08 
(s, 1H), 8.05 (s, 1H), 7.73–7.69 [7.79–7.75] (m, 4H), 7.60 (s, 1H), 7.50–7.19 (m, 21H), 7.14 (ddd, J = 15.9, 9.3, 5.6 
Hz, 1H), 6.90–6.76 (m, 3H), 6.31 (d, J = 15.9 Hz, 1H), 5.75 [5.83] (dt, J = 15.4, 7.4 Hz, 1H), 5.47 [5.35] (dd, J = 
15.4, 6.1 Hz, 1H), 5.12 [5.17] (t, J = 7.7 Hz, 1H), 4.77 (AB quart, J = 7.0 Hz, 2H), 4.56 (AB quart, J = 11.5 Hz, 
2H), 4.44 (t, J = 4.6 Hz, 1H), 4.34 (d, J = 3.5 Hz, 1H), 4.27 (m, 1H), 3.86–3.80 (m, 1H), 3.85 (s, 3H), 3.84 (s, 3H), 
3.48–3.38 (m, 2H), 3.40 [3.43] (s, 3H), 3.33–3.25 (m, 1H), 3.29 (s, 3H), 3.27 (s, 3H), 3.23–3.16 (m, 1H), 3.07 (br 
s, 1H), 3.05–2.95 (m, 2H), 2.72–2.46 (m, 4H), 2.45–2.36 (m, 1H), 2.27–2.19 (m, 1H), 2.15–2.05 (m, 1H), 2.02–
1.77 (m, 4H), 1.74–1.35 (m, 8H), 1.02 [1.05] (s, 9H), 0.90 (d, J = 7.0 Hz, 3H), 0.86 (d, J = 7.0 Hz, 3H), 0.84–0.82 
(m, 6H), 0.79 [0.62] (d, J = 6.8 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 170.5, 162.5, 156.5, 154.9, 149.0, 148.7, 
144.4 (3C), 141.0, 139.5 (2C), 137.13, 137.09, 136.2, 136.0 (4C), 135.0, 134.4, 134.0, 131.5, 130.4, 129.9, 129.53, 
129.47, 128.6 (6C), 127.7 (6C), 127.5 (2C), 127.4 (2C), 126.8 (3C), 120.5, 116.8, 111.1, 111.0, 94.5, 86.4, 81.6, 
81.4, 80.7, 80.3, 77.2, 72.9, 72.0, 70.21, 70.16, 61.9, 57.99, 57.96, 57.4, 55.9, 55.8, 42.2, 40.7, 39.5, 39.3, 37.9, 35.2, 
33.0, 32.0, 31.8, 29.5, 29.4, 27.6, 27.1 (3C), 19.3, 17.4, 15.5, 11.5, 9.5, 8.5; IR (CHCl3) 3167, 3027, 3020, 3007, 
2937, 1732, 1655, 1517, 1463, 1427, 1379, 1261, 1157, 1109, 1027, 977, 916, 824, 797, 707, 666 cm–1; HRMS 
(ESI) m/z 1514.7504 (calcd for C88H109N3NaO16Si [M+Na]+, Δ +2.9 mmu). 
 
 
Ketone 75. To a stirred solution of trityl ether 76 (12.4 mg, 8.3 μmol) in dry CH2Cl2 (0.4 mL) was added activated 
manganese dioxide (58 mg, 0.66 mmol) [Cat. No. CMD-100, Chuo Denki Kogyo Co. Ltd] at room temperature. 
After being stirred for 48 h at room temperature, the resulting mixture was diluted with EtOH (1 mL) and further 
stirred for 1.5 h at room temperature. The resulting mixture was filtered on Celite, and the residue was sufficiently 
washed with EtOH (30 mL) and EtOAc (30 mL). The combined filtrate and washings were concentrated. The crude 
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material was purified with a SiO2 column chromatography (FL60D 0.5 g, benzene / acetone = 10/1 to 5/1) to give 
ketone 75 (9.8 mg, 80%) as a colorless oil. 75: Rf 0.38 (benzene / acetone = 5/1); [α]D25 –30 (c 0.49, CHCl3); 1H 
NMR (600 MHz, CDCl3) δ 8.12 (s, 1H), 8.06 (s, 1H), 7.72–7.67 (m, 4H), 7.67 (s, 1H), 7.45–7.33 (m, 12H), 7.30–
7.18 (m, 9H), 7.15–7.06 (m, 2H), 6.88–6.85 (m, 2H), 6.79 (d, J = 8.6 Hz, 1H), 6.32 (d, J = 15.9 Hz, 1H), 5.91 (d, J 
= 16.1 Hz, 1H), 5.14 (dt, J = 1.6, 8.2 Hz, 1H), 4.76 (AB quart, J = 7.0 Hz, 2H), 4.55 (AB quart, J = 11.5 Hz, 2H), 
4.42–4.40 (m, 1H), 4.38 (d, J = 9.5 Hz, 1H), 4.18 (dq, J = 9.4, 7.0 Hz, 1H), 3.87–3.80 (m, 1H), 3.85 (s, 3H), 3.84 
(s, 3H), 3.42–3.39 (m, 2H), 3.32–3.26 (m, 1H), 3.29 (s, 3H), 3.23–3.17 (m, 1H), 3.22 (s, 3H), 3.10 (s, 3H), 3.04–
2.97 (m, 2H), 2.80–2.64 (m, 4H), 2.46–2.38 (m, 1H), 2.32–2.24 (m, 1H), 1.93–1.37 (m, 12H), 1.03 (s, 9H), 0.855 
(d, J = 6.8 Hz, 3H), 0.849 (d, J = 7.0 Hz, 3H), 0.845 (d, J = 6.7 Hz, 3H), 0.82 (d, J = 6.8 Hz, 3H), 0.79 (d, J = 6.9 
Hz, 3H); 13C NMR (150 MHz, CDCl3) δ 203.0, 170.5, 162.5, 156.6, 155.6, 149.0, 148.7, 144.4 (3C), 143.9, 139.7, 
139.1, 137.3, 137.0 (2C), 135.9 (4C), 135.1, 133.8, 133.6, 131.5, 130.3, 129.94, 129.86, 129.7, 128.6 (4C), 127.7 
(12C), 126.8 (3C), 120.5, 116.4, 111.2, 111.0, 94.5, 86.4, 81.7, 81.4, 79.8, 77.2, 73.5, 70.6, 70.2, 68.9, 61.9, 57.7, 
57.4, 56.3, 55.9, 55.8, 42.9, 41.0, 39.8, 39.6, 37.9, 34.8, 32.8, 32.5, 31.8, 29.7, 29.6, 29.4, 27.1 (3C), 19.3, 17.4, 
15.7, 14.7, 11.4, 8.1; IR (CHCl3) 3446, 3008, 2961, 2933, 2879, 2858, 1729, 1658, 1517, 1464, 1378, 1263, 1241, 
1158, 1102, 1028, 980, 918, 822, 767, 742, 707, 633, 612 cm–1; HRMS (ESI) m/z 1512.7328 (calcd for 
C88H107N3NaO16Si [M+Na]+, Δ +1.0 mmu). 
 
 
Acetate 77. A mixture of ketone 75 (1.4 mg, 0.94 μmol) and N,N-dimethyl-4-aminopyridine (ca. 0.2 mg) in dry 
pyridine (0.1 mL) and acetic anhydride (0.1 mL) was stirred at room temperature for 20.5 h. The resulting mixture 
cooled at 0 °C was quenched with EtOAc (1 mL) and sat. NaHCO3 aq. (3 mL) and extracted with EtOAc (3 mL × 
4). The combined extracts were washed with brine, dried with Na2SO4, and concentrated. The crude material was 
purified with a SiO2 column chromatography (FL60D 0.5 g, hexane / acetone = 9/1 to 9/2) to give acetate 77 (1.4 
mg, 97%) as a light yellow oil. 77: Rf 0.44 (benzene / acetone = 5/1); [α]D25 –23 (c 0.51, CHCl3); 1H NMR (400 
MHz, CDCl3) δ 8.11 (s, 1H), 8.06 (s, 1H), 7.72–7.65 (m, 4H), 7.67 (s, 1H), 7.46–7.16 (m, 21H), 7.15–7.05 (m, 2H), 
6.90–6.75 (m, 3H), 6.31 (d, J = 15.9 Hz, 1H), 5.97 (d, J = 16.1 Hz, 1H), 5.15 (t, J = 8.0 Hz, 1H), 4.96 (dd, J = 9.7, 
2.3 Hz, 1H), 4.69 (AB quart, J = 7.0 Hz, 2H), 4.52 (AB quart, J = 11.6 Hz, 2H), 4.50–4.37 (m, 1H), 4.38 (d, J = 9.5 
Hz, 1H), 4.18 (dq, J = 9.4, 7.0 Hz, 1H), 3.85 (s, 3H), 3.84 (s, 3H), 3.40 (t, J = 6.6 Hz, 1H), 3.35–3.15 (m, 2H), 3.28 
(s, 3H), 3.23 (s, 3H), 3.10 (s, 3H), 3.05–2.94 (m, 2H), 2.83–2.62 (m, 4H), 2.48–2.35 (m, 1H), 2.33–2.24 (m, 1H), 
1.97 (s, 3H), 1.93–1.40 (m, 12H), 1.03 (s, 9H), 0.91 (d, J = 7.0 Hz, 3H), 0.87 (d, J = 6.9 Hz, 3H), 0.85 (d, J = 6.9 
Hz, 3H), 0.80 (d, J = 6.9 Hz, 3H), 0.69 (d, J = 6.7 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 203.0, 170.8, 170.4, 
162.5, 156.6, 155.6, 149.0, 148.5, 144.3 (3C), 143.7, 139.7, 139.1, 137.3, 137.01, 136.96, 135.9 (4C), 135.1, 133.8, 
133.5, 131.5, 130.8, 130.3, 129.9, 129.7, 128.6 (6C), 127.70 (6C), 127.60 (4C), 126.9 (3C), 120.4, 116.4, 111.2, 
110.9, 95.3, 86.5, 81.8, 79.8, 78.7, 78.6, 77.2, 73.6, 69.5, 68.8, 61.4, 57.6, 57.4, 56.3, 55.9, 55.8, 42.9, 41.0, 39.8, 
39.6, 36.7, 34.4, 32.8, 32.3, 31.0, 30.7, 29.6, 27.1 (3C), 26.4, 21.1, 19.3, 16.9, 15.7, 14.8, 9.6, 8.1; IR (CHCl3) 3020, 
2963, 2935, 2880, 1725, 1659, 1516, 1464, 1383, 1257, 1178, 1158, 1139, 1102, 1030, 980, 918, 707 cm–1; HRMS 
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(ESI) m/z 1554.7417 (calcd for C90H109N3NaO17Si [M+Na]+, Δ –0.7 mmu). 
 
 
Primary alcohol 78. To a stirred solution of acetate 77 (3.6 mg, 2.3 μmol) in dry Et2O (0.6 ml) cooled at 0 °C was 
added formic acid (0.4 mL, 11 μmol). After being stirred for 1 h at room temperature, the resulting mixture cooled 
at 0 °C was quenched with EtOAc (1 mL) and 10% NaHCO3 aq. (15 mL), and extracted with EtOAc (6 mL × 3). 
The combined extracts were washed with 10% NaHCO3 aq. and brine, dried with Na2SO4 and concentrated. The 
crude material was purified with a SiO2 column chromatography (FL60D 0.5 g, hexane / acetone = 7/1 to 2/1) to 
give primary alcohol 78 (2.3 mg, 77%) as a colorless oil. 78: Rf 0.42 (benzene / acetone = 3/1); [α]D25 –29 (c 0.30, 
CHCl3); 1H NMR (400 MHz, CDCl3) δ 8.12 (s, 1H), 8.06 (s, 1H), 7.75–7.65 (m, 4H), 7.67 (s, 1H), 7.45–7.33 (m, 
6H), 7.18–7.05 (m, 2H), 6.87–6.79 (m, 3H), 6.33 (d, J = 16.1 Hz, 1H), 5.91 (d, J = 16.1 Hz, 1H), 5.12 (t, J = 7.5 
Hz, 1H), 4.95 (dd, J = 9.6, 2.6 Hz, 1H), 4.68 (AB quart, J = 7.0 Hz, 2H), 4.52 (AB quart, J = 11.6 Hz, 2H), 4.49–
4.41 (m, 1H), 4.38 (d, J = 9.6 Hz, 1H), 4.19 (dq, J = 9.4, 7.0 Hz, 1H), 3.86 (s, 3H), 3.85 (s, 3H), 3.81–3.70 (m, 1H), 
3.67–3.58 (m, 1H), 3.44 (t, J = 6.6 Hz, 1H), 3.37–3.25 (m, 1H), 3.29 (s, 3H), 3.24 (s, 3H), 3.10 (s, 3H), 3.04–2.97 
(m, 1H), 2.86–2.65 (m, 4H), 2.49–2.38 (m, 1H), 2.33–2.24 (m, 1H), 2.01 (s, 3H), 2.06–1.20 (m, 13H), 1.03 (s, 9H), 
0.89 (d, J = 6.5 Hz, 3H), 0.87 (d, J = 6.2 Hz, 3H), 0.86 (d, J = 7.0 Hz, 3H), 0.85 (d, J = 6.6 Hz, 3H), 0.79 (d, J = 6.9 
Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 203.1, 170.8, 170.5, 162.5, 156.6, 155.6, 148.9, 148.5, 143.8, 139.8, 139.1, 
137.3, 137.04, 137.00, 135.0 (4C), 135.1, 133.8, 133.5, 131.4, 130.7, 130.2, 129.9, 129.7, 127.7 (2C), 127.6 (2C), 
120.4, 116.3, 111.2, 110.9, 95.2, 81.7, 79.7, 78.4, 78.3, 77.2, 73.6, 69.6, 68.7, 60.6, 57.8, 57.5, 56.3, 55.9, 55.8, 42.8, 
41.0, 39.7, 39.6, 36.5, 34.6, 32.9, 32.7, 30.9, 30.5, 29.7, 27.1 (3C), 26.8, 21.1, 19.3, 16.9, 15.6, 14.8, 9.5, 8.1; IR 
(CHCl3) 3168, 3073, 3026, 3008, 2961, 2935, 2860, 1726, 1659, 1517, 1464, 1378, 1258, 1178, 1158, 1139, 1103, 
1030, 980, 918, 822, 772, 704, 669 cm–1; HRMS (ESI) m/z 1312.6356 (calcd for C71H95N3NaO17Si [M+Na]+, Δ 
+2.8 mmu). 
 
 
Aldehyde 79. To a stirred solution of primary alcohol 78 (18.6 mg, 14.4 μmol) in dry CH2Cl2 (1.4 mL) were added 
dry pyridine (12 μL, 150 μmol) and Dess–Martin periodinane (9.2 mg, 22 μmol). After being stirred for 30 min at 
room temperature, the resulting mixture was diluted with EtOAc (1 mL) and a mixture of sat. Na2S2O3 aq. – sat. 
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NaHCO3 aq. – water (15 mL, 1:1:1 [v/v/v]) at 0 °C, and extracted with EtOAc (10 mL × 3). The combined extracts 
were washed with water and brine, dried with Na2SO4, and concentrated. The crude material was purified with a 
SiO2 column chromatography (FL60D 0.5 g, hexane / acetone = 9/1 to 7/1) to give aldehyde 79 (18.4 mg, 99%) as 
a colorless oil. 79: Rf 0.50 (benzene / acetone = 1/1); [α]D25 –37 (c 0.62, CHCl3); 1H NMR (400 MHz, CDCl3) δ 
9.74 (br s, 1H), 8.11 (s, 1H), 8.06 (s, 1H), 7.54–7.65 (m, 4H), 7.67 (s, 1H), 7.45–7.33 (m, 6H), 7.16–7.03 (m, 2H), 
6.89–6.78 (m, 3H), 6.33 (d, J = 16.2 Hz, 1H), 5.91 (d, J = 16.2 Hz, 1H), 5.11 (t, J = 8.0 Hz, 1H), 4.98 (dd, J = 9.2, 
3.0 Hz, 1H), 4.68 (AB quart, J = 7.0 Hz, 2H), 4.51 (AB quart, J = 11.6 Hz, 2H), 4.49–4.40 (m, 1H), 4.38 (d, J = 9.6 
Hz, 1H), 4.18 (dq, J = 9.5, 7.0 Hz, 1H), 3.86 (s, 3H), 3.85 (s, 3H), 3.45–3.42 (m, 1H), 3.36–3.25 (m, 1H), 3.28 (s, 
3H), 3.23 (s, 3H), 3.10 (s, 3H), 3.05–2.97 (m, 1H), 2.83–2.65 (m, 4H), 2.52–2.37 (m, 3H), 2.33–2.22 (m, 2H), 2.02 
(s, 3H), 1.86–1.37 (m, 9H), 1.03 (s, 9H), 0.94 (d, J = 6.7 Hz, 3H), 0.86 (d, J = 6.9 Hz, 6H), 0.85 (d, J = 6.9 Hz, 3H), 
0.78 (d, J = 6.9 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 203.0, 201.7, 170.5 (2C), 162.5, 156.5, 155.6, 148.9, 148.5, 
143.6, 139.7, 139.0, 137.3, 137.0 (2C), 135.9 (4C), 135.1, 133.7, 133.5, 131.4, 130.6, 130.2, 129.9, 129.7, 127.7 
(2C), 127.6 (2C), 120.4, 116.3, 111.1, 110.9, 95.1, 81.8, 79.6, 78.3, 77.6, 77.3, 73.6, 69.6, 68.7, 57.6, 57.4, 56.2, 
55.9, 55.8, 44.8, 42.8, 40.9, 39.7, 39.6, 36.9, 34.4, 32.7, 32.6, 30.6, 29.6, 27.1 (3C), 26.4, 21.0, 19.3, 18.1, 15.7, 
14.8, 9.7, 8.1; IR (CHCl3) 3027, 3007, 2962, 2935, 2860, 1726, 1660, 1595, 1562, 1517, 1464, 1427, 1380, 1242, 
1210, 1177, 1158, 1134, 1103, 1030, 980, 917, 789, 745, 728 cm–1; HRMS (ESI) m/z 1310.6193 (calcd for 
C71H93N3NaO17Si [M+Na]+, Δ +2.1 mmu). 
 
 
Secondary alcohol 81. A solution of aldehyde 79 (10.7 mg, 8.3 μmol), N-methylformamide (150 μL, 2.6 mmol), 
hydroquinone (1.8 mg, 16 μmol), and pyridinium p-toluenesulfonate (4.2 mg, 17 μmol) in dry benzene (17 mL) was 
stirred at reflux temperature for 8 h under a nitrogen stream with continuous removal of water using MS3A. The 
resulting mixture was diluted with triethylamine (12 μL) and sat. NaHCO3 aq. (10 mL) at 0 °C, and extracted with 
EtOAc (10 mL × 4). The combined extracts were washed with brine, dried with Na2SO4, and concentrated. The 
crude material was partially purified with two SiO2 column chromatographies (FL60D 0.5 g, benzene / MeOH = 
40/1; FL60D 0.5 g, benzene / MeOH = 7/1 to 3/1) to give crude enamide 80 (6.5 mg) and recovered aldehyde 80 
(3.5 mg, 33%) as colorless oils. 
To a stirred solution of the crude enamide 80 (6.5 mg) in CH2Cl2 (0.98 mL), tert-butyl alcohol (50 μL), and 1.0 M 
phosphate buffer (pH 6.0, 50 μL) was added 2,3-dichloro-5,6-dicyano-p-benzoquinone (DDQ) (3.9 mg, 17 μmol) 
at 0 °C. After being stirred at room temperature for 1 h, DDQ (2.0 mg, 8.8 μmol) and 1.0 M phosphate buffer (pH 
6.0, 25 μL) was further added, and the mixture was stirred at room temperature for 2 h. After being diluted with 
EtOAc (2 mL) and 1.0 M phosphate buffer (pH 6.0, 3 mL), the mixture was stirred for 1.5 h and extracted with 
EtOAc (5 mL × 3). The combined extracts were washed with 5% NaHCO3 aq. and brine, dried with Na2SO4, and 
concentrated. The crude material was purified with a SiO2 column chromatography (FL60D 0.4 g, benzene / acetone 
= 7/1 to 3/1) to give secondary alcohol 81 (2.8 mg, 29% from aldehyde 79) as a colorless oil. 81: Rf 0.47 (benzene 
/ acetone = 2/1); [α]D25 –55 (c 0.72, CHCl3); 1H NMR (500 MHz, CDCl3) δ 8.27 [8.05] (s, 1H), 8.12 (s, 1H), 8.06 
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(s, 1H), 7.73–7.65 (m, 4H), 7.67 (s, 1H), 7.44–7.34 (m, 6H), 7.15–7.04 (m, 2H), 6.48 [7.16] (d, J = 14.0 [14.6] Hz, 
1H), 6.34 (d, J = 15.8 Hz, 1H), 5.91 (d, J = 16.1 Hz, 1H), 5.12 (dt, J = 1.7, 8.2 Hz, 1H), 4.99 [5.02] (dd, J = 13.9, 
9.5 Hz, 1H), 4.80 [4.79] (dd, J = 9.8, 3.1 Hz, 1H), 4.43 (br s, 1H), 4.38 (d, J = 9.5 Hz, 1H), 4.18 (dq, J = 9.2, 7.1 
Hz, 1H), 3.42 (br s, 1H), 3.36–3.35 (m, 1H), 3.281 [3.277] (s, 3H), 3.237 [3.243] (s, 3H), 3.102 [3.105] (s, 3H), 
3.04–2.97 (m, 1H), 3.00 [3.04] (s, 3H), 2.79–2.67 (m, 4H), 2.63–2.54 (m, 1H), 2.48–2.39 (m, 2H), 2.32–2.25 (m, 
1H), 2.13 [2.12] (s, 3H), 1.84–1.20 (m, 9H), 1.03 (s, 9H), 0.90–0.80 (m, 12H), 0.77 [0.76] (d, J = 7.3 [6.8] Hz, 3H). 
Chemical shifts of the minor rotamer at the N-methylenamide moiety (2/1) are within parentheses (square blankets); 
13C NMR (150 MHz, CDCl3) δ 203.0, 172.3, 170.5, 162.5, 162.1 [161.0], 156.6, 155.6, 143.8, 139.7, 139.1, 137.3, 
137.0 (2C), 136.0 (4C), 135.1, 133.8, 133.5, 131.4, 130.2, 129.8, 129.7, 129.4, 127.7 (2C), 127.6 (2C), 116.4, 110.2 
[112.0], 81.6, 79.7, 79.4, 79.2, 73.5, 70.0, 68.7, 57.6, 57.5, 56.3, 42.8, 41.0, 39.6 [39.7], 39.5 [39.4], 36.4, 36.2, 34.8 
[34.7], 32.7, 32.5, 29.7, 27.7, 27.5 [33.0], 27.1 (3C), 26.9, 20.9, 19.3 [19.4], 15.7, 14.8, 8.5 [8.4], 8.2; IR (CHCl3) 
3676, 3025, 3005, 2959, 2932, 1731, 1697, 1657, 1603, 1559, 1458, 1375, 1253, 1211, 1179, 1103, 1047, 980, 917, 
779, 745, 732 cm–1; HRMS (ESI) m/z 1171.5641 (calcd for C63H84N4NaO14Si [M+Na]+, Δ –1.0 mmu). 
 
 
2,3-Di-O-methylglyceric ester 82. To a stirred solution of secondary alcohol 81 (1.6 mg, 1.4 μmol) and 2,3-di-O-
methyl-D-glyceric acid (4.5 mg, 34 μmol) in dry benzene (0.5 mL) were added a 0.65 M solution of triethylamine 
in benzene (0.1 mL, 65 μmol), a 0.51 M solution of 2,4,6-trichlorobenzoyl chloride in benzene (0.1 mL, 51 μmol), 
and a 0.34 M solution of 4-(dimethylamino)pyridine in benzene (0.1 mL, 34 μmol). The mixture was stirred at room 
temperature for 1 h, diluted with EtOAc (1 mL) and 10% citric acid aq. (10 mL), and extracted with EtOAc (5 mL 
× 3). The combined extracts were washed with brine, dried with Na2SO4, and concentrated. The crude material was 
purified with two SiO2 column chromatographies (FL60D 0.5 g, benzene / acetone = 10/1 to 3/1; FL60D 0.3 g, 
benzene / acetone = 5/1) to give 2,3-di-O-methylglyceric ester 82 (1.3 mg, 71%) as a colorless oil. 82: Rf 0.51 
(benzene / acetone = 2/1); [α]D25 –50 (c 0.56, CHCl3); 1H NMR (400 MHz, CDCl3) δ 8.27 [8.04] (s, 1H), 8.12 (s, 
1H), 8.07 (s, 1H), 7.73–7.66 (m, 4H), 7.67 (s, 1H), 7.45–7.34 (m, 6H), 7.15–7.03 (m, 2H), 6.47 [7.14] (d, J = 14.2 
[14.6] Hz, 1H), 6.34 (d, J = 15.8 Hz, 1H), 5.91 (d, J = 16.2 Hz, 1H), 5.14–5.05 (m, 2H), 4.96 (dt, J = 14.2, 9.6 Hz, 
1H), 4.74 (dd, J = 10.1, 2.8 Hz, 1H), 4.45–4.39 (m, 1H), 4.38 (d, J = 9.5 Hz, 1H), 4.18 (dq, J = 9.5, 6.9 Hz, 1H), 
3.910 (dd, J = 6.6, 3.4 Hz, 1H), 3.69–3.57 (m, 2H), 3.46 (s, 3H), 3.38 (s, 3H), 3.34–3.26 (m, 1H), 3.264 [3.261] (s, 
3H), 3.22 [3.23] (s, 3H), 3.10 (s, 3H), 3.02–2.95 (m, 1H), 2.99 [3.04] (s, 3H), 2.80–2.65 (m, 4H), 2.60–2.49 (m, 
1H), 2.46–2.37 (m, 1H), 2.31–2.23 (m, 1H), 2.06 [2.05] (s, 3H), 1.85–1.20 (m, 9H), 1.03 (s, 9H), 1.00 [0.99] (d, J 
= 6.9 Hz, 3H), 0.94 [0.93] (d, J = 6.9 [7.0] Hz, 3H), 0.85 (d, J = 6.8 Hz, 3H), 0.84 (d, J = 6.8 Hz, 3H), 0.76 (d, J = 
6.8 Hz, 3H). Chemical shifts of the minor rotamer at the N-methylenamide moiety (2/1) are within parentheses 
(square blankets); 13C NMR (125 MHz, CDCl3) δ 203.0, 170.7, 170.6, 170.2, 162.6, 162.1 [161.0], 156.5, 155.6, 
144.0, 139.7, 139.0, 137.3, 137.1 (2C), 135.9 (4C), 135.0, 133.8, 133.5, 131.3, 130.1, 129.8, 129.7, 129.4 [125.4], 
127.6 (4C), 116.5, 110.3 [112.0], 81.6, 80.7, 79.8, 77.3, 76.4, 73.4, 73.0 (2C), 68.8, 59.3, 58.6, 57.5, 57.4, 56.3, 
42.8, 40.9, 39.7, 39.5, 37.5 [37.4], 36.9 [37.0], 34.0 [33.8], 32.7, 32.1 [31.9], 30.5 [30.3], 29.7, 27.5 [33.0], 27.1 
[26.9] (3C), 26.4 [26.3], 20.9, 19.3 [19.4], 15.8, 14.6, 9.7 [9.6], 8.2; IR (CHCl3) 3072, 3032, 2999, 2932, 1732, 1692, 
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1656, 1461, 1375, 1243, 1221, 1181, 1106, 980, 918, 787, 782, 774, 728 cm–1; HRMS (ESI) m/z 1287.6107 (calcd 
for C68H92N4NaO17Si [M+Na]+, Δ –1.7 mmu). 
 
 
Mycalolide B. To a stirred solution of 2,3-di-O-methylglyceric ester 82 (6.9 mg, 5.5 μmol) in dry THF (1.4 mL) 
cooled at 0 °C were added a 1.0 M solution of TBAF/AcOH (1:1) in THF (0.164 mL, 0.164 mmol) [prepared by 
adding AcOH (114.5 μL, 2.0 mmol) to a 1.0 M solution of TBAF in THF (2.0 mL, 2.0 mmol)]. After being stirred 
for 60 h at room temperature, the reaction mixture was diluted with EtOAc (1 mL) and sat. NaHCO3 aq. (5 mL) at 
0 °C, and extracted with EtOAc (5 mL × 3). The combined extracts were washed with brine, dried with Na2SO4, 
and concentrated. The crude oil was purified with a SiO2 column chromatography (BW-820MH 0.5 g, CHCl3 / 
MeOH = 40/1) to give mycalolide B (5.5 mg, 98%) as a colorless oil. Synthetic mycalolide B: Rf 0.43 (CHCl3 / 
MeOH = 40:1); [α]D25 –55 (c 0.55, CHCl3); 1H NMR (400 MHz, CDCl3) δ 8.29 [8.07] (s, 1H), 8.10 (s, 1H), 8.07 (s, 
1H), 7.66 (s, 1H), 7.29 (m, 1H), 7.14 (m, 1H), 6.49 [7.16] (d, J = 14.0 [14.5] Hz, 1H), 6.35 (d, J = 15.8 Hz, 1H), 
6.24 (d, J = 16.0 Hz, 1H), 5.47 (d, J = 4.5 Hz, 1H, OH), 5.25 (br t, J = 8.1 Hz, 1H), 5.12 [5.09] (br t, J = 6.1 [8.4] 
Hz, 1H), 4.96 [4.99] (dd, J = 14.0, 9.4 [14.5, 9.6] Hz, 1H), 4.77 (dd, J = 10.0, 2.8 Hz, 1H), 4.44 (m, 1H), 4.35 (d, J 
= 8.3 Hz, 1H), 4.00 (dq, J = 7.1, 7.1 Hz, 1H), 3.93 (dd, J = 6.6, 3.4 Hz, 1H), 3.69–3.60 (m, 2H), 3.49 (s, 3H), 3.46 
(m, 1H), 3.40 (s, 3H), 3.35 (s, 3H), 3.30 (s, 3H), 3.19 (s, 3H), 3.02 [3.06] (s, 3H), 2.97 (m, 1H), 2.68 (m, 1H), 2.66–
2.45 (m, 5H), 2.43 (m, 1H), 2.079 [2.076] (s, 3H), 1.89–1.79 (m, 2H), 1.77–1.72 (m, 1H), 1.70–1.22 (m, 6H), 1.01 
[1.00] (d, J = 6.8 [6.7] Hz, 3H), 0.97 [0.96] (d, J = 6.9 [6.8] Hz, 3H), 0.93 (d, J = 6.8 Hz, 3H), 0.91 (d, J = 7.0 Hz, 
3H), 0.844 [0.838] (d, J = 6.9 [6.8] Hz, 3H). Chemical shifts of the minor rotamer at the N-methylenamide moiety 
(2/1) are within parentheses (square blankets). OH signal was assigned based on deuterium exchange experiments; 
13C NMR (150 MHz, CDCl3) δ 202.5, 172.0, 170.7, 170.3, 162.8, 162.1 [161.0], 156.4, 155.5, 146.0, 140.7, 139.3, 
137.3, 137.2, 137.1, 133.2, 131.0, 129.9, 129.4 [125.4], 116.2, 110.3 [112.0], 81.6, 80.7, 79.6, 77.5, 76.4, 73.1 (2C), 
73.0, 67.6, 59.3, 58.6, 58.2 [58.3], 57.9 [57.8], 56.8, 43.9, 42.8, 41.1, 40.8, 37.5 [37.4], 36.9 [37.1], 35.2 [35.4], 34.7 
[34.5], 32.0 [31.9], 30.5 [30.3], 27.5 [33.0], 27.0 [27.8], 21.0, 19.4 [19.5], 15.6, 13.1, 9.8 [9.6], 9.0; IR (CHCl3) 
3689, 3503, 3022, 3008, 2934, 1711, 1656, 1603, 1558, 1457, 1418, 1362, 1222, 1192, 1092, 979, 918, 767, 746, 
739 cm–1; HRMS (ESI) m/z 1049.4954 (calcd for C52H74N4NaO17 [M+Na]+, Δ +0.7 mmu). 
 
 
TBDPS-protected mycalolide A (83).[14] To a stirred solution of secondary alcohol 81 (0.50 mg, 0.43 μmol) in dry 
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CH2Cl2 (0.42 mL) were added a 1.0 M solution of pyridine in CH2Cl2 (4.3 μL, 4.3 μmol) and a 0.3 M solution of 
Dess–Martin periodinane in CH2Cl2 (6 μL, 1.8 μmol). After being stirred for 1 h at room temperature, the resulting 
mixture was diluted with a mixture of sat. Na2S2O3 aq. – sat. NaHCO3 aq. – water (2.5 mL, 1:1:1 [v/v/v]) at 0 °C, 
and extracted with EtOAc (3 mL × 3). The combined extracts were washed with water and brine, dried with Na2SO4, 
and concentrated. The crude material was partially purified with a SiO2 column chromatography (FL60D, 0.2 g, 
benzene / acetone = 5/1 to 3/1) to give crude TBDPS-protected mycalolide A (83) (ca. 0.3 mg) as a colorless oil, 
which was used for the next step without further purification. 83: Rf 0.60 (benzene / acetone = 2/1); 1H NMR (400 
MHz, CDCl3) δ 8.28 (s, 1H), 8.11 (s, 1H), 8.07 (s, 1H), 7.73–7.66 (m, 4H), 7.67 (s, 1H), 7.45–7.34 (m, 6H), 7.15–
7.03 (m, 2H), 6.48 [7.15] (d, J = 13.4 [14.6] Hz, 1H), 6.33 (d, J = 15.9 Hz, 1H), 5.92 (d, J = 16.2 Hz, 1H), 5.17–
5.08 (m, 2H), 4.97 (dt, J = 14.2, 10.2 Hz, 1H), 4.47–4.39 (m, 1H), 4.38 (d, J = 9.4 Hz, 1H), 4.18 (m, 1H), 3.34–3.26 
(m, 1H), 3.29 (s, 3H), 3.25 (s, 3H), 3.11 (s, 3H), 3.02–2.95 (m, 1H), 3.02 [3.06] (s, 3H), 2.77–2.65 (m, 6H), 2.57–
2.38 (m, 2H), 2.33–2.25 (m, 1H), 2.01 [2.00] (s, 3H), 1.87–1.17 (m, 5H), 1.04–1.01 (m, 6 H), 1.03 (s, 9H), 0.87 (d, 
J = 7.0 Hz, 3H), 0.86 (d, J = 6.9 Hz, 3H), 0.74 (d, J = 6.8 Hz, 3H). Chemical shifts of the minor rotamer at the N-
methylenamide moiety (2/1) are within parentheses (square blankets); HRMS (ESI) m/z 1169.5516 (calcd for 
C63H82N4NaO14Si [M+Na]+, Δ +2.1 mmu). 
  
 
Mycalolide A. To a stirred solution of the above crude TBDPS-protected mycalolide A (83) (ca. 0.3 mg) in dry 
THF (110 μL) cooled at 0 °C were added a 1.0 M solution of TBAF/AcOH (1:1) in THF (13 μL, 13 μmol) [prepared 
by adding AcOH (114.5 μL, 2.0 mmol) to a 1.0 M solution of TBAF in THF (2.0 mL, 2.0 mmol)]. After being 
stirred for 53 h at room temperature, the reaction mixture was diluted with EtOAc (2 mL) and sat. NaHCO3 aq. (3 
mL) at 0 °C, and extracted with EtOAc (2 mL × 3). The combined extracts were washed with brine, dried with 
Na2SO4, and concentrated. The crude oil was purified with a reversed-phase HPLC [Develosil ODS-HG-5 ( 20 × 
250 mm), 70% MeOH, 5 mL/min, UV254 nm] to give mycalolide A (62 nmol, quantified by 1H NMR spectrum, 
14% from secondary alcohol 83) as a colorless oil. Synthetic mycalolide A: Rf 0.45 (benzene / acetone = 2/1); 1H 
NMR (400 MHz, CDCl3) δ 8.29 [8.08] (s, 1H), 8.10 (s, 1H), 8.07 (s, 1H), 7.65 (s, 1H), 7.30 (m, 1H), 7.17 (m, 1H), 
6.50 [7.16] (d, J = 14.0 Hz, 1H), 6.36 (d, J = 15.6 Hz, 1H), 6.24 (d, J = 15.9 Hz, 1H), 5.44 (m, 1H, OH), 5.28 (t, J 
= 8.2 Hz, 1H), 5.14 (m, 1H), 4.97 [5.00] (t, J = 9.1 [9.4] Hz, 1H), 4.44 (m, 1H), 4.35 (d, J = 8.5 Hz, 1H), 3.99 (t, J 
= 7.8 Hz, 1H), 3.48 (m, 1H), 3.36 (s, 3H), 3.32 (s, 3H), 3.19 (s, 3H), 3.03 [3.07] (s, 3H), 3.00 (m, 1H), 2.81–2.56 
(m, 3H), 2.53–2.42 (m, 7H), 2.014 [2.006] (s, 3H), 1.90 (m, 1H), 1.79–1.37 (m, 4H), 1.25 (m, 1H), 1.07 (d, J = 7.1 
Hz, 3H), 1.05 [1.04] (d, J = 7.0 [6.9] Hz, 3H), 0.932 (d, J = 6.8 Hz, 3H), 0.928 (d, J = 6.8 Hz, 3H), 0.834 (d, J = 6.7 
Hz, 3H) Chemical shifts of the minor rotamer at the N-methylenamide moiety (2/1) are within parentheses (square 
blankets); HRMS (ESI) m/z 931.4332 (calcd for C47H64N4NaO14 [M+Na]+, Δ +1.5 mmu). 
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